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Abstract	  
Background:	   I	   aimed	   to	   identify	   genes	   that	   are	   differentially	   expressed	   in	   whole	  
blood	  in	  patients	  following	  myocardial	  infarction	  (MI)	  and	  assess	  these	  functionally	  
in	  zebrafish.	  
Methods:	  We	   recruited	  patients	   admitted	  with	   acute	   coronary	   syndromes	   (MI	   or	  
unstable	  angina).	  We	  performed	  whole	  genome	  microarrays	  on	  RNA	  extracted	  from	  
whole	   blood	   at	   1,	   3,	   7,	   30	   and	   90d	   post	   admission,	   comparing	   the	   whole	   blood	  
transcriptome	  of	  patients	  with	  MI	  with	  unstable	  angina.	  I	  then	  assessed	  the	  role	  of	  
one	  such	  candidate	  (KIAA1109)	  in	  zebrafish	  cardiovascular	  development.	  
Results:	   From	   >54000	   genes	   assessed,	   39	   genes	   were	   significantly	   differentially	  
expressed	   in	   peripheral	   blood	   at	   1d	   post	   MI,	   returning	   to	   baseline	   at	   later	   time	  
points.	  27	  of	  these	  39,	  have	  clear	  zebrafish	  homologues,	  14	  with	  protein	  similarity	  
>50%.	  9	  genes	  were	  up	  regulated	  in	  MI,	  while	  5	  were	  down	  regulated,	   including	  a	  
gene	   of	   unknown	   function;	   KIAA1109.	   I	   therefore	   knocked	   down	   KIAA1109	   in	  
developing	   zebrafish	   and	   assessed	   its	   role	   in	   vascular	   development.	   I	   also	  
performed	  a	  microarray	  comparing	  whole	  embryo	  RNA	  from	  36h	  post	   fertilization	  
KIAA1109	   morphants	   with	   control	   to	   assess	   the	   transcriptional	   effect	   of	   loss	   of	  
function	  of	  KIAA1109.	  	  
KIAA1109	  morphant	  Fli1:GFP/Gata1:dsRED	  transgenic	  zebrafish	  were	  examined	  by	  
confocal	  microscopy	   for	   evidence	   of	   vascular	   abnormalities.	   KIAA1109	  morphants	  
developed	  cerebral	  haemorrhage	  (3dpf	  control	  10%,	  vs.	  KIAA1109	  morphants	  50%	  
p<0.05).	   KIAA1109	   knockdown	   induced	   a	   significant	   decrease	   in	   the	   number	   of	  
endothelial	   cells	   (EC)	   in	   the	   forebrain	   of	   KIAA1109	   morphants	   (47±4	   vs.	   73±6	   in	  
control)	  and	  hindbrain	   (53±4	  morphants	  vs.	  95±7	   in	  control)	  at	  2dpf.	  There	  was	  a	  
significant	   decrease	   in	   the	   number	   of	   EC	   nuclei	   in	   the	   cardinal	   vein	   of	   KIAA1109	  
morphants	  (68±6	  vs.	  101±8	  in	  control).	  The	  phenotype	  of	  KIAA1109	  knockdown	  was	  
rescued	  by	  administration	  of	  the	  VEGF	  inducer	  GS4012.	  
The	  microarray	  of	  total	  RNA	  from	  36hpf	  KIAA1109	  morphants	  identified	  genes	  that	  
were	  significantly	  down	  regulated	  by	  KIAA1109	  knockdown	  such	  as	  protocadherin	  1	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gamma	  2,	   involved	   in	   the	  cadherin-­‐signalling	  pathway	  and	   ligand	  of	  numb-­‐protein	  
X1,	  involved	  in	  the	  NOTCH	  pathway.	  	  
Conclusion:	  KIAA1109	  is	  significantly	  down	  regulated	  in	  human	  whole	  blood	  1d	  post	  
MI.	   Knockdown	   of	   KIAA1109	   induces	   severe	   cerebral	   haemorrhage	   in	   developing	  
zebrafish	  and	  significant	  differential	  expression	  of	  important	  developmental	  genes.	  
Functional	   and	   transcriptomic	   assessment	   in	   zebrafish	   suggests	   KIAA1109	   is	  
required	  for	  vascular	  integrity	  and	  may	  be	  a	  therapeutic	  target	  post	  MI.	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   Coronary	  artery	  disease	  
CADi	   Coronary	  artery	  disease	  index	  
CAMK2g2	   Calcium/calmodulin-­‐dependent	  protein	  kinase	  	  
CCV	   Common	  cardinal	  vein	  
CHD	   Coronary	  heart	  disease	  
CK	   Creatine	  kinase	  
CtA	   Central	  artery	  
cTn	   Cardiac	  troponins	  
DAVID	   Database	  for	  annotation,	  visualisation	  and	  integrated	  discovery	  
DIG	   Digoxigenin	  
DLV	   Dorsal	  longitudinal	  vein	  
dpf	   Days	  post	  fertilization	  
EC	   Endothelial	  cell	  
ECG	   electrocardiograph	  
FC	   Fold	  change	  
fli-­‐1	   Friend	  leukaemia	  integration	  1	  
fps	   Frames	  per	  second	  
FSA	   Fragile	  site	  associated	  
GFP	   Green	  fluorescent	  protein	  
GRIN1a	   Glutamate	  receptor,	  ionotropic,	  N-­‐methyl	  D-­‐aspartate	  1a	  	  
dpf	   Hours	  post	  fertilization	  
HYB-­‐	   Hybridization	  mix	  minus	  tRNA	  
ICAM	   Intracellular	  adhesion	  molecule	  
IOC	   Inner	  optic	  circle	  
IPH	   Interplaque	  haemorrhage	  
IVT	   in	  vitro	  transcription	  
LDA	   Lateral	  dorsal	  artery	  
LDL	   Low	  density	  lipoprotein	  
LNX1	   Ligand	  of	  numb	  protein	  X-­‐1	  
MCeV	   Mesencephalic	  vein	  
MCP-­‐1	   Monocyte	  chemotactic	  protein	  1	  
MCV	   Middle	  cerebral	  vein	  
MI	   Myocardial	  infarction	  
mib	   Mindbomb	  
miRNA	   Micro	  RNA	  
MMP	   Matrix	  metalloproteinases	  	  
mRNA	   Messenger	  RNA	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Msv	   Mesencephalic	  vein	  
MtA	   Mesencephalic	  artery	  
NCA	   Nasal	  cilary	  artery	  
NDR2	   Nodal	  related	  2	  
NGH	   Northern	  general	  teaching	  hospital	  
NIHR	   National	  institute	  of	  health	  research	  
NSTEMI	   Non	  ST	  elevation	  myocardial	  infarction	  
OV	   Optic	  vein	  
Ox-­‐LDL	   Oxidised	  LDL	  
PAK2A	   p21-­‐activated	  kinase	  2a	  	  
PANTHER	   Protein	  analysis	  through	  evolutionary	  relationships	  
PBT	   Phosphate	  buffered	  saline	  +	  tween	  20%	  
PCDH1γ2	   Protocadherin	  1	  gamma	  2	  	  
PCeV	   Posterior	  (caudal)	  cardinal	  vein	  
PCI	   Percutaneous	  coronary	  intervention	  
PHBC	   Primordial	  hindbrain	  channel	  
PHS	   Primary	  head	  sinus	  
PIV	   Particle	  image	  velocimetry	  
PMBC	   Primordial	  hindbrain	  channel	  
PPLR	   Probability	  of	  positive	  log	  ratio	  
PPrA	   Primitive	  prosencephalic	  artery	  
PrA	   Prosencephalic	  artery	  
PUMA	   Propagating	  uncertainty	  in	  microarray	  analysis	  
qRT-­‐PCR	   Quantitative	  real	  time	  polymerase	  chain	  reaction	  
RA	   Rheumatoid	  arthritis	  
RAS	   Renin-­‐angiotensin	  system	  	  
rcf	   Relative	  centrifugal	  force	  
Ren	   Renin	  
ROS	   Reactive	  oxygen	  species	  
RT	   Room	  Temperature	  
SMC	   Smooth	  muscle	  cell	  
SSC	   Saline-­‐sodium	  citrate	  
STEMI	   ST	  elevation	  myocardial	  infarction	  
STRING	   Search	  tool	  for	  the	  retrieval	  of	  interacting	  genes/proteins	  
T1D	   Type	  1	  diabetes	  
TPM	   Transcripts	  per	  million	  
UA	   Unstable	  angina	  
VA	   Ventral	  aorta	  
VCAM	   Vascular	  cell	  adhesion	  molecule	  
VE-­‐cadherin	   Vascular	  endothelial	  cadherin	  
VEGF	   Vascular	  endothelial	  growth	  factor	  
VEGFR	   Vascular	  endothelial	  growth	  factor	  receptor	  
WISH	   Whole	  mount	  in	  situ	  hybridization	  	  
YSL	   Yolk	  syncytial	  layer	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  1.	  Introduction	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1.1.	  Cardiovascular	  disease	  
Coronary	  heart	  disease	  (CHD)	  is	  the	  leading	  cause	  of	  adult	  mortality	  in	  the	  UK,	  killing	  one	  in	  four	  men	  and	  one	  in	  six	  women.	  In	  the	  UK,	  approximately	  94,000	  deaths	   occur	   each	   year	   due	   to	   CHD	  with	   an	   estimated	   2	  million	   people	   living	  with	  angina	  (NHS).	  
1.1.1.	  Atherosclerosis	  Atherosclerosis	  is	  a	  progressive	  disease	  that	  starts	  at	  an	  early	  age	  and	  develops	  at	   a	   rate	   dependent	   upon	   factors	   such	   as	   exercise,	   diet	   and	   genetic	  predisposition	  (Glass	  and	  Witztum,	  2001).	  Endothelial	   dysfunction	   is	   the	   initial	   trigger	   for	   atherosclerosis	   arising	   due	   to	  events	  such	  as	  vessel	  injury	  or	  changes	  in	  haemodynamic	  force	  (Papaioannou	  et	  al.,	  2006).	  This	  leads	  to	  up-­‐regulation	  of	  adhesion	  molecules/receptors	  such	  as	  vascular	   cell	   adhesion	   molecule	   (VCAM)	   and	   intracellular	   adhesion	   molecule	  (ICAM).	  This	  allows	  monocytes	  to	  adhere	  to	  the	  endothelium	  and	  with	  the	  help	  of	   monocyte	   chemotactic	   protein	   1	   (MCP-­‐1)	   differentiate	   into	   macrophages	  (Hansson,	   2009),	   (Tiwari	   et	   al.,	   2008).	   	   These	   then	   accumulate	   oxidised	   low-­‐density	  lipoprotein	  (Ox-­‐LDL)	  leading	  to	  formation	  of	  foam	  cells.	  	  Simultaneous	   to	   these	   events,	   smooth	   muscle	   cells	   (SMCs)	   migrate	   from	   the	  medial	  portion	  of	  the	  arterial	  wall	  and	  with	  the	  foam	  cells	  form	  a	  fibrous	  plaque	  within	  the	  intima.	  Plaque	  formation	  leads	  to	  an	  inflammatory	  response	  in	  which	  macrophages	  undergo	  apoptosis	  leading	  to	  their	  phagocytic	  clearance,	  inducing	  release	  of	  metalloproteases	  which	  alongside	  neovascularization	  leads	  to	  plaque	  instability	  and	  rupture	  (Moulton,	  2007).	  Following	  plaque	  rupture,	  blood	  is	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exposed	  to	  the	  lipid	  rich	  necrotic	  plaque	  core,	  stimulating	  a	  coagulation	  cascade	  of	   platelet	   activation	   leading	   to	   thrombus	   formation	   (Croce	   and	   Libby,	   2007)	  which	   can	  precipitate	  disease	   such	  as	   stroke	  or	  myocardial	   infarction.	   	   Figure	  1.1	  summarises	  the	  processes	  of	  atherogenesis.	  
1.1.2.	  Plaque	  Neovascularization	  In	   a	   healthy	   state	   neovascularization	   is	   essential	   for	  maintaining	   haemostasis	  and	  restoration	  of	  healthy	  tissue	  (Moreno	  et	  al.,	  2012).	  	  In	  a	  normal	  vessel	  wall	  oxygen	   diffuses	   through	   the	   lumen	   to	   the	   intima;	   however	   when	   an	  atherosclerotic	  lesion	  evolves,	  luminal	  surface	  increases	  and	  exceeds	  the	  oxygen	  diffusion	   threshold,	   causing	   local	   hypoxia	   and	   inducing	   neovascularization	  (Moreno	  et	  al.,	  2012).	  The	  presence	  of	  neo-­‐vessels	  makes	   the	  plaque	  prone	   to	  rupture	  due	   to	   their	   fragile	   structure,	  making	   them	  susceptible	   to	   interplaque	  haemorrhage.	  This	  neo-­‐vessel	  haemorrhaging	  releases	  red	  blood	  cells	   into	   the	  plaque,	  increasing	  lipid	  peroxidation	  and	  macrophage	  activation.	  The	  presence	  of	   neo-­‐vessels	   in	   plaques	   provides	   potential	   therapies	   using	   anti	   angiogenic	  therapy	  to	  prevent	  erythrocyte	  accumulation	  in	  the	  plaque	  (Jain	  et	  al.,	  2007).	  	  	  
1.1.3.	  Acute	  coronary	  syndromes	  Acute	   coronary	   syndrome	   (ACS)	   is	   a	   term	   used	   which	   encompasses	   a	   wide	  range	  of	  presentations	   induced	  by	  acute	  plaque	   rupture,	   including	  myocardial	  infarction	   and	   unstable	   angina	   (UA).	   Diagnosis	   of	   disease	   is	   based	   on	  electrocardiographic	  (ECG)	  changes	  and	  biochemical	  cardiac	  markers.	  	  
	   	  
	   	   Sara	  Solaymani-­‐Kohal	  25	  
Figure	  1.1.	  Simplified	  summary	  of	  mechanisms	  and	  processes	  in	  plaque	  formation	  Adapted	   from	   (Lindsay	   and	  Choudhury,	   2008).	   Reprinted	   by	   permission	   from	  Macmillan	   Publishers	   Ltd:	   Nature	   Reviews	   Drug	   Discovery	   7,	   517-­‐529	   (June	  2008)	  |	  doi:10.1038/nrd2588	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1.1.3.1.Myocardial	  infarction	  	  Upon	  plaque	  rupture	  the	  contents	  of	  the	  plaque	  are	  released	  into	  the	  blood	  and	  a	  coagulation	  cascade	  is	  triggered	  leading	  to	  complete	  or	  partial	  obstruction	  of	  an	  epicardial	  coronary	  artery,	  diminishing	  the	  availability	  of	  oxygen	  to	  cardiac	  muscle	  causing	  necrosis.	  Upon	   admission	   to	   hospital	   with	   chest	   pain	   the	   standard	   diagnostic	  investigation	  is	  an	  electrocardiograph.	  A	  normal	  ECG	  reading	  is	  shown	  in	  figure	  1.2.	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Figure	  1.2.	  Electrocardiographic	  changes	  seen	  in	  ACS	  Single	   lead	   ECG	   readings	   in	   different	   disease	   states,	   normal,	   ST-­‐elevation	   and	  Non-­‐ST	  elevation	  myocardial	   infarctions.	   (Clinical	  diagnosis	  requires	  at	   least	  a	  12-­‐lead	  ECG,	  where	  these	  features	  may	  be	  seen	  in	  only	  one	  or	  two	  leads.)	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An	  ECG	  with	  an	  elevated	  ST	  segment	  demonstrates	  that	  the	  patient	  has	  suffered	  an	   ST	   elevation	   myocardial	   infarction	   (STEMI),	   which	   is	   generally	   the	   most	  severe	   form	  of	  ACS.	  An	   elevated	  ST	   segment	   indicates	   a	   significant	   amount	  of	  the	  heart	  has	  been	  compromised.	  	  When	  the	  ECG	  displays	  either	  a	  depressed	  ST	  segment	  or	  an	  inverted	  T	  wave	  a	  diagnosis	   of	   Non-­‐ST	   elevation	   myocardial	   infarction	   (NSTEMI)	   is	   made,	  although	   NSTEMI	   can	   occur	   with	   no	   ECG	   abnormalities.	   	   Such	   patients	   have	  suffered	  damage	  to	  the	  heart	  but	  the	  coronary	  artery	  is	  usually	  not	  completely	  occluded,	   with	   myocardial	   necrosis	   often	   the	   consequence	   of	   microvascular	  obstruction	  due	  to	  thrombus	  embolization	  from	  the	  ruptured	  plaque	  (Abbate	  et	  al.,	  2012)	  Although	   diagnosis	   of	   STEMI	   is	   usually	   obvious	   due	   to	   typical	   ECG	   changes,	  diagnosis	  of	  both	  STEMI	  and	  NSTEMI	  requires	  evidence	  of	  myocardial	  necrosis,	  typically	   by	   elevation	   or	   serum	   troponin	   levels.	   In	   the	   absence	   of	   myocyte	  necrosis,	  patients	  are	  generally	  considered	  to	  be	  suffering	  from	  unstable	  angina.	  (Antman	  et	  al.,	  1996).	  Unstable	   angina	   increases	   the	   risk	   of	   suffering	   a	   subsequent	  MI	  with	   12%	   of	  patients	   with	   unstable	   angina	   progressing	   to	   myocardial	   infarction	   within	   2	  weeks	   (Gazes	   et	   al.,	   1973,	   Rahimtoola	   et	   al.,	   1983).	   One-­‐year	   mortality	   of	  patients	  with	   unstable	   angina	   ranges	   from	   5-­‐14%	  with	   approximately	   half	   of	  deaths	   occurring	   within	   4	   weeks	   (Rahimtoola	   et	   al.,	   1983).	   Unstable	   angina	  patients	   are	   prescribed	   aspirin,	   which	   reduces	   the	   risk	   of	   thrombosis	   by	  inhibiting	   platelet	   aggregation	   and	   decreases	   cardiac	   death	   or	   nonfatal	  MI	   by	  30-­‐51%	  (Verheugt	  et	  al.,	  1990).	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1.2.	  Role	  of	  peripheral	  blood	  components	   in	  Acute	  Coronary	  
Syndromes	  
As	  described	  above,	  the	  interaction	  between	  circulating	  blood	  and	  the	  ruptured	  plaque	  is	  central	  to	  development	  of	  ACS.	  Blood	  is	  a	  complex	  mixture	  of	  cellular	  and	   soluble	   factors,	   many	   of	   which	   play	   a	   proven	   or	   potential	   role	   in	   both	  atherogenesis	  and	  ACS.	  Below,	  I	  outline	  these	  components.	  
1.2.1.	  Platelets	  The	  first	  step	  of	  thrombus	  formation	  includes	  platelet	  adhesion,	  activation	  and	  aggregation.	  Platelet	  adhesion	  is	  triggered	  by	  exposure	  of	  plaque	  components	  to	  the	   blood.	   Upon	   platelet	   adhesion	   the	   thrombotic	   response	   is	   amplified	   and	  inflammatory	   cells	   such	   as	  monocytes	   are	   recruited	   to	   the	   site	   of	   injury.	   This	  increases	   secretion	   of	   adhesion	  molecules,	   sometimes	   leading	   to	   occlusion	   of	  the	  artery	  and	  tissue	  death.	  Due	  to	  the	  important	  role	  of	  platelets	  in	  MI	  Trip	  et	  al	  suggested	  that	  the	  use	  of	  platelet	  aggregation	  markers	  could	  be	  used	  to	  predict	  future	   coronary	   events	   in	   MI	   survivors	   (Trip	   et	   al.,	   1990).	   Preventive	  approaches	   using	   therapies	   to	   prevent	   platelet	   aggregation	   reduce	   the	   risk	   of	  sudden	   death	   or	   non-­‐fatal	   MI	   (Wada	   et	   al.,	   2010).	   Patients	   with	   angina	   have	  elevated	   circulating	   thrombin	   (Abbate	   et	   al.,	   2012)	   and	   in	   unstable	   angina	   an	  increased	   expression	   of	  monocyte	   pro-­‐coagulant	   activity	  may	   be	   the	   cause	   of	  augmented	   thrombin	   formation	   (Neri	   Serneri	   and	   Modesti,	   1991).	   Neri	   et	   al	  found	   that	   increased	  monocyte	   tissue	   factor	   activity	  was	   not	   due	   to	   coronary	  artery	  disease	  (CAD)	  but	  unstable	  angina	  as	  they	  are	  not	  detectable	  in	  the	  same	  patients	  restudied	  8-­‐12	  weeks	  later	  (Neri	  Serneri	  et	  al.,	  1997).	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1.2.2.	  Leukocytes	  Leukocytes	  are	  white	  blood	  cells	  and	  have	  many	  subsets	   including	  monocytes	  and	  macrophages.	  Total	  peripheral	   leukocyte	  count	  correlates	  with	  severity	  of	  coronary	   atherosclerosis	   and	   can	   be	   used	   as	   a	   predictor	   of	   cardiovascular	  outcome	  (Grimm	  et	  al.,	  1985).	  Endothelial	  dysfunction	  triggers	  an	  inflammatory	  response,	   attracting	   monocytes	   and	   macrophages	   to	   the	   site	   of	   injury.	  Monocytes	   are	   actively	   involved	   in	   atherosclerotic	   progression	   and	   lesions	  contain	   a	   large	   number	   of	   lipid-­‐laden	   macrophages,	   known	   as	   foam	   cells,	  derived	  from	  circulating	  monocytes	  (Shimada,	  2009).	  The	   interaction	  between	  monocytes,	   neutrophils	   and	   platelets	   leads	   to	   leukocyte	   activation	   and	   cell-­‐adhesion	  molecule	  expression,	  and	  activates	  release	  of	  enzymes	  such	  as	  Matrix	  Metalloproteinases	   (MMPs),	   which	   degrade	   the	   subendothelial	   basement	  membrane,	  leading	  to	  plaque	  rupture	  or	  thrombogenicity.	  
The	   formation	   of	   monocyte-­‐platelet	   aggregates	   is	   important	   in	   constituting	   a	  pro-­‐coagulant	   state	   in	   ACS	   patients	   (Shantsila	   and	   Lip,	   2009)	   and	   has	   been	  shown	   to	   be	   an	   early	   marker	   of	   acute	   myocardial	   infarction	   and	   to	   cause	  complications	   after	   percutaneous	   coronary	   intervention	   (PCI)	   (Shantsila	   and	  Lip,	  2009).	  
1.2.3.	  Erythrocytes	  Interplaque	   haemorrhage	   (IPH)	   is	   defined	   as	   red	   blood	   cell	   extravasation	  admixed	  with	  fibrin	  and	  platelet	  matrix	  within	  the	  plaque	  (Moreno	  et	  al.,	  2012).	  IPH	  also	  contributes	  to	  increase	  in	  plaque	  burden.	  Erythrocyte	  membranes	  are	  very	  rich	  in	  cholesterol,	  contributing	  to	  lipid	  expansion	  (Kolodgie	  et	  al.,	  2003).	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This	  may	  explain	  the	  rapid	  progression	  of	  advanced,	  high-­‐risk	  plaques,	  in	  which	  up	  to	  40%	  display	  IPH	  (Moreno	  et	  al.,	  2012).	  Red	  blood	  cell	   lysis	  releases	  free	  haemoglobin	  (Hb),	  generating	  reactive	  oxygen	  species	  (ROS)	  and	  increases	  lipid	  peroxidation	   and	   macrophage	   activation	   within	   the	   atherosclerotic	   plaque	  (Moreno	  et	  al.,	  2009).	  Plaques	  with	  IPH	  are	  associated	  with	  rapid	  progression	  of	  disease,	  recurrent	  haemorrhage,	  and	  clinical	  events	  (Takaya	  et	  al.,	  2005).	  
1.2.4.	  Plasma	  Factors	  The	  main	  role	  of	  plasma	  is	  to	  transport	  components	  of	  the	  blood	  throughout	  the	  body.	  It	  is	  55%	  of	  blood	  volume	  and	  contains	  antibodies	  and	  clotting	  factors.	  	  The	   higher	   concentrations	   of	   plasma	   tissue	   factor	   in	   unstable	   angina	   patients	  are	  related	  to	  a	  marked	  increase	  of	  thrombin	  generation,	  suggesting	  a	  key	  role	  of	  this	  glycoprotein	  in	  initiating	  coagulation	  (Abbate	  et	  al.,	  2012).	  
Fibrinogen	  is	  a	  key	  player	  in	  blood	  coagulation	  and	  there	  is	  compelling	  evidence	  indicating	   that	   raised	   plasma	   fibrinogen	   level	   is	   a	   major	   risk	   predictor	   for	  myocardial	   infarction	   and	   stroke.	   Furthermore,	   raised	   fibrinogen	   level	  predisposes	  to	  the	  development	  of	  advanced	  atherosclerotic	  plaques	  (Motterle	  et	   al.,	   2012).	   Thrombin	   interacts	  with	   fibrinogen,	   forming	   fibrin	   and	   inducing	  activation	  of	   factors	  V,	  VIII	   and	  XII	   that	   amplify	   the	   coagulation	   cascade,	   until	  clot	  formation	  and	  cross-­‐linking	  with	  factor	  XIIIa.	  Thrombin	  formed	  during	  the	  initial	   phases	   of	   coagulation	   is	   increased	   by	   a	   positive	   feedback	   loop	   and	  platelet	  activation	  (Abbate	  et	  al.,	  2012).	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1.3.	  Use	  of	  microarrays	  for	  gene	  expression	  profiling	  
Alongside	   the	   sequencing	   of	   the	   human	   genome,	   advances	   in	   microarray	  technology	  permit	   large-­‐scale	   genomic	   studies	   in	   clinical	  medicine.	   Previously	  methods	   such	   as	   northern	   blotting	   were	   used	   to	   measure	   individual	   gene	  expression,	  but	   could	  only	  examine	  a	   few	  genes	  at	  a	   time.	  Microarrays	  permit	  expression	   of	   thousands	   of	   genes	   to	   be	   quantified	   simultaneously;	   so-­‐called	  
transcriptional	  profiling.	  In	  this	  approach,	  changes	  in	  gene	  expression	  that	  occur	  normally	  or	  as	  a	  response	  to	  disease	  are	  determined	  through	  quantification	  of	  thousands	  of	   individual	   cDNAs	   in	  a	   single	   sample.	  Under	   certain	  physiological	  and	   pathologic	   conditions,	   gene	   expression	   can	   alter	   and	   this	   can	   be	  investigated	  by	  transcriptomic	  analysis	  (Burgess,	  2001).	  	  Microarrays	  consist	  of	  a	  chip	  or	  slide	  that	  contains	  thousands	  of	  antisense	  DNA	  sequences,	   which	   bind	   complimentarily	   to	   cDNA,	   which	   has	   been	   labelled	   to	  allow	   quantification	   of	   binding.	   The	   initial,	   and	   most	   important	   step	   is	   RNA	  isolation.	   Acquiring	   a	   high	   quality,	   reproducible	   concentration	   of	   RNA	   is	  essential	  for	  sensitivity	  and	  therefore	  accuracy	  of	  the	  microarray	  results.	  Lander	  
et	   al	   showed	   that	   differential	   expression	   can	   be	   detected	   between	   batches	   of	  cultured	   cells	   with	   the	   only	   difference	   being	   the	   media	   in	   which	   they	   are	  cultured	   (Lander,	   1999).	   Expression	   profiling	   of	   blood	   samples	   require	  additional	   treatment	   in	   order	   to	   remove	   globin	   mRNA	   as	   it	   can	   reduce	   the	  sensitivity	  of	  the	  hybridization	  results.	  Kits	  have	  been	  designed	  to	  stabilize	  RNA	  in	  order	  to	  increase	  sensitivity.	  If	  RNA	  levels	  are	  low	  techniques	  such	  as	  linear	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amplification	  are	  used	   to	  enhance	   the	  quantity	  of	  RNA	   to	  allow	  accurate	  gene	  expression	  profiling.	  Affymetrix	  GeneChips	  use	   a	   single	   fluorescent	   probe,	  which	   is	   attached	   to	   the	  cDNA	   through	   a	   serious	   of	   washes,	   designed	   to	   increase	   the	   intensity	   of	   the	  signal	  upon	  imaging.	  To	  further	  increase	  gene	  specificity	  they	  also	  have	  a	  unique	  design	  printed	  with	  a	  pair	  of	  probes	  for	  each	  target	  called	  a	  probe	  set,	  which	  is	  made	  of	  11-­‐22	  oligonucleotides	  and	  is	  25	  base	  pairs	  long.	  One	  is	  a	  perfect	  match	  (PM)	   probe,	   and	   the	   other	   a	   mismatch	   (MM)	   probe.	   PM	   probes	   are	  complimentary	   strands	   to	   the	   RNA	   of	   interest;	   MM	   probes	   are	   created	   by	  alteration	   of	   the	   13th	   base	   pair	   in	   the	   PM	   probe	   (Irizarry	   et	   al.,	   2003).	   The	  mismatch	   probe	   measures	   the	   level	   of	   cross	   hybridization,	   and	   so	   the	   more	  targets	   hybridized	   to	   the	   MM	   probe,	   the	   greater	   the	   error	   at	   that	   point	   and	  genes	  with	   significant	  MM	   intensities	   can	  be	   excluded	  by	  analysis	   software	   to	  provide	  a	  more	  significant	  list	  of	  genes	  that	  are	  differentially	  expressed.	  
1.3.1.Whole	  blood	  gene	  expression	  profiling	  in	  cardiovascular	  disease	  When	  investigating	  human	  disease	  researchers	  have	  used	  peripheral	  blood	  as	  a	  high	   throughput,	   non-­‐invasive	   and	   practical	   source	   of	   RNA	   that	   can	   provide	  insight	   into	   subtle	   changes	   in	   the	   body	   in	   response	   to	   disease	   as	   well	   as	  treatments	  (Taurino	  et	  al.,	  2010).	  The	   rationale	   for	   using	   peripheral	   blood	   in	   investigating	   CHD	   is	   that	   after	   a	  myocardial	   infarction	   for	   example,	   there	   is	   a	  well-­‐characterized	   inflammatory	  response	  to	  the	  event	  and	  initially,	  polymorphs	  migrate	  into	  the	  ischemic	  tissue	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Figure	  1.3.	  A	  summary	  of	  the	  microarray	  process	  RNA	   is	   isolated	   from	   control	   and	   sample	   cells,	   fluorescently	   labelled	   and	  hybridized	  into	  a	  microarray	  chip.	  The	  chip	  is	  then	  imaged	  and	  then	  normalized	  and	  analysed	  accordingly.	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followed	  by	  a	  more	  prolonged	  and	  extensive	  monocyte–macrophage	  infiltration	  (Sinnaeve	  et	  al.,	  2009).	  Taurino	  et	  al	  carried	  out	  a	  microarray	  using	  microRNA	  (miRNA)	   and	   mRNA	   extracted	   from	   whole	   blood	   of	   coronary	   artery	   disease	  patients	   before	   and	   after	   completion	   of	   cardiac	   rehabilitation	   programme	  following	   surgical	   coronary	   revascularization	   (Taurino	   et	   al.,	   2010).	   They	  identified	   several	   differentially	   expressed	   miRNA	   such	   as	   Has-­‐miR-­‐92,	   which	  modulates	  neointima	  formation	   in	  a	  rat	  model	  of	  vascular	   injury	  (Cheng	  et	  al.,	  2006).	   This	   approach	   may	   identify	   and	   can	   help	   identify	   other	   genes	   and	  pathways	   that	   play	   a	   role	   in	   the	   pathogenesis	   and	   progression	   of	   coronary	  artery	  disease	  (CAD)	  (Taurino	  et	  al.,	  2010).	  	  Sinnaeve	  et	  al	  selected	  patients	  according	  to	  their	  coronary	  artery	  disease	  index	  (CADi),	   a	   validated	   angiographical	   measure	   of	   the	   extent	   of	   coronary	  atherosclerosis	  that	  correlates	  with	  outcome	  (Sinnaeve	  et	  al.,	  2009).	  They	  found	  160	   differentially	   expressed	   genes	   involved	   in	   apoptosis,	   cell	   adhesion	   and	  inflammatory	   and	   immune	   response	   processes	   known	   to	   modulate	  atherosclerosis.	   The	   identified	   differentially	   expressed	   gene	   expression	  correlated	   with	   the	   severity	   of	   angiographically	   documented	   coronary	   artery	  atherosclerosis	  validated	  by	   in	  situ	   expression.	  This	   supports	   the	   concept	   that	  peripheral	  blood	  expression	  may	  reflect	  pathophysiology	  in	  the	  vascular	  wall.	  In	  addition	  to	  the	  studies	  in	  cardiovascular	  disease,	  whole	  blood	  gene	  expression	  profiling	  has	  identified	  specific	  gene	  expression	  signatures	  associated	  with	  the	  development	  of	  autoimmune	  type	  1	  diabetes	  (Reynier	  et	  al.,	  2010).	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1.4.	  Zebrafish	  are	  a	  useful	  tool	  for	  gene	  function	  assessment	  
The	  zebrafish	  is	  being	  increasingly	  used	  as	  a	  genetic	  model	  for	  the	  assessment	  of	   disease.	   Although	   less	   homologous	   to	   the	   human	   genome	   than	  mammalian	  models,	   its	   high	   fecundity,	   low	   maintenance	   cost	   and	   ease	   of	   genetic	  manipulation	  makes	   it	  a	  very	  good	  candidate	   for	  gene	   function	  assessment.	   In	  regards	  to	  cardiovascular	  research	  its	  greatest	  asset	  is	  optical	  clarity,	   in	  which	  organogenesis,	  cardiac	  contraction	  and	  circulation	  can	  be	  directly	  observed.	  The	  zebrafish	  embryo	  can	  survive	  and	  develop	  without	  circulation,	  as	  shown	  by	  the	  
gridlock	   mutant,	   which	   suffers	   an	   aortic	   occlusion,	   since	   the	   embryo	   can	  oxygenate	  via	  diffusion	  (Jia	  et	  al.,	  2007).	  Vascular	  development	  can	  be	  visualised	  using	   transgenics	   that	   label	   specific	   cell	   types	   (Lawson	   and	  Weinstein,	   2002,	  Asakawa	  and	  Kawakami,	  2008,	  Jin	  et	  al.,	  2005).	  
1.4.1.	  Vascular	  formation	  in	  the	  zebrafish	  Blood	  vessels	   in	   a	   zebrafish	   embryo	   are	   composed	  of	   a	   single	   endothelial	   cell	  layer	   surrounded	   by	   supporting	   mural	   cells	   (Santoro	   et	   al.,	   2009).	  Vasculogenesis	   is	   the	   primary	   process	   in	   which	   blood	   vessels	   from	   the	  coalescence	  of	  angioblasts.	  The	  second	  process,	  angiogenesis,	  is	  the	  formation	  of	  new	   vessels	   from	   pre-­‐existing	   ones.	   Lawson	   et	   al	   developed	   a	   fli1:EGFP	  transgenic	   embryo,	   in	   which	   endothelial	   cells	   express	   enhanced	   green	  fluorescent	   protein	   (GFP),	   to	   better	   visualize	   embryonic	   angiogenesis	   during	  vascularization	   of	   the	   developing	   zebrafish	   brain	   (Lawson	   and	   Weinstein,	  2002).	   At	   approximately	   24	   hours	   post	   fertilization	   (hpf),	   circulation	  commences	   and	   the	   lateral	   dorsal	   aorta	   (LDA)	   is	   formed	   (Isogai	   et	   al.,	   2001).	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The	  LDA	  helps	  supply	  cranial	  blood	  flow	  by	  forming	  serial	  connections	  with	  the	  aortic	  arches	   (Fujita	  et	   al.,	   2011).	  At	  2	  days	  post	   fertilization	   (dpf)	   the	  middle	  cerebral	   vein	   (MCV)	   in	   the	   brain	   and	   mesencephalic	   vein	   (MCeV)	   in	   the	  hindbrain	  form.	  From	  2-­‐3dpf	  the	  complex	  central	  artery	  network,	  which	  forms	  via	  sprouting	  angiogenesis,	   forms	   in	   the	  hindbrain	   (Fujita	  et	  al.,	  2011).	  1-­‐3dpf	  brain	  vascular	  formation	  can	  be	  seen	  in	  figure	  1.4.	  	  
1.4.2.	  Vascular	  Endothelial	  Growth	  Factor	  (VEGF)	  Vascular	  Endothelial	  Growth	  Factor	  (VEGF)	  is	  a	  major	  driver	  of	  vasculogenesis,	  angiogenesis	  and	  vascular	  permeability.	  It	  has	  also	  been	  implicated	  in	  vascular	  protection	  and	  maintenance	   (Zachary	  et	   al.,	   2000).	  Mammalian	  VEGFs	  bind	   to	  VEGF	  receptor	  (VEGFR)	  tyrosine	  kinases.	  VEGFA	  and	  B	  bind	  to	  VEGFR1,	  VEGFA	  and	  E	  bind	  to	  VEGFR2	  and	  VEGFC	  and	  D	  bind	  to	  VEGFR3	  (Olsson	  et	  al.,	  2006).	  	  Buchner	   et	   al	   identified	   the	   redhead	   mutant,	   which	   displays	   cerebral	  haemorrhages	  between	  2-­‐3dpf	  due	  to	  a	  mutation	  in	  the	  p21-­‐activated	  kinase	  2a	  (pak2a),	   part	   of	   the	   PAK	   family	   which	   is	   activated	   by	   VEGF	   and	   has	   been	  implicated	   in	   angiogenesis	   in	   vitro.	   Gene	   knockdown	   of	   pak2a	   resulted	   in	  normal	   vessel	   patterning	   and	   cerebral	   haemorrhaging,	   indicating	   that	   loss	   of	  
pak2a	   leads	  to	  a	  vascular	  integrity	  defect	  without	  affecting	  vascular	  patterning	  (Buchner	  et	  al.,	  2007).	  Formation	  of	   the	  vasculature	  can	  be	  abolished	  by	  VEGF	  disruption.	  Fujita	  et	  al	  treated	  embryos	  with	  SU5416,	  a	  VEGF	  inhibitor	  drug,	  and	  found	  that	  embryos	  had	   a	   disruption	   in	   the	   primordial	   hindbrain	   channel	   formation	   (Fujita	   et	   al.,	  2011).	   Conversely,	   Peterson	   et	   al	   used	   GS4012,	   a	   VEGF	   inducer,	   to	   rescue	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circulation	   in	   gridlock	   mutants,	   by	   correcting	   the	   aortic	   coarctation	   of	   the	  mutant	   (Peterson	   et	   al.,	   2004).	   Examining	   neovascularization	   in	   a	   zebrafish	  tumour	  model	   Zhao	   et	   al	   found	   the	   presence	   of	   VEGFR2	   positive	   endothelial	  cells	  during	  formation	  of	  the	  tumour	  vascular	  network	  and	  that	  treatments	  with	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Figure	  1.4.	  An	  illustration	  of	  brain	  vascular	  formation	  in	  1-­‐3dpf	  zebrafish	  The	  illustrations	  show	  brain	  vasculature	  formation	  as	  of	  1dpf	  (left	  panel),	  2dpf	  (middle	  panel)	  and	  3dpf	  (right	  panel).	  	  Abbreviations	  are	  as	  follows:	  ACV	  Anterior	  cardinal	  vein,	  BA	  Basilar	  artery,	  CCV	  Common	   cardinal	   vein,	  CtA	   Central	   artery,	  DLV	   Dorsal	   longitudinal	   vein,	   IOC	  Inner	   optic	   circle,	  LDA	   Lateral	   dorsal	   artery,	  MCeV	   Mesencephalic	   vein,	  MCV	  Middle	   cerebral	   vein,	  MtA	   Mesencephalic	   artery,	  NCA	   Nasal	   cilary	   artery,	  OV	  Optic	  vein,	  PCeV	  Posterior	   (caudal)	   cardinal	  vein,	  PHBC	  Primordial	  hindbrain	  channel,	  PHS	  Primary	  head	  sinus,	  PMBC	   Primordial	   hindbrain	   channel,	   PPrA	  Primitive	  prosencephalic	  artery,	  PrA	  Prosencephalic	  artery,	  VA	  Ventral	  aorta.	  	  Adapted	  from	  Isogai	  et	  al.	  	  Adapted	  and	  Reprinted	  from	  The	  vascular	  anatomy	  of	  the	  developing	  zebrafish:	  an	   atlas	   of	   embryonic	   and	   early	   larval	   development.	   Dev	   Biol,	   230,	   278-­‐301,	  with	  permission	  from	  Elsevier	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SU5416	   significantly	   inhibited	   vascularization	   and	   growth	   of	   melanoma	  xenografts,	  but	  had	  little	  effect	  on	  normal	  vessels	  (Zhao	  et	  al.,	  2011).	  
1.4.3.	  Vascular	  integrity	  Blood	  vessels	  consist	  of	   two	  main	  cell	   types,	  endothelial	  cells	   lining	   the	  vessel	  and	  peri-­‐endothelial	   cells.	  EC	  survival	   is	  promoted	  by	  a	  number	  of	   factors	   the	  most	   prominent	   being	   VEGF.	   ECs	   are	   linked	   together	   by	   adherens	   junctions,	  vascular	   endothelial	   (VE)-­‐cadherin	   that	   interacts	   with	   catenins,	   namely	   beta-­‐catenin,	   as	   a	   binding	   partner	   to	   ensure	   vessel	   integrity.	   The	   zebrafish	   VE-­‐
cadherin	  gene	   is	   specifically	   expressed	   in	   the	   vascular	   endothelial	   cell	   lineage	  beginning	   with	   the	   differentiation	   and	   migration	   of	   angioblasts	   and	   persists	  throughout	   vasculogenesis,	   angiogenesis,	   and	   endocardium	   development	  (Larson	   et	   al.,	   2004).	   In	   addition,	   an	   elegant	   study	   on	   lumen	   formation	   in	  zebrafish	   demonstrated	   the	   presence	   of	   β-­‐catenin,	   a	   binding	   partner	   of	   VE-­‐cadherin,	  in	  EC–EC	  contacts	  (Jin	  et	  al.,	  2005).	  	  
Several	   signalling	   mechanisms	   are	   involved	   in	   vascular	   formation.	   Notch	  signalling	   plays	   an	   important	   role	   in	   blood	   vessel	   development	   as	   well	   as	  arterial-­‐venous	  formation,	  inducing	  an	  arterial	  specific	  fate.	  Disruption	  in	  Notch	  signalling	   in	   the	   zebrafish	   mutant	   mindbomb	   (mib)	   induces	   severe	   cerebral	  haemorrhage	  as	  well	  as	  the	  reduction	  of	  expression	  of	  venous	  specific	  markers	  (Lawson	   et	   al.,	   2001).	   Using	   Tg(fli1:EGFP);mib	  mutant	   embryos	   Lawson	   et	   al	  found	   that	   the	   severe	   haemorrhaging	   was	   due	   to	   the	   disorganization	   of	   the	  structure	  of	  the	  hindbrain	  (Lawson	  and	  Weinstein,	  2002).	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1.5.	  Genetic	  manipulation	  in	  zebrafish	  
One	   of	   the	   advantages	   of	   zebrafish	   is	   ease	   of	   genetic	   manipulation.	   Notably,	  transgenic	   embryos	   can	   greatly	   help	   in	   delineating	   the	   effects	   of	   gene	  manipulation	  on	  organogenesis	  and	  development,	  while	  morpholino	  antisense	  allows	  rapid	  and	  efficient	  temporary	  knockdown	  of	  gene	  function.	  	  
1.5.1.	  Transgenesis	  Transgenic	  embryos	  have	  been	  utilised	   for	  visualisation	  of	   gene	  expression	   in	  different	  cell	  types	  within	  the	  embryo.	  In	  these	  embryos	  the	  promoter	  region	  of	  the	  gene	  of	  interest	  is	  used	  to	  drive	  expression	  of	  an	  exogenous	  protein,	  such	  as	  green	  fluorescent	  protein.	  Double	  transgenesis	  or	  the	  crossing	  of	  two	  transgenic	  lines	  allows	  simultaneous	  visualisation	  of	  multiple	  components.	  Although	  creating	  a	  stable	  transgenic	  line	  can	  be	  time	  consuming,	  it	  is	  extremely	  useful	  for	  investigations	  in	  adult	  fish	  as	  well	  as	  during	  embryonic	  development.	  	  Targeted	   vascular	   reporter	   expression	   was	   established	   by	   Lawson	   et	   al	   by	  expressing	  GFP	  in	   friend	  leukaemia	  integration	  1	  (fli-­‐1)	  positive	  cells	  which	  are	  specific	  to	  endothelial	  cells	  (Lawson	  and	  Weinstein,	  2002).	  Long	  et	  al	  used	  the	  
GATA-­‐1	   promoter	   (an	   erythroid-­‐	   specific	   transcription	   factor)	   to	   produce	   a	  transgenic	  (Long	  et	  al.,	  1997)	  that	  labels	  erythrocytes	  with	  dsRED.	  
1.5.2.	  Use	  of	  antisense	  oligonucleotides	  for	  gene	  knockdown	  Use	  of	  antisense	  oligonucleotides	  for	  gene	  knockdown	  was	  developed	  by	  Izant	  and	  Weintraub	  in	  1984	  and	  first	  used	  on	  xenopus	  oocytes	  (Izant	  and	  Weintraub,	  1984).	   Morpholino	   antisense	   oligonucleotides	   are	   synthetic	   ~25	   base	   pair	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oligos	   designed	   to	   block	   translation	   by	   targeting	   the	   5’UTR	  or	  modifying	   pre-­‐mRNA	   splicing	   by	   targeting	   splice	   junctions	   and	   preventing	   expression	   of	   the	  gene	  of	  interest.	  Morpholinos	  are	  injected	  at	  the	  1-­‐4	  cell	  stage	  for	  optimum	  gene	  function	   knockdown.	   Morpholinos	   are	   similar	   to	   DNA	   and	   RNA	   nucleotides	  however	   have	   a	  morphine	   ring	   as	   opposed	   to	   a	   ribose	   ring.	   They	   also	   do	   not	  carry	   a	   negatively	   charged	   backbone	   and	   are	   therefore	   less	   likely	   to	   interact	  non-­‐specifically	   (Eisen	  and	  Smith,	  2008).	  Quantification	  of	   the	  effectiveness	  of	  the	   knockdown	   can	   be	   carried	   out	   by	   western	   blotting	   for	   the	   translational	  blocking	   morpholino	   and	   RT-­‐PCR	   for	   splice	   blocking	   morpholinos.	   	   	   A	  morpholino	  oligo	  is	  different	  from	  natural	  nucleic	  acids,	  with	  morpholine	  rings	  replacing	   the	   ribose	   or	   deoxyribose	   sugar	   moieties	   and	   non-­‐ionic	  phosphorodiamidate	   linkages	   replacing	   the	   anionic	   phosphates	   of	   DNA	   and	  RNA.	   Each	  morpholine	   ring	   suitably	   positions	   one	   of	   the	   standard	  DNA	  bases	  (A,C,G,T)	   for	   pairing,	   so	   that	   a	   25-­‐base	   morpholino	   oligo	   strongly	   and	  specifically	  binds	   to	   its	   complementary	  25-­‐base	   target	   site	   in	  a	   strand	  of	  RNA	  via	  Watson-­‐Crick	  pairing.	  Because	   the	  uncharged	  backbone	  of	   the	  morpholino	  oligo	  is	  not	  recognized	  by	  enzymes	  or	  signalling	  proteins,	  it	  is	  not	  degraded	  by	  nucleases	  and	  does	  not	  trigger	  an	  innate	  immune	  response	  through	  the	  Toll-­‐like	  receptors	   (Eisen	   and	   Smith,	   2008).	   This	   avoids	   the	   problems	   of	   oligo	  degradation,	   inflammation	   and	   interferon	   induction,	   which	   are	   commonly	  encountered	  with	  other	  gene	  knockdown	  reagents	   (Summerton,	  2007).	   	  Table	  1.1.	  outlines	  the	  main	  advantages	  and	  disadvantages	  of	  morpholino	  technology.	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Table	  1.	  1.	  Advantages	  and	  disadvantages	  of	  morpholino	  technology	  
	   	  
Advantages	   Disadvantages	  
• Resistant	  to	  nucleases	  and	  
therefore	  stable	  (Eisen	  and	  
Smith,	  2008)	  
• Can	  inhibit	  both	  zygotic	  and	  
maternal	  transcripts	  (Nasevicius	  
and	  Ekker,	  2000)	  
• No	  negatively	  charged	  
backbone	  therefore	  less	  likely	  
to	  interact	  non-­‐specifically	  
(Eisen	  and	  Smith,	  2008)	  
• Rapid	  phenotype	  observation	  	  
• Ease	  of	  use	  
• Off-­‐target	  effects	  (Nasevicius	  
and	  Ekker,	  2000)	  
• Difficult	  to	  quantify	  
knockdown	  
• Effect	  wears	  off	  in	  3-­‐5dpf	  (Bill	  
et	  al.,	  2009)	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1.6.	  Hypotheses	  
• I	   hypothesise	   that	   peripheral	   blood	   gene	   expression	   will	   differ	   in	  patients	   who	   present	   with	   a	   myocardial	   infarction	   compared	   to	   those	  presenting	  with	  unstable	  angina.	  
• I	   further	   hypothesise	   that	   examination	   of	   the	   phenotype	   of	   zebrafish	  embryos	  with	  induced	  loss-­‐of-­‐function	  of	  the	  candidates	  identified	  above	  will	  provide	  novel	  data	  on	  their	  role	  in	  cardiovascular	  development.	  
1.7.	  Aims	  
1. Characterise	  differentially	  expressed	  genes	  in	  whole	  blood	  following	  ACS	  2. Assess	  function	  of	  differentially	  expressed	  genes	  using	  a	  zebrafish	  model	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Chapter	  2:	  Materials	  and	  Methods	  
	   	  
	   Sara	  Solaymani-­‐Kohal	  46	  
2.1.Patients	  and	  Blood	  Collection	  
2.1.1.	  Recruitment	  criteria	  Patients	   were	   recruited	   by	   the	   Sheffield	   NIHR	   Cardiovascular	   Biomedical	  Research	  Unit,	  which	  sought	  to	  establish	  a	  resource	  of	  well	  phenotyped	  patients	  with	   a	   range	   of	   cardiovascular	   diseases	   for	   basic	   science	   and	   translational	  research.	   Patients	  were	   approached	   and	   consented	   by	   research	   nurses	   under	  ethical	  approval	  granted	  to	  Dr	  Allison	  Morton.	  All	  patients	  recruited	  to	  the	  study	  detailed	   in	   this	   thesis	   presented	   to	   the	   Northern	   General	   Hospital	   (NGH)	   in	  Sheffield	  with	  acute	  onset	  chest	  pain	  of	  cardiac	  nature,	  without	  evidence	  of	  non-­‐cardiac	   causes	   for	   the	   pain	   (such	   as	   pulmonary	   embolism	   or	   infection,	  musculoskeletal	   features,	   etc).	   Inclusion	   criterion	   for	   subjects	   were;	   acute	  cardiac	   sounding	   chest	   pain,	   <48	   hours	   from	   onset	   of	   symptoms.	   Exclusion	  criteria	  were;	  age	  <18,	  years	  old,	  serious	  co-­‐morbidities,	  end	  stage	  renal	  disease	  requiring	  renal	  replacement	  therapy,	  pregnancy.	  
2.1.2.	  Patient	  demographics	  50	   patients	   with	   typical	   ACS	   symptoms	   were	   recruited	   from	   The	   Northern	  General	  Hospital	  (NGH)	  Sheffield	  from	  April	  2009.	  	  Due	  to	  the	  on	  going	  and	  prospective	  nature	  of	  this	  study,	  19	  patients	  with	  data	  from	  each	  time	  point	  up	  to	  3	  months	  have	  currently	  been	  analysed.	  This	  is	  the	  cohort,	  which	  will	  be	  described	  throughout	  the	  rest	  of	  this	  thesis.	  We	  recruited	  five	  patients	  with	  UA,	  ten	  with	  NSTEMI	  and	  four	  with	  STEMI.	  No	  patients	  died	  during	  the	  follow-­‐up.	  Of	  these	  patients,	  fifteen	  were	  men	  and	  four	  were	  women.	  Three	  were	  aged	  between	  40-­‐50	  years	  old,	  four	  were	  aged	  between	  51-­‐60	  years	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old,	  10	  were	  aged	  between	  61-­‐70	  years	  old	  and	  two	  were	  aged	  between	  71-­‐80	  years	  old.	  Fourteen	  had	  a	  positive	   family	  history	  of	  CAD	  and	  5	  had	  a	  negative	  family	  history	  of	  CAD,	  which	  was	  defined	  as	  one	  or	  more	   first	  degree	   relative	  affected	   by	   CAD.	   Four	   were	   current	   smokers,	   nine	   were	   ex	   smokers	   and	   six	  were	   non-­‐smokers.	   Nine	   patients	   did	   not	   suffer	   from	   diabetes,	   six	   patients	  suffered	   from	   impaired	   glucose	   tolerance,	   two	   suffered	   from	   non-­‐insulin	  dependent	  diabetes	  mellitus	  and	  two	  suffered	  from	  insulin	  dependent	  diabetes	  mellitus.	  All	  participants	  were	  of	  white	  British	  ethnicity.	  	  Further	  details	  can	  be	  found	  in	  appendix	  1.	  	  	  
2.1.3.	  Blood	  collection	  Blood	  was	  collected	  from	  146	  donors.	  Blood	  samples	  were	  frozen	  at	  minus	  20°C	  until	  transported.	  	  RNA	  was	  isolated	  within	  a	  week	  and	  kept	  at	  minus	  80°C	  after	  extraction.	   RNA	   quality	   was	   assessed	   by	   examining	   UV	   absorbance	   ratios	   of	  260/280	  and	  260/230	  using	  a	  NanoDrop®	  ND-­‐1000	  UV-­‐Vis	  Spectrophotometer	  (Labtech,	  East	  Sussex,	  UK).	  
2.2.	  RNA	  extraction	  from	  human	  blood	  	  
2.2.1.	  Tempus™	  Blood	  RNA	  Tube	  Protocol	   was	   carried	   out	   as	   described	   by	   the	   Tempus™	   Blood	   RNA	   Tube	  protocol	   by	   Applied	   Biosystems.	   3mL	   of	   blood	   was	   drawn	   directly	   into	   a	  Tempus	   Blood	   RNA	   Tube.	   Immediately	   after	   the	   Tempus	   tube	   was	   filled,	   the	  blood	   was	   stabilised	   by	   vortexing	   for	   20	   seconds	   to	   ensure	   that	   the	   Applied	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Biosystems	   Stabilising	   Reagent	   made	   uniform	   contact	   with	   the	   sample.	   The	  samples	  were	   kept	   at	  minus	   20°C	   and	   transported	   in	   dry	   ice	   containers.	   The	  samples	  were	  thawed	  in	  the	  Tempus	  tube	  at	  room	  temperature	  (18	  to	  25	  °C)	  for	  approximately	  20	  minutes.	  The	   contents	  were	  poured	   into	   a	   clean	  50mL	   tube	  making	   sure	   that	   all	   the	   contents	   were	   transferred.	   1✕	   phosphate-­‐buffered	  saline	  (PBS;	  Ca2+/Mg2+-­‐free)	  was	  added	  to	  the	  transferred	  blood	  to	  bring	  the	  total	   volume	   to	   12mL.	   The	   tube	  was	   then	   vortexed	   vigorously	   for	   at	   least	   30	  seconds	   to	   ensure	   proper	   mixing	   of	   the	   contents.	   The	   sample	   was	   then	  centrifuged	  at	  4	   °C	  at	  3,000	  x	  g	  relative	   centrifugal	   force	   (rcf)	   for	  30	  minutes.	  The	   supernatant	  was	   carefully	   poured	   off	   into	   a	   bleach	   bucket.	   The	   tube	  was	  inverted	  on	  absorbent	  paper	  for	  2	  minutes.	  The	  remaining	  drops	  of	  liquid	  were	  cleared	  off	  the	  rim	  of	  the	  tube	  with	  clean	  absorbent	  paper	  and	  the	  inside	  of	  the	  tube	   was	   cleaned	   with	   medical	   tissue	   wrapped	   around	   a	   pipette	   tip,	   treated	  with	   RNase	   Zap	   (Ambion,	   Warrington,	   UK).	   400μL	   of	   RNA	   Purification	   Re-­‐suspension	  Solution	  was	  added	  into	  the	  tube,	  and	  the	  sample	  vortexed	  briefly	  to	  re-­‐suspend	   the	   RNA	   pellet.	   The	   re-­‐suspended	   RNA	  was	   kept	   on	   ice.	   The	   RNA	  purification	   filters	   were	   pre-­‐wet	   by	   adding	   100μL	   of	   RNA	   Purification	   Wash	  Solution	  1	  into	  the	  purification	  filter	  and	  then	  left	  to	  stand	  for	  1	  minute.	  The	  re-­‐suspended	  RNA	  was	  transferred	  from	  the	  50	  mL	  tube	  into	  the	  purification	  filter,	  and	  then	  centrifuged	  at	  4	  °C	  at	  3,000	  x	  g	  (rcf)	  for	  30	  sec.	  The	  flow-­‐through	  was	  discarded	  and	  500μL	  of	  RNA	  Purification	  Wash	  Solution	  1	  was	  added	  onto	  the	  purification	  filter,	  then	  centrifuged	  at	  4	  °C	  at	  3,000	  x	  g	  (rcf)	  for	  30	  sec.	  The	  flow-­‐through	   was	   discarded	   and	   500μL	   of	   RNA	   Purification	   Wash	   Solution	   2	   was	  added	  onto	  the	  purification	  filter,	  then	  centrifuged	  at	  4	  °C	  at	  3,000	  x	  g	  (rcf)	  for	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30	   sec.	   The	   flow-­‐through	   was	   discarded	   and	   the	   sample	   centrifuged	   for	   an	  additional	  minute	  to	  dry	  the	  membrane.	  The	  purification	  filter	  was	  transferred	  to	  a	  new	  collection	  tube	  and	  labelled.	  100μL	  of	  Nucleic	  Acid	  Purification	  Elution	  Solution	  was	  added	  into	  the	  purification	  filter	  and	  the	  tube	  incubated	  in	  a	  heat	  block	  for	  2	  minutes	  at	  a	  temperature	  of	  70°C,	  then	  centrifuged	  for	  30	  seconds	  at	  3,000	   x	  g	  (rcf).	   The	   collected	  RNA	  was	   eluted	  back	   into	   the	  purification	   filter,	  and	  then	  centrifuged	  for	  2	  minutes	  at	  3,000	  x	  g	  (rcf).	  The	  purification	  filter	  was	  discarded	  and	  90μL	  of	   the	  RNA	  was	   transferred	   to	  a	   labelled	  cryovial	  and	   the	  remaining	  RNA	  was	  stored	  at	  minus	  80°C	  for	  long-­‐term	  storage.	  	  	  
2.3.	  RNA	  treatment	  
2.3.1.	  	  Using	  GLOBINclear™	  to	  deplete	  haemoglobin	  RNA	  Protocol	  was	  carried	  out	  as	  described	  by	  the	  GLOBINclear™	  protocol	  (Ambion,	  Warrington,	  UK).	  Before	  beginning	   the	   experiment	   a	  dry	   incubator	  was	   set	   to	  50°C.	  2X	  Hybridization	  Buffer	  and	  the	  Streptavidin	  Bead	  Buffer	  were	  warmed	  to	  50°C	   for	   at	   least	  15	  min	  before	   starting	   the	  procedure,	  making	   sure	   to	   vortex	  well	   before	   use.	   30μL	   of	   Streptavidin	   Magnetic	   Beads	   were	   used	   for	   each	  sample.	  The	  tube	  of	   the	  Streptavidin	  Magnetic	  Beads	  was	  vortexed	  to	  suspend	  the	   settled	   beads,	   and	   the	   volume	   needed	   transferred	   into	   a	   1.5mL	   non-­‐stick	  tube	  provided	  with	  the	  kit.	  Up	  to	  20	  reactions	  can	  be	  processed	  in	  a	  single	  tube.	  The	  tube	  was	  briefly	  centrifuged	  (<2	  sec)	  at	  low	  speed	  (<1000	  x	  g)	  to	  collect	  the	  mixture	  at	  the	  bottom	  of	  the	  tube.	  The	  tube	  was	  then	  placed	  on	  a	  magnetic	  stand	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to	  capture	   the	  Streptavidin	  Magnetic	  Beads.	  The	   tube	  was	   left	   in	   the	  magnetic	  stand	  until	  the	  mixture	  became	  transparent	  (~3–5	  min),	  indicating	  that	  capture	  was	   complete.	  The	   capture	   time	  will	   depend	  on	   the	  magnetic	   stand	  used.	  The	  supernatant	   was	   carefully	   aspirated	   using	   a	   pipette	   without	   disturbing	   the	  Streptavidin	   Magnetic	   Beads.	   The	   supernatant	   was	   discarded,	   and	   the	   tube	  removed	   from	   the	  magnetic	   stand.	   Streptavidin	  Bead	  Buffer	  was	  added	   to	   the	  Streptavidin	   Magnetic	   Beads.	   The	   beads	   were	   vortexed	   vigorously	   until	  resuspended.	  The	  prepared	  Streptavidin	  Magnetic	  Beads	  were	  kept	  at	  50°C,	  the	  beads	   should	   remain	   at	   50°C	   for	   at	   least	   15	   min	   before	   they	   are	   used	   in	  additional	  steps.	  	  1–10μg	  of	  human	  whole	  blood	  total	  RNA	  was	  added	  to	  1μL	  of	  Capture	   Oligo	   Mix	   in	   a	   1.5mL	   non-­‐stick	   tube.	   15μL	   of	   50°C	   2X	   Hybridization	  Buffer	   was	   added	   to	   the	   sample	   and	   vortexed	   briefly	   to	   mix	   and	   centrifuged	  briefly	  at	  low	  speed	  to	  collect	  the	  contents	  in	  the	  bottom	  of	  the	  tube.	  The	  sample	  was	   placed	   in	   a	   pre-­‐warmed	  50°C	   incubator	  which	   allows	   the	  Globin	   Capture	  Oligo	  Mix	  to	  hybridize	  to	  the	  globin	  mRNA	  for	  15	  min.	  The	  previously	  prepared	  Steptavidin	   Magnetic	   Beads	   were	   removed	   from	   the	   50°C	   incubator,	   and	  resuspended	  by	  gentle	  vortexing.	  The	  sample	  was	  then	  briefly	  centrifuged	  (<2	  sec)	  at	   low	  speed	  (<1000	  x	  g)	  to	  collect	  the	  mixture	  at	  the	  bottom	  of	  the	  tube.	  30μL	  of	  prepared	  Streptavidin	  Magnetic	  Beads	  was	  added	  to	  each	  RNA	  sample.	  The	   RNA	   bead	   mixture	   was	   placed	   at	   50°C	   and	   incubated	   for	   30	   min.	   The	  sample	   was	   removed	   from	   the	   incubator,	   and	   vortexed	   briefly	   to	   mix.	   The	  sample	  was	  then	  centrifuged	  briefly	  at	   low	  speed	  to	  collect	  the	  contents	  in	  the	  bottom	   of	   the	   tube.	   The	   Streptavidin	   Magnetic	   Beads	   were	   captured	   on	   a	  magnetic	   stand.	   The	   tube	   was	   left	   on	   the	   magnetic	   stand	   until	   the	   mixture	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became	  transparent	  (~3–5	  min),	   indicating	  that	  capture	   is	  complete.	  100μL	  of	  pre-­‐prepared	  RNA	  Binding	  Buffer	  was	  added	  to	  each	  enriched	  RNA	  sample.	  The	  Bead	  Resuspension	  Mix	  was	  vortexed	  and	  20μL	  immediately	  dispensed	  to	  each	  sample.	  The	  sample	  was	  vigorously	  vortexed	  for	  10	  sec	  to	  fully	  mix	  the	  reagents,	  and	   to	   allow	   the	   RNA	   Binding	   Beads	   to	   bind	   the	   RNA.	   The	   sample	   was	   then	  briefly	  centrifuged	  (<2	  sec)	  at	   low	  speed	  (<1000	  x	  g)	   to	  collect	   the	  mixture	  at	  the	  bottom	  of	   the	   tube.	  The	  RNA	  Binding	  Beads	  were	   captured	  by	  placing	   the	  tube	   on	   a	   magnetic	   stand.	   The	   tube	   was	   left	   in	   the	   magnetic	   stand	   until	   the	  mixture	  became	  transparent	  (~3–5	  min),	  indicating	  that	  capture	  was	  complete.	  The	  supernatant	  was	  carefully	  aspirated	  using	  a	  pipette	  without	  disturbing	  the	  RNA	  Binding	  Beads,	  discarding	  the	  supernatant.	  200μL	  RNA	  Wash	  Solution	  was	  added	   to	   each	   sample	   removed	   from	   the	  magnetic	   stand	   and	   vortexed	   for	   10	  sec.	   The	   RNA	   Binding	   Beads	   may	   not	   fully	   disperse	   during	   this	   step;	   this	   is	  expected,	   and	   will	   not	   affect	   RNA	   purity	   or	   yield.	   The	   sample	   was	   briefly	  centrifuged	   (<2	   sec)	   at	   low	   speed	   (<1000	   x	   g)	   to	   collect	   the	   mixture	   at	   the	  bottom	  of	  the	  tube.	  The	  RNA	  Binding	  Beads	  were	  captured	  in	  a	  magnetic	  stand	  as	  in	  the	  previous	  magnetic	  bead	  capture	  steps	  and	  carefully	  aspirated	  with	  the	  supernatant	   discarded.	   Remove	   the	   tube	   from	   the	  magnetic	   stand	   and	   briefly	  centrifuge	  the	  tube	  as	  in	  previous	  steps	  and	  place	  it	  back	  on	  the	  magnetic	  stand.	  Any	  liquid	  in	  the	  tube	  was	  removed	  with	  a	  small-­‐bore	  pipette	  tip.	  The	  tube	  was	  removed	  from	  the	  magnetic	  stand	  and	  the	  beads	  were	  allowed	  to	  air-­‐dry	  for	  5	  minutes	  with	  the	  caps	  left	  open.	  30μL	  of	  pre-­‐warmed	  (58°C)	  Elution	  Buffer	  was	  added	   to	   each	   sample	   and	   vortexed	   vigorously	   for	   ~10	   sec	   to	   thoroughly	   re-­‐suspend	  the	  RNA	  Binding	  Beads.	  The	  mixture	  was	  then	  incubated	  at	  58°C	  for	  5	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minutes.	   The	   sample	   was	   vortexed	   vigorously	   for	   ~10	   sec	   to	   thoroughly	   re-­‐suspend	   the	   RNA	   Binding	   Beads	   and	   centrifuged	   briefly	   at	   low	   speed	   as	   in	  previous	  steps	  to	  collect	  the	  mixture	  at	  the	  bottom	  of	  the	  tube.	  The	  RNA	  Binding	  Beads	   were	   captured	   in	   a	   magnetic	   stand	   as	   in	   the	   previous	   magnetic	   bead	  capture	  steps.	  The	  supernatant	  containing	  the	  RNA	  was	  collected	  into	  a	  1.5mL	  Non-­‐stick	  tube	  and	  stored	  at	  minus	  20°C.	  
2.3.2.	  Agilent	  Bioanalyzer™	  Assessment	  The	  Agilent	  2100	  Bioanalyzer™	  used	  in	  conjunction	  with	  the	  Agilent	  6000	  Nano	  Kit™	   assessed	   the	   quality,	   quantity	   and	   integrity	   of	   extracted	   and	  GLOBINcleared	  mRNA.	  This	  assessment	  was	  used	  as	  a	  screening	  tool	  to	  prevent	  badly	  degraded	  samples	  continuing	  to	  Microarray.	  The	   Agilent	   2100	   Bioanalyzer™	   uses	   Lab-­‐on-­‐a-­‐chip	   technology	   to	   run	   micro-­‐capillary	   electrophoresis.	   This	   is	   similar	   to	   using	   standard	   agarose	   gel	   and	  ethidium	   bromide	   capillary	   electrophoresis	   but	   on	   a	   much	   smaller	   scale.	  Importantly,	  as	  the	  samples	  after	  GLOBINclear™	  are	  only	  approximately	  30µL	  in	  volume,	   this	   technique	   requires	   only	   1µL	   for	   assessment.	   The	   additional	  information	  the	  Bioanalyzer	  provides	  is	  a	  RNA	  Integrity	  Number	  (RIN).	  A	  RIN	  is	  achieved	   based	   on	   comparisons	   made	   across	   several	   regions	   of	   the	   whole	  electropherogram	   trace	   rather	   than	   18s	   and	   28s	   peaks	   alone.	   A	   RIN	   is	   a	  quantitative	   assessment	   of	   RNA	   integrity	   that	   allows	   us	   to	   compare	   between	  data	  sets.	  It	  can	  therefore	  provide	  a	  numerical	  benchmark	  for	  samples	  that	  can	  continue	   into	   further	  processing.	  A	  RIN	   less	   than	  7	   indicates	   samples	   that	   are	  badly	   degraded	   or	   contaminated	   and	   these	   samples	   do	   not	   continue	   to	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Microarray.	   	   As	   the	   extraction	   protocol	   binds	   all	   RNA	   non-­‐specifically	   to	   the	  filter,	  there	  are	  always	  small	  amounts	  of	  small	  RNA	  such	  as	  microRNA	  present	  in	  the	  samples.	  These	  are	  not	  contaminants	  and	  will	  not	  be	  detected	  at	  array	  as	  the	  probes	  are	  only	  designed	  to	  bind	  to	  mRNAs.	   	  All	  reagents	  described	  in	  this	  protocol	  are	  provided	  with	  the	  Agilent	  6000	  Nano	  Kit™.	  The	  gel	  for	  the	  analyser	  was	  prepared	  by	   spinning	  550µl	  of	  RNA	  6000	  Nano	  gel	  matrix	   in	  a	   spin	   filter	  (provided)	  at	  1500g	  for	  10	  minutes	  at	  room	  temperature	  (RT).	  1µl	  of	  RNA	  6000	  Nano	   Dye	   concentrate	  was	   added	   to	   65µl	   of	   the	   filtered	   gel	   in	   an	   RNase-­‐free	  microfuge	   tube	   forming	   a	   gel-­‐dye	   mix.	   The	   solution	   was	   vortexed	   well	   and	  centrifuged	  at	  13000g	  for	  10	  minutes	  at	  room	  temperature.	  	  9µl	  of	  this	  gel-­‐dye	  mix	   was	   pipetted	   onto	   the	   chip	   and	   put	   under	   pressure	   via	   a	   syringe	   and	  plunger.	  The	  plunger	  was	  pushed	  until	  held	  by	  the	  clip	  and	   left	   in	  position	   for	  exactly	  30sec.	  The	  clip	  was	  released	  and	  timed	  for	  5	  seconds;	  the	  plunger	  was	  then	   gently	   moved	   back	   to	   its	   original	   position.	   9µl	   of	   gel-­‐dye	   mix	   was	   then	  added	  to	  the	  two	  wells	  marked	  G.	  5µl	  of	  RNA	  6000	  Nano	  Marker	  was	  added	  to	  each	   sample	  well	   (up	   to	  12	   sample	  wells)	   and	  also	   in	   the	  well	  marked	  by	   the	  ladder	   symbol.	   1	   µL	   of	   Ladder	   was	   added	   to	   the	   well	   marked	   by	   the	   ladder	  symbol.	   1µl	   of	   sample	  was	   added	   to	   each	  of	   the	  wells.	   1µl	   of	  RNA	  6000	  Nano	  Marker	   was	   added	   to	   each	   unused	   well.	   The	   chip	   was	   vortexed	   using	   the	  adapter	  provided	  for	  the	  IKA	  vortexer	  for	  1	  min	  at	  2400rpm.	  After	  completion	  the	  chip	  was	  run	  in	  the	  Bioanalyzer	  within	  5	  minutes.	  mRNA	  samples	  achieving	  a	  RIN≥7	  progressed	  to	  amplification	  and	  labelling.	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2.3.3	  Linear	  Amplification	  and	  labelling	  The	   Affymetrix	   GeneChip®	   3’	   IVT	   Express	   Kit	   was	   used	   to	   amplify	   and	   label	  RNA	  samples	  before	  hybridising	  to	  Microarray	  chips.	  For	  input	  samples	  of	  RNA	  50-­‐500ng,	   a	   complimentary	   DNA	   strand	   is	   synthesized	   using	   an	   oligo(dT)	  primer	  with	   a	   T7	   promoter	   attached.	   A	   second	   complimentary	  DNA	   strand	   is	  synthesized	   from	   this	   to	   produce	   double	   stranded	   cDNA	   (completing	   the	   two	  reverse	   transcription	  stages).	  Using	  T7	  RNA	  polymerase,	  which	  recognises	   the	  T7	   promoter,	   the	   cDNA	   is	   amplified	   whilst	   simultaneously	   incorporating	   a	  Biotinylated	   nucleotide	   into	   the	   sequence	   (the	   in	   vitro	   transcription	   step).	  Labelled	   aRNA	   (amplifiedRNA)	   is	   gained	   as	   output.	   It	   is	   this	   anti-­‐sense	   aRNA	  that	  will	  hybridize	  to	  the	  array.	  Exogenous	  Poly-­‐A	  control	  genes	  are	  added	  at	  an	  early	   stage	   of	   this	   protocol	   and	   are	   amplified	   and	   labelled	   alongside	   the	  RNA	  sample.	  Analysis	  of	  the	  hybridisation	  intensities	  of	  the	  poly-­‐A	  controls	  enables	  quantification	   of	   the	   success	   of	   the	   labelling	   process.	   	   This	   protocol	   required	  mRNA	   to	   have	   a	   starting	   quantity	   of	   100ng	   in	   3µL	   of	   eluate.	   Some	   samples	  however	  despite	  satisfactory	  RINs	  had	  a	  lower	  concentration	  than	  the	  required	  33µL.	   A	   protocol	   was	   included	  with	   the	   GLOBINclear	   for	  mRNA	   precipitation	  and	   concentration;	   however	   this	   involved	   another	   interaction	  with	   the	  mRNA	  and	   could	   have	   stimulated	   more	   degradation.	   The	   Eppendorf	   vaccufuge	  concentrator	  was	  used	  instead	  to	  remove	  some	  of	  the	  supernatant.	  Running	  the	  machine	   for	   7.5	   minutes	   removed	   approximately	   4µL	   of	   supernatant	   and	  concentrated	  most	  of	  the	  poorer	  samples	  to	  acceptable	  levels.	  Smaller	  volumes	  of	   samples	   with	   a	   higher	   concentration	   were	   aliquoted	   and	   brought	   up	   to	  100ng/3µL	  with	  nuclease-­‐free	  water.	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2.3.4	  Linear	  IVT	  
2.3.4.1.	   Assembling	   the	   first-­‐strand	   master	   mix	   (to	   synthesize	   the	   first-­‐strand	  
cDNA)	  For	   a	   single	   reaction,	   4µL	   of	   First-­‐Strand	   Buffer	   Mix	   and	   1µL	   First-­‐Strand	  Enzyme	  Mix	  were	  mixed	  to	  create	  the	  First-­‐Strand	  Master	  Mix.	  	  5µL	  of	  the	  First-­‐Strand	  Master	  Mix	  was	  added	   to	  each	  sample/Poly-­‐A	  mix	  and	   incubated	   for	  2	  hours	  at	  42°C	  in	  a	  PCR	  thermal	  cylinder.	  	  
2.3.4.2	   Assembling	   the	   Second-­‐Strand	   Master	   Mix	   (to	   synthesize	   the	   second-­‐
strand	  cDNA)	  For	  a	  single	  sample,	  13µL	  of	  nuclease-­‐free	  water,	  5µL	  Second-­‐Strand	  Buffer	  Mix,	  2µL	   second-­‐Strand	   Enzyme	  Mix	   were	  mixed	   on	   ice.	   20µL	   was	   added	   to	   each	  sample	  and	  incubated	  at	  16°C	  for	  1	  hour,	  followed	  by	  65°C	  for	  10	  minutes.	  After	  incubation,	  samples	  could	  be	  frozen	  at	  minus	  20°C.	  
2.3.4.3	  Assembling	  the	  IVT	  Master	  Mix	  (to	  label	  the	  RNA	  with	  Biotin)	  	  For	   a	   single	   sample,	   4µL	  Biotin	   Label,	   20µL	   IVT	  Labelling	  Buffer	   and	  6µL	   IVT	  Enzyme	  Mix	  were	  mixed	  at	  room	  temperature.	  30µL	  of	  the	  IVT	  Master	  Mix	  was	  added	   to	   each	   sample	   and	   incubated	   at	   40°C	   for	   16	  hours.	   The	  RNA	   could	   be	  frozen	  at	  minus	  20°C	  after	  this	  incubation	  if	  required.	  
2.3.4.4	  Purification	  of	  amplified	  RNA	  The	   amplified	   samples	   were	   purified	   to	   remove	   salts,	   enzymes	   and	   free	  nucleotides	  using	  a	  magnetic	  bead	  method	  similar	  to	  the	  GLOBINclear	  protocol.	  The	  aRNA	  elution	  solution	  was	  pre-­‐heated	  at	  60°C	  for	  at	  least	  10	  minutes.	  aRNA	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binding	  mix	  was	  prepared	  from	  10µL	  of	  RNA	  binding	  beads	  and	  50µL	  Binding	  Buffer	   Concentrate	   	   for	   each	   sample.	   60µL	   of	   Binding	  Mix	  was	   then	   added	   to	  each	   sample.	   The	   samples	   were	   transferred	   to	   the	   bottom	   of	   a	   96	   well	   u-­‐bottomed	  plate	  and	  mixed	  by	  pipetting	  up	  and	  down.	  120µL	  of	  100%	  ethanol	  was	  added	  to	  each	  sample	  and	  mixed	  by	  pipetting.	  The	  plate	  was	  gently	  shaken	  for	  4	  minutes	  and	  then	  placed	  on	  a	  magnetic	  stand	  to	  capture	  the	  beads	  for	  10	  minutes.	  The	  supernatant	  was	  aspirated	  and	  discarded.	  	  With	   the	   plate	   removed	   from	   the	   magnetic	   stand,	   120µL	  Wash	   solution	   was	  added	  to	  each	  sample	  and	  shaken	  at	  a	  moderate	  speed	  for	  4	  minutes	  to	  wash	  the	  beads.	  The	  beads	  were	   then	  recaptured	  on	   the	  magnetic	  stand	   for	  10	  minutes	  and	  the	  supernatant	  aspirated	  and	  discarded.	  This	  step	  was	  repeated	  one	  more	  time.	  The	   purified	   RNA	   was	   eluted	   from	   the	   beads	   by	   adding	   50	   µL	   of	   pre-­‐heated	  Elution	  Solution	  to	  sample	  wells	  and	  shaking	  the	  plate	  vigorously	   for	  at	   least	  6	  minutes	  or	  until	  the	  beads	  dispersed.	  The	  beads	  were	  captured	  for	  10	  minutes	  and	  the	  supernatant	  containing	  eluted	  RNA	  was	  aspirated	  and	  placed	  in	  a	  clean	  PCR	  tube.	  RNA	  could	  be	  stored	   for	  up	  to	  1	  year	  at	  minus	  80°C	  at	   this	  stage	  or	  temporarily	  stored	  on	  ice.	  After	  amplification,	  aRNA	  was	  assessed	  using	  the	  Agilent	  2100	  Bioanalyzer™	  to	  see	   if	   samples	   had	   been	   amplified	   effectively,	   remained	   high	   quality	   or	   if	   any	  degradation	  had	  occurred.	  	  Samples	   were	   then	   tested	   using	   the	   NanoDrop	   to	   achieve	   an	   accurate	  concentration	   measurement	   and	   samples	   below	   700ng/µL	   were	   repeated.	  
	   Sara	  Solaymani-­‐Kohal	  57	  
Different	  volumes	  of	  RNA	  added	  to	  an	  array	  can	  be	  a	  major	  source	  of	  interchip	  variation,	  which	  needs	  to	  be	  minimised	  to	  allow	  comparison.	  
2.3.5	  Evaluation	  and	  Fragmentation	  of	  RNA	  RNA	  molecules	   are	   three-­‐dimensional	   and	   can	   take	   on	   different	   structures	   in	  space.	  Secondary	  and	   tertiary	  structures	  can	   interfere	  with	  RNA	  hybridization	  to	  an	  array	  by	  reducing	  a	  probe’s	  ability	  to	  capture	  target	  RNA.	  Fragmentation	  reagents	   were	   provided	   with	   the	   3’IVT	   Express	   Kit.	   15ng	   of	   sample	  (concentration	   assessed	   via	   NanoDrop)	   was	   mixed	   with	   8µL	   5x	   Array	  fragmentation	  buffer	  and	  topped	  up	  with	  nuclease	  free	  water	  to	  a	  final	  volume	  of	  40µL.	  The	  mixture	  was	  incubated	  at	  94°C	  for	  45minutes	  to	  fragment.	  Samples	  were	  placed	  on	   ice	   immediately	  after	   incubation	  and	  assessed	  again	  using	   the	  Agilent	   Bioanalyzer.	   Two	   distinct	   peaks	   should	   be	   seen	   with	   RNA	   fragments	  distribute	  in	  the	  larger	  peak	  between	  25	  and	  200nt.	  	  	  
2.4.	  Hybridization	  	  
All	   reagents	   described	   in	   this	   section	   were	   provided	   in	   the	   GeneChip®	  Hybridization,	  Wash	  and	  Stain	  Kit.	  A	   hybridization	   cocktail	   was	   made	   for	   each	   sample	   containing	   12.5ng	   of	  fragmented	  and	  labelled	  RNA	  sample,	  4.2µL	  Control	  Oligonucleotide	  B2,	  12.5µL	  20X	  Hybridization	  Controls,	  125µL	  2X	  Hybridization	  Mix,	  25µL	  DMSO,	  and	  up	  to	  50µL	  Nuclease-­‐free	  water	   to	   take	   the	   total	  volume	   to	  250µL.	  The	  cocktail	  was	  heated	  at	  99°C	  for	  5	  minutes	  then	  45°C	  for	  5	  minutes	  in	  a	  heat	  block.	  It	  was	  then	  spun	  at	  maximum	  speed	  in	  a	  microfuge	  for	  5	  minutes.	  Whilst	  the	  solution	  was	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heating,	  the	  array	  was	  wetted	  with	  200µL	  Pre-­‐Hybridization	  mix	  and	  incubated	  at	  45°C	   for	  10	  minutes	  with	   rotation	   (60rpm).	  The	  pre-­‐hybridization	  mix	  was	  then	  removed	  from	  the	  chip	  and	  the	  hybridization	  cocktail	  injected	  in	  its	  place.	  The	   array	   was	   then	   incubated	   at	   45°C	   for	   16	   hours	   at	   60	   rpm.	   After	  hybridization,	   the	   chip	  was	  washed	   using	   an	   automated	  machine,	   courtesy	   of	  Affymetrix,	   for	   2	   hours	   to	   remove	   un-­‐hybridized	   nucleotides	   and	   salts	   and	  scanned	  by	  the	  computer	  to	  construct	  an	  array	  image.	  
2.5.	  Microarray	  
2.5.1.	  Affymetrix	  microarray	  Human	   microarrays	   were	   carried	   out	   by	   Dr	   Paul	   Heath	   in	   the	   University	   of	  Sheffield	   Microarray	   Core	   Facility	   using	   an	   Affymetrix	   HG_U133	   plus.2	  GeneChip.	  To	  construct	  an	  array	  image,	  a	  laser	  is	  used	  to	  scan	  the	  chip	  and	  ‘excite’	  labelled	  targets	   that	   have	   hybridized	   to	   probes	   to	   emit	   light.	   The	   intensity	   of	   light	  emitted	  is	  proportionate	  to	  the	  volume	  of	  sample	  at	  that	  particular	  point	  and	  a	  heat	  map	  is	  produced.	  So	  dependable	  data	  can	  be	  extracted	  from	  the	  array,	  the	  array	  itself	  needs	  to	  be	  assessed	  for	  quality	  and	  reliability.	  Variations	  within	  the	  chip	   and	   across	   chips	   also	   need	   to	   be	   accounted	   for	   before	   chips	   can	   be	  compared.	  To	  ensure	  input	  RNA	  is	  of	  good	  quality,	  it	  is	  assessed	  at	  each	  stage	  of	  handling	   before	   array.	   To	   quantify	   labelling	   and	   hybridization	   efficiency	  however,	   specific	   controls	   are	   added	   at	   the	   RNA	   labelling	   and	   hybridization	  steps	   respectively.	   Poly-­‐A	   controls	   are	   added	   during	   linear	   IVT	   to	   assess	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labelling	  efficiency.	  These	  controls,	  lys,	  phe,	  thr	  and	  dap	  are	  spiked	  directly	  into	  mRNA	  samples	  before	   labelling.	  Probe	   sets	  on	   the	   chip	   contain	  3’	   end	  probes,	  mid	  probes	  and	  5’	  end	  probes	  for	  each	  control.	  As	  cDNA	  is	  synthesized	  from	  the	  3’	  end	  there	  may	  be	  a	  slightly	  higher	  signal	  from	  3’	  probe	  sets	  than	  5’	  probe	  sets.	  A	  ratio	  (3’/5’)	  in	  ‘spike-­‐in	  controls’	  of	  more	  than	  3	  indicates	  either	  a	  problem	  in	  the	   sample	   itself	   or	   in	   target	   synthesis.	   In	   these	   cases,	   data	   from	   the	   chip	   is	  questionable	   and	   for	   this	   study	   chips	   that	   fell	   below	   this	   threshold	  were	   run	  again	   with	   fresh	   mRNA	   from	   samples	   stored	   in	   the	   bio	   repository.	   20X	  Eukaryotic	   Hybridization	   Controls	   are	   added	   to	   the	   hybridization	   cocktail	   to	  measure	   hybridization	   efficiency.	   They	   are	   comprised	   of	   a	   mixture	   of	  biotinylated	   and	   fragmented	   cRNA	   of	   the	   prokaryotic	   genes;	   bioB,	   bioC,	   bioD	  and	  cre.	  At	  1.5	  pM,	  bioB	  is	  at	  the	  detection	  limit	  for	  most	  expression	  arrays	  and	  is	   anticipated	   to	   be	   called	   ‘Present’	   at	   least	   70%	   of	   the	   time.	   In	   contrast,	   the	  other	  controls	  should	  be	  called	   ‘Present’	  all	  of	   the	   time,	  with	   increasing	  Signal	  values	  (bioC,	  bioD,	  and	  cre,	  respectively).	  ‘Absent’	  calls,	  or	  relatively	  low	  signal	  values,	   indicate	   a	   potential	   problem	   with	   the	   hybridization	   reaction	   or	  subsequent	   washing	   and	   staining	   steps.	   The	   Affymetrix	   Microarray	   scanning	  software	  produces	   a	  document	  on	  Microarray	  quality	   including	   assessment	  of	  the	   two	   variables	   above	   upon	  which	   any	   failed	   arrays	   are	   highlighted.	   These	  control	  procedures	  ensure	  that	  high	  standards	  are	  maintained	  across	  arrays	  to	  allow	  accurate	  comparisons	  between	  them.	  Although	  variability	  between	  arrays	  can	   be	   reduced	   in	   this	   way	   it	   is	   impossible	   to	   remove	   all	   variation.	  Normalisation	   is	   needed	   to	   provide	   an	   even	   platform	   of	   expression	   between	  chips	  before	  fair	  comparisons	  can	  be	  made.	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2.5.2.	  Validation	  by	  quantitative	  Real	  Time-­‐PCR	  Taqman	   primers	   were	   ordered	   from	   the	   Applied	   Biosystems	   website	  (Biosystems)	  qRT-­‐PCR	   was	   carried	   out	   in	   accordance	   with	   the	   ABI	   protocol	   (Biosystems)	  using	  an	  ABI	  ht7900	  plate	  reader.	  Table	  2.1.	  contains	  the	  assay	  ID	  codes	  for	  the	  used	  Taqman	  primer	  used.	  	  
2.5.3.	  Zebrafish	  morphant	  microarray	  The	  KIAA1109	  morphant	  microarray	  was	  carried	  out	  by	  the	  Genome	  Institute	  of	  Singapore.	  The	  custom	  made	  microarray	  used	  as	  published	  by	  Mathavan	  et	  al.	  (Mathavan	  et	  al.,	  2005)	  
2.5.3.1.	  Whole	  embryo	  RNA	  extraction	  Approximately	   300	   whole	   control	   and	   KIAA1109	   morphant	   embryos	   were	  immersed	   in	   tricaine	   for	  20	  minutes	  at	  36hpf.	  The	  solution	  was	  then	  removed	  and	   the	   embryos	   washed	   with	   PBS.	   250μl	   Tri-­‐reagent	   (Sigma,	   T9424)	   was	  added	  and	  a	  25G	  needle	  used	   to	  homogenize	   the	  embryos.	  50μl	  of	  chloroform	  was	   added	   to	   the	   sample	   and	   inverted	   for	   15	   seconds.	   The	   sample	   was	   then	  incubated	   at	   room	   temperature	   for	   3	   minutes	   prior	   to	   being	   centrifuged	   at	  13,000	  rpm	  for	  15	  minutes	  at	  40C.	   	  The	  clear	  supernatant	  that	  had	  risen	  to	  the	  top	   of	   the	   tube	   was	   then	   transferred	   to	   a	   new	   Eppendorf,	   to	   which	   85μl	   of	  isopropanol	  was	  added	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Table	  2.1.	  Assay	  ID	  of	  Taqman	  primers	  
Gene	  name	   Assay	  ID	  
pcdh1g2	   AI20S9R	  
camk2g2	   AI39RFZ	  
ndr2	   Dr03125298_m1	  
grin1a	   Dr03091890_m1	  
renin	   Dr03081915_m1	  
lnx1	   Dr03148957_m1	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and	  inverted	  gently	  before	  incubating	  at	  room	  temperature	  for	  10	  minutes.	  	  The	  sample	  was	   then	  centrifuged	  at	  13,000	  rpm	  for	  15	  minutes	  at	  40C	  after	  which	  the	  supernatant	  was	  discarded	  and	  250μl	  of	  75%	  ethanol	  was	  added	  to	  the	  tube.	  The	   sample	   was	   then	   vortexed	   to	   dislodge	   the	   pellet	   and	   centrifuged	   for	   5	  minutes	  at	  40C.	  The	  supernatant	  was	  discarded	  and	  the	  pellet	  allowed	  to	  air	  dry	  for	  5	  minutes	  after	  which	  the	  RNA	  pellet	  was	  resuspended	  in	  DEPC-­‐H2O.	  	  
2.6.	  Zebrafish	  Husbandry	  
2.6.1.	  Home	  Office	  Regulations	  All	   studies	   conformed	   to	   Home	   Office	   regulations	   for	   the	   use	   of	   animals	   in	  scientific	   research	   and	   were	   carried	   out	   in	   accordance	   with	   project	   licence	  number	  40/3031	  which	  was	  then	  renewed	  to	  40/3434	  held	  by	  Dr	  TJA	  Chico	  and	  personal	  licence	  number	  40/9599	  held	  by	  myself.	  Zebrafish	  were	  raised	  and	  fed	  by	  aquarium	  staff	  and	  following	  a	  14:10	  hour	  light:dark	  cycle.	  
2.6.2.	  Embryo	  Collection	  Breeding	  tanks	  were	  set	  up	  in	  adult	  tanks	  the	  previous	  night	  consisting	  of	  a	  wire	  mesh	  tank	  with	  marbles	  placed	  within	  an	  opaque	  tank	  to	  encourage	  breeding.	  The	  next	  morning	  the	  embryos	  were	  sorted	  into	  groups	  of	  30	  fertilised	  offspring	  and	  placed	   in	  Petri	  dishes	   containing	   fresh	  E3	  medium	  with	  added	  Methylene	  Blue.	   Embryos	   were	   incubated	   at	   280C	   up	   to	   a	   maximum	   of	   5.2dpf	   at	   which	  point	  they	  were	  anaesthetized	  using	  tricaine	  and	  destroyed	  using	  bleach.	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2.6.3.	  Zebrafish	  Strains	  and	  Lines	  Utilised	  Listed	  wildtype	  and	   transgenic	  embryos	   (table	  2.2.)	  were	  collected	   from	  adult	  tanks	  using	  a	  breeding	  trap	  that	  prevents	  adults	  from	  ingesting	  embryos	  by	  the	  presence	   of	   a	   physical	  mesh	   barrier.	   Embryos	  were	   sorted	   into	   groups	   of	   40	  fertilised	   offspring	   and	   placed	   in	   Petri	   dishes	   containing	   fresh	   E3	   medium.	  Embryos	  were	   incubated	  at	  28°C	   for	  use	  up	   to	  5.2dpf	  and	  remaining	  embryos	  were	  destroyed	  using	  bleach.	  	  
2.6.4.	  Zebrafish	  anaesthesia	  and	  mounting	  To	   immobilise	   embryos	   for	   observation,	   MS222	   (Sigma)	   was	   used	   in	   E3.	   To	  observe	  anaesthetised	  embryos	  under	  a	  stereo	  microscope	  they	  were	  mounted	  	  on	   a	   coverslip	   in	   1%	   low	  melting	   point	   agarose	   in	   E3	   and	  MS222.	   For	   longer	  time	  lapse	  imaging	  an	  E3	  bath	  was	  used	  to	  prevent	  the	  agarose	  drying	  out.	  	  
2.7	  Morpholino	  injections	  
Morpholinos	   were	   custom	   designed	   and	   purchased	   from	   Gene	   Tools	   Inc,	  Oregon,	  USA.	  Morpholinos	  were	  diluted	  to	  a	  stock	  solution	  of	  1mM	  and	  stored	  at	  minus	  200C,	  aliquots	  were	  defrosted	  and	  1:1	  ratio	  of	  phenyl	  red	  was	  added	  to	  aid	  observation	  of	  injection.	  	  One-­‐cell	  stage	  embryos	  were	  injected	  with	  0.5-­‐1nl	  (0.025pmol)	   morpholino	   and	   kept	   in	   E3	   medium	   at	   280C.	   Sequences	   can	   be	  found	   in	   table	   2.3.	   For	   all	   morpholino	   knockdown	   experiments	   the	   start	   site	  ATG	   morpholino	   was	   used,	   unless	   stated	   otherwise.	   All	   reference	   to	   control	  embryos	  also	  refers	  to	  the	  mismatch	  control	  morpholino	  injected	  embryos.	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Table	  2.2:	  Name	  and	  phenotype	  of	  strains	  of	  zebrafish	  used	  	  
	  





	   	  
Zebrafish	  Line	   Phenotype	  
Nacre	  wildtype	   Wildtype	   embryo	   that	   lacks	   pigmentation	  
for	  easier	  visualisation	  
Fli1:GFP/Gata1:dsRED	   Fli1	   positive	   cells	   (endothelial	   cells)	   are	  
tagged	   with	   GFP	   and	   Gata1	   positive	   cells	  
(red	  blood	  cells)	  are	  tagged	  with	  dsRED.	  
Flk1:GFP-­‐NLS	   Flk1	   positive	   cells	   are	   tagged	   with	   nuclear	  
localised	  GFP	  
	   Sequence	  5'	  -­‐	  3'	   Target	  
Control	   CCTCTTACCTCAGTTACAATTTATA	   Mismatch	  sequence	  
ATG	   GGAGACTGTTGTTGCCTTTATCCAT	   Translation	  blocking	  
ATG-­‐2	   TGCAGATAAACAGAGCGGACATCAC	   Translation	  blocking	  
Splice	   ACAAATCATAAATCACTTACCCACA	   Intron	  -­‐exon	  1	  boundary	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2.8.	  RNA	  probe	  synthesis	  
Antisense	  RNA	  probes	  were	  synthesised	  for	  KIAA1109.	  Sense	  probes	  were	  also	  synthesised	   as	   controls.	   Primers	   designed	   using	   Primer3	   software	  (Primer3Plus)	  was	  used	  for	  KIAA1109	  RNA	  probe	  synthesis:	  Forward	  sequence:	  5’-­‐	  TGGAGGTCTCTCATCCCTGT	  Reverse	  sequence:	  5’-­‐	  TTCACACTGCCAGGACTGAG	  Amplified	   cDNAs	   from	   reverse	   transcription-­‐PCR	   were	   inserted	   into	   pCRII-­‐TOPO	   cloning	   vector	   and	   grown	   in	   selective	  media.	   The	   cloning	   vectors	  were	  then	   purified	   using	   a	   plasmid	  midi	   kit	   (Qiagen)	   and	   then	   linearized	   using	   the	  appropriate	   restriction	   enzymes	   and	   purified	   using	   the	   QIAquick	   PCR	  purification	  kit	   (Qiagen).	  For	  KIAA1109	  sense	  probe	  restriction	  enzymes	  KpnI	  and	  NEB1	  were	  used	  and	   for	  KIAA1109	  antisense	  probe	  Not1	  and	  NEB3	  were	  used.	   The	   linearized	   plasmid	   template	   (1	   µg),	   2µl	   of	   10X	   transcription	   buffer,	  1µl	   of	   DIG	   RNA,	   2µl	   of	   T7	   or	   SP6	  RNA	   polymerase,	   and	  RNase-­‐free	  H20	  were	  mixed	   in	  a	   total	  reaction	  volume	  of	  20	  µl.	  The	  mixture	  was	   incubated	  at	  370C;	  after	   2	   hours,	   DNase	   I	   (10	   µl)	   was	   added	   and	   the	   incubation	   continued	   for	  another	  15	  min.	  After	  stopping	   the	  reaction	  by	  adding	  EDTA	  (1	  µl,	  0.5M),	  LiCl	  (2.5µl,	  4M)	  and	  EtOH	  (75µl,	  100%),	  that	  had	  been	  stored	  in	  the	  minus	  700C	  for	  30	   minutes	   prior	   to	   being	   added.	   The	   solution	   was	   then	   centrifuged	   at	  12,000rpm	   for	   30	  minutes	   at	   room	   temperature.	   The	  pellet	  was	  washed	  with	  70%	  ethanol	  and	   then	   left	   to	  dry	  and	  re-­‐suspended	   in	  20µl	  of	   sterile	  H2O	  and	  35µl	  of	  100%	   formamide	  and	  stored	  at	  minus	  800C.	  To	  dilute	   the	  probe	   to	  be	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used	   for	   in	   situ	   hybridization	   it	   was	   diluted	   to	   a	   1:200	   solution	   in	   Hyb-­‐	   and	  stored	  at	  minus	  200C.	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2.9.	  Whole	  Mount	  In-­‐Situ	  Hybridization	  
Whole-­‐mount	   in	   situ	   hybridization	   was	   performed	   according	   to	   Thisse	   et	   al	  (Thisse	  and	  Thisse,	  2008).	  	  Embryos	   were	   previously	   fixed	   in	   4%	   (wt/vol)	   paraformaldehyde	   (PFA)	   and	  kept	   in	   100%	  methanol.	  Nacre	   embryos	   (Lister	   et	   al.,	   1999)	   were	   utilized	   as	  they	  are	  non-­‐pigmented	  due	  to	  a	  lack	  of	  melanophores	  and	  so	  the	  stain	  could	  be	  easily	   visualised.	   Embryos	   were	   then	   rehydrated	   by	   successive	   five	   minute	  incubations	   at	   RT	   in	  methanol	   in	   1xPBS,	   5	  min	   in	   75%	   (vol/vol)	  methanol;	   5	  min	  in	  50%	  (vol/vol)	  methanol;	  and	  5	  min	  in	  25%	  (vol/vol)	  methanol	  and	  then	  washed	  four	  times,	  5	  min	  per	  wash,	  in	  100%	  PBT.	  Embryos	  were	  permeabilized	  by	  digestion	  with	  proteinase	  K	  (Roche	  Diagnostics,	  cat.	  no.	  1092766,	  prepared	  at	  10	  µg	  ml-­‐1)	  at	  RT	  for	  30	  mins.	  This	  is	  to	  allow	  the	  probe	  to	  enter	  the	  cells.	  It	  is	  important	  to	  determine	  the	  right	  incubation	  time,	  as	  under-­‐digestion	  would	  not	  allow	  the	  probe	  to	  get	   in,	  whereas	  over-­‐digestion	  will	  alter	   the	  morphology	  of	  the	  embryo.	  The	  proteinase	  K	  digestion	  was	  stopped	  by	  incubating	  the	  embryos	  for	  30	  min	  in	  4%	  (wt/vol)	  PFA	  in	  1xPBS.	  Embryos	  were	  then	  washed	  four	  times,	  5	   min	   per	   wash,	   in	   1xPBT	   to	   remove	   residual	   PFA.	   The	   embryos	   were	   then	  prehybridized	  with	  700	  µl	  of	  hybridization	  mix	  (HM)	  for	  3	  hrs	  in	  a	  70	  0C	  water	  bath.	  The	  HM	  was	  discarded	  and	  replaced	  with	  200	  µl	  of	  HM	  containing	  700	  ng	  of	   antisense	   DIG-­‐labelled	   probe,	   the	   right	   amount	   of	   RNA	   probe	   should	   be	  determined	  to	  avoid	  background	   labelling.	  The	  embryos	  were	   then	  hybridized	  overnight	  at	  70	  0C.	  This	  high	  hybridization	  temperature	  and	  the	  percentage	  of	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formamide	   in	   the	   HM	   buffer	   ensure	   high	   stringency	   of	   hybridization	   and	  decrease	  the	  occurrence	  of	  cross-­‐hybridization.	  The	  embryos	  were	  then	  washed	  for	  10	  min	  in	  pre-­‐warmed	  at	  70	  0C	  solutions	  of	  75%	   HM,	   50%	   HM,	   25%	   HM	   and	   100%	   2xSSC.	   Embryos	   were	   then	   washed	  twice,	   for	   30	   min	   per	   wash,	   in	   0.2xSSC	   at	   70	   0C,	   which	   prevents	   nonspecific	  hybridization	  of	   the	  probe.	  The	  embryos	  were	  then	  put	   through	  a	  series	  of	  10	  min	   washes	   in	   75%	   0.2xSSC,	   50%	   0.2xSSC,	   25%,	   0.2xSSC	   and	   1xPBT.	   The	  embryos	  were	  then	  incubated	  for	  3	  hrs	  at	  RT	  in	  blocking	  buffer;	  this	  saturates	  nonspecific	   binding	   sites	   for	   the	   antibody.	   The	   embryos	  were	   then	   incubated	  with	  anti-­‐DIG	  antibody	  solution	  diluted	  at	  1/10,000	  with	  blocking	  buffer	  at	  4	  0C	  with	   gentle	   agitation	   at	   40	   r.p.m.	   overnight.	   The	   antibody	   solution	   was	   then	  discarded	  and	  embryos	  washed	  briefly	  in	  PBT.	  Embryos	  were	  then	  washed	  six	  times,	  15	  min	  per	  wash,	  in	  PBT	  at	  room	  temperature	  with	  gentle	  agitation	  at	  40	  r.p.m.	   Embryos	   were	   then	   incubated	   at	   RT	   three	   times,	   5	   min	   per	   wash,	   in	  alkaline	   Tris	   buffer	  with	   gentle	   agitation	   at	   40	   r.p.m.	   The	   alkaline	   Tris	   buffer	  was	  replaced	  with	  freshly	  prepared	  staining	  solution	  and	  kept	  in	  the	  dark	  at	  RT	  with	  gentle	  agitation	  40	  r.p.m.	  Once	  the	  desired	  staining	  intensity	  was	  reached	  the	  reaction	  was	  stopped	  by	  washing	  embryos	   in	  1xPBT	  four	  times,	  5	  min	  per	  wash,	  in	  4%PFA	  for	  20	  min,	  1xPBT	  for	  two	  ten	  min	  washes	  and	  finally	  a	  series	  of	  5	  min	  washes	  in	  25%,	  50%	  and	  75%	  glycerol.	  For	  observation	  the	  embryos	  were	  mounted	  in	  100%	  glycerol.	  A	  Nikon	  Coolpix5400	  camera	  was	  attached	  to	  a	  Nikon	  SMZ1500	  stereomicroscope	  to	  capture	  images	  of	  the	  embryos.	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2.10.	  Phenotypic	  analysis	  of	  KIAA1109	  knockdown	  
2.10.1.	  Heart	  rate	  measurements	  Heart	  rates	  were	  measured	  (without	  the	  administration	  of	  tricaine)	  in	  embryos	  by	  counting	  heart	  beat	  number	  for	  thirty	  seconds.	  	  This	  was	  then	  multiplied	  by	  two	  and	  expressed	  as	  beats	  per	  minute.	  	  
2.10.2.	  Velocity	  calculation	  measurements	  Embryos	   were	   mounted	   in	   1%	   low	   melting	   point	   agarose	   and	   recorded	   on	  Video	   Savant	   4.0	   software	   at	   300	   frames	   per	   second	   (fps)	   using	   a	   high	   speed	  camera	   (Olympus	   IX81).	   Erythrocyte	   velocity	   in	   the	   arterial	   and	   venous	  circulation	   of	   the	   embryos	   was	   calculated	   using	   particle	   image	   velocimetry	  (PIV)	   software	   (LaVision	   -­‐	   DaVis).	   	   Measurements	   were	   taken	   at	   the	   sites	   of	  interest	  (shown	  in	  figure	  2.1.)	  of	  which	  the	  mean	  was	  plotted.	  	  
2.10.3.	  Vessel	  diameter	  measurements	  Embryos	   were	   mounted	   in	   1%	   low	   melting	   point	   agarose	   and	   recorded	   on	  Video	   Savant	   4.0	   software	   at	   300	   frames	   per	   second	   (fps)	   using	   a	   high	   speed	  camera	   (Olympus	   IX81).	   Images	   were	   then	   saved	   as	   one	   extended	   image.	  	  Measurements	  were	   taken	   at	   the	   sites	   of	   interest	   (shown	   in	   figure	  2.1.)	   using	  ImageJ	  and	   the	  diameter	   calculated	   from	  pixels	   to	  μm	  of	  which	   the	  mean	  was	  plotted.	  	  
2.10.4.	  Haemorrhage	  volume	  quantification	  Embryos	  were	  mounted	   in	   1%	   low	  melting	   point	   agarose	   and	   z-­‐stack	   images	  were	  taken	  through	  the	  head	  using	  a	  spinning	  disc	  confocal	  microscope	  (Perkin	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Figure	  2.1.	  Sites	  of	  measurements	  of	  vessel	  size	  and	  haemodynamics.	  	  Measurements	   were	   taken	   from	   the	   tail	   to	   the	   head.	   The	   numbers	   show	   the	  number	   of	   intersegmental	   vessels.	   The	   red	   stars	   represent	   the	   location	   of	  arterial	   measurements.	   The	   blue	   stars	   represent	   the	   location	   of	   venous	  measurements.	  The	   letters	  represent	   the	  space	   in-­‐between	   the	   intersegmental	  vessels.	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Elmer	   Ultraview	   VoX	   spinning	   disc	   confocal	   system	   running	   on	   an	   Olympus	  IX81	  motorized	  microscope.	   Images	   were	   analysed	   as	   extended	   focus	   images	  using	  Volocity	   6.1.1.	   software.	   The	   area	   of	   haemorrhage	  was	   selected	   and	   the	  volume	  calculated.	  	  
2.10.5.	  Endothelial	  cell	  nuclei	  quantification	  Embryos	  were	  mounted	   in	   1%	   low	  melting	   point	   agarose	   and	   z-­‐stack	   images	  were	   taken	   through	   the	   whole	   embryos	   using	   a	   spinning	   disc	   confocal	  microscope	  (Perkin	  Elmer	  Ultraview	  VoX	  spinning	  disc	  confocal	  system	  running	  on	  an	  Olympus	  IX81	  motorized	  microscope).	  Images	  were	  exported	  as	  extended	  focus	  images	  to	  ImageJ	  for	  analysis	  using	  the	  “Analyze particles” tool. The desired 
particle size can be selected and the software gives information on the size and area 
of each identified particle. This technique has been established and data reproduced 
within the lab and the number of calculated cell numbers compared with those 
calculated manually as well as compared with established normal endothelial cell 
numbers. Areas of interest are also comparable with established protocol.  
2.10.6.	  Dextran	  injection	  A	  high	  molecular	  weight	  rhodamine-­‐dextran	  conjugate	  (2,000,000	  MW	  TAMRA)	  that	   is	   normally	   too	   large	   to	   pass	   through	   the	   vessel	  wall	  was	   used	   to	   assess	  vessel	  integrity	  as	  described	  by	  Van	  Rooijen	  (van	  Rooijen	  et	  al.,	  2010).	  	  Embryos	  were	   mounted	   in	   1%	   low	   melting	   point	   agarose	   and	   1nl	   of	   dextran	   (life	  technologies,	  D-­‐7139)	  was	  injected	  directly	  into	  the	  circulation	  via	  the	  common	  cardinal	   vein	   over	   the	   yolk	   sac	   of	   2	   and	  3dpf	   embryos.	   Confocal	   images	  were	  taken	  after	  5	  minutes	  of	  which	  the	  dye	  had	  been	  taken	  up	  into	  the	  circulation.	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2.10.7.	  Response	  to	  laser	  injury	  Embryos	  were	  mounted	  in	  1%	  low	  melting	  point	  agarose	  and	  laser	  injury	  was	  carried	  out	  using	  a	  Micropoint	  laser	  attached	  to	  a	  high-­‐speed	  camera	  (Olympus	  IX81).	  	  20	  pulses	  of	  laser	  were	  administered	  to	  the	  arterial	  wall	  above	  the	  anus	  of	  3dpf	  embryos	  as	  shown	  in	  figure	  2.2.	  Time	  to	  adhesion	  was	  calculated	  as	  well	  as	   thrombus	  size	  after	  2	  minutes.	   ImageJ	  was	  used	   to	  measure	   thrombus	  size.	  Protocol	  adapted	  from	  Thattaliyath	  et	  al.	  (Thattaliyath	  et	  al.,	  2005)	  
2.11.	  The	  effect	  of	  small	  molecule	  VEGF	  induction	  
The	  VEGF	  inducer	  GS4012	  (Calbiochem,	  676491)	  was	  diluted	  using	  DMSO	  and	  5μg/ml	   GS4012	   was	   added	   to	   E3	   media	   at	   24hpf	   and	   changed	   daily	   until	  imaging	  at	  3dpf.	  Protocol	  adapted	  from	  Peterson	  et	  al.	  (Peterson	  et	  al.,	  2004).	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Figure	  2.2.	  Site	  of	  laser	  injury	  Image	  above	   is	  of	  a	  5dpf	  double	   transgenic	  embryo,	  Fli1:GFP/Gata1:dsRED.	  Star	  demonstrates	  the	  site	  of	  laser	  injury.	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2.12.	  Statistical	  Analysis	  
All	  data	  presented	  has	  a	  stated	  n	  number	  in	   its	  corresponding	  section.	  For	  the	  experiments	   in	   which	   animals	   were	   used,	   the	   number	   of	   embryos	   per	  experiment	   has	   been	   stated	   in	   its	   corresponding	   section.	   Typically	   data	   is	  shown	  as	  mean	  ±	  standard	  error	  of	  the	  mean.	  All	  analysis	  was	  conducted	  using	  the	   GraphPad	   Prism	   statistical	   analysis	   programme	   and	   results	   reported	   as	   p	  values	   in	   corresponding	   sections.	   Statistical	   comparisons	  were	  made	  between	  multiple	  treatment	  groups	  using	  one-­‐way	  analysis	  of	  variance	  (ANOVA)	  with	  a	  Bonferroni	  post-­‐test	  to	  assess	  multiple	  comparisons	  between	  each	  group.	  	  
2.12.1	  Microarray	  normalization	  Dr	  Marta	   Milo,	   a	   bioinformatician	   in	   the	   Cardiovascular	   Biomedical	   Research	  Unit,	   carried	   out	   normalization.	   The	   first	   stage	   in	   normalization	   is	   to	   balance	  hybridization	   intensities	   across	   chips	   to	   allow	  meaningful	   comparisons	   to	   be	  made.	  To	  do	  this	  a	  set	  of	  genes	  that	  should	  be	  equally	  expressed	  in	  both	  test	  and	  control	   samples	   are	   identified.	   Affymetrix	   GeneChips	   include	   over	   100	  ‘housekeeping	  genes’	  which	  are	  common	  genes	  assumed	  to	  be	  expressed	  to	  the	  same	   level	   in	   every	   cell	   type,	   these	   genes	   include	   cytoskeleton	   (B	   actin).	   As	  these	  genes	  are	  expected	  to	  have	  the	  same	  expression,	  their	  expression	  ratio	  is	  set	  as	  1.	  From	  this,	  a	  normalization	  factor	  can	  be	  applied	  to	  all	  genes	  in	  the	  chip.	  	  PUMA	  (Propagating	  Uncertainty	  through	  Microarray	  Analysis)	  is	  a	  probabilistic	  statistical	   package	   designed	   for	   the	   analysis	   of	   Affymetrix	   GeneChips	   that	  incorporates	   the	   measurement	   of	   uncertainty	   gained	   from	   the	   PM	   and	   MM	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probes	   to	  provide	   an	   estimate	  of	   gene	   expression	  of	   the	   gene	   together	  with	   a	  credibility	  interval	  (akin	  to	  a	  confidence	  interval)	  (Milo	  et	  al.,	  2003b,	  Pearson	  et	  al.,	   2009b).	  This	   approach	   to	  probe	   level	   analysis	  has	  been	   shown	   to	   improve	  the	   accuracy	   of	   differentially	   expressed	   gene	   identification	   and	   thus	   increase	  reproducibility	  of	  the	  FC	  seen	  (Milo	  et	  al.,	  2003b).	  Once	  accurate	  levels	  of	  expression	  have	  been	  found	  for	  each	  probe	  set	  on	  each	  chip,	  these	  can	  be	  compared	  using	  Principle	  Component	  Analysis	  (PCA).	  	  PCA	   is	  a	  method	  of	  visualising	  data	   in	   terms	  of	  components	  of	  variability.	  The	  arrays	  from	  each	  patient	  at	  each	  time	  point	  will	  contain	  multiple	  variabilities	  for	  example,	   differences	   in	   sex	   gene	   expression,	   and	   differences	   as	   a	   result	   of	  phenotypic	  characteristics.	  By	  plotting	  arrays	  against	  a	   component	  accounting	  for	   maximal	   variability,	   it	   is	   possible	   to	   see	   the	   spread	   of	   patients	   and	   time	  points	  across	  this	  component.	  	  Arrays	  that	  group	  together	  are	  the	  most	  similar	  and	  arrays	  separated	  by	  a	  large	  distance	  are	  the	  most	  different	  in	  terms	  of	  the	  component.	   Adding	   a	   second	   component	   accounting	   for	   as	   much	   of	   the	  remaining	   variability	   as	   possible,	   can	   further	   distinguish	   between	   arrays	   and	  even	  a	  third	  component	  can	  be	  added.	  	  Standard	   PCA	   assumes	   that	   the	   uncertainty	   of	   each	   gene	   in	   each	   comparable	  chip	  is	  constant.	  However	  it	  has	  been	  argued	  that	  this	  is	  often	  an	  unreasonable	  assumption	  when	  applied	   to	  highly	  variable	  biological	  data	   (Sanguinetti	   et	   al.,	  2005).	   PUMA	   takes	   a	   probabilistic	   approach	   utilising	   credibility	   intervals	   to	  include	   the	   variability	   of	   each	   gene	   in	  PCA.	  This	   approach	  has	  been	   shown	   to	  remove	   ‘noise’	   from	   the	  dataset	   and	   lead	   to	   tighter	   groupings	  within	   the	  plot.	  Due	  to	  the	  lack	  of	  replicates	  in	  this	  study,	  statistical	  errors	  are	  likely	  to	  be	  high	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and	  standard	  PCA	  may	  not	  show	  groups	  of	  similarity	  due	  to	  this.	  By	  taking	  into	  account	   the	   uncertainty	   using	   PUMA,	   patterns	   in	   array	   distribution	   may	   be	  noticed.	  	  To	  determine	  the	  significance	  of	  changes	  in	  expression	  the	  expression	  ratio	  was	  calculated	  using	  the	  below	  equation,	  g	  represents	  gene,	  Tg	  the	  test	  sample	  and	  
Cg	  the	  control	  sample.	  	  
Eg=	  Tg/Cg	  When	  the	   level	  of	  g	   is	   the	  same	   in	  both	   the	   test	  and	  control	  samples	   the	  ratio	  will	  equal	  1.	  Where	  g	  is	  up	  regulated	  in	  the	  test	  sample	  the	  ratio	  will	  be	  greater	  than	  1	  and	  when	  down	  regulated	  it	  will	  be	  between	  1	  and	  0.	  The	  fold	  change	  can	  now	  be	  calculated	  by	  multiplying	  the	  reciprocal	  of	  down	  regulated	  genes	  by	  -­‐1.	  We	   defined	   differential	   expression	   using	   a	   cut	   off	   of	   a	   fold	   change	   of	   greater	  than	  2	  or	  -­‐2.	  In	  order	   to	   improve	   the	   robust	  detection	  of	  differentially	  expressed	  genes	   the	  Probability	  of	  Positive	  Log	  Ratio	  (PPLR)	  uses	  a	  Bayesian	  hierarchical	  model	  to	  combine	   probe-­‐level	   measurement	   error	   and	   between	   replicate	   variance	   and	  adopts	   the	  variational	  method	  to	  estimate	  the	  parameters.	   It	  also	  accounts	   for	  the	   variance	   seen	   between	   chips	   by	   using	   uncertainty	   measurements	   from	  replicate	  experiments	  to	  calculate	  point	  estimations	  and	  standard	  errors	  of	  the	  expression	   levels.	   This	   means	   that	   PUMA	   accounts	   for	   both	   within	   chip	   and	  across	   chip	   variance	   when	   identifying	   differentially	   expressed	   genes.	   PUMA	  uses	   the	  point	  estimate	  and	  standard	  error	  measurements	   to	  calculate	  a	  PPLR	  score	  for	  each	  probe	  set.	  This	  can	  be	  used	  to	  order	  probe	  sets	  by	  probability	  of	  differential	  expression	  between	  two	  events	  such	  as	  MI	  vs.	  UA.	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Of	  those	  genes	  with	  a	  fold	  change	  >2	  or	  -­‐2,	  those	  with	  a	  PPLR	  of	  greater	  than	  0.8	  or	   less	   than	  0.2	  were	   classed	   as	   significant.	   These	   are	   arbitrary	   values,	  which	  have	   been	   previously	   used	   as	   significant	   cut	   off	   values	   for	   up	   regulated	   and	  down	   regulated	   differentially	   expressed	   genes	   analysed	   using	   PUMA	  (Quackenbush,	  2002).	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Chapter	   3:	   Identifying	   Differentially	  
Expressed	   Genes	   in	   Peripheral	   Blood	  
of	   Patients	   Presenting	   with	   Acute	  
Coronary	  Syndrome	  (ACS)	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3.1.	  Introduction	  	  
3.1.1.	  Expression	  analysis	  of	  patient	  peripheral	  blood	  	  Gene	   expression	   profiling	   of	   RNA	   extracted	   from	   peripheral	   blood	   has	   the	  potential	   to	   be	   an	   informative	   method	   for	   identification	   of	   biomarkers,	  examination	   of	   disease	   states,	   stratification	   of	   patient	   populations	   and	  investigation	  of	   immune	  responses.	  However,	   the	  relatively	  high	  proportion	  of	  globin	  messenger	   RNA	   present	   in	   total	   RNA	   extracted	   from	  whole	   blood	   can	  reduce	  the	  efficacy	  of	  the	  microarray	  assay	  by	  interfering	  with	  the	  detection	  of	  less	  abundant	  gene	  transcripts	  (Feezor	  et	  al.,	  2004,	  Liu	  et	  al.,	  2006a).	  Common	  laboratory	   practice	   often	   includes	   fractionation	   of	   whole	   blood	   components	  prior	   to	   RNA	   extraction.	   Depending	   on	   the	   fractionation	   method	   selected,	  partial	   or	   complete	   removal	   of	   erythrocytes	   and	   reticulocytes,	   the	   primary	  source	  of	   globin	  RNA,	  may	  be	  achieved.	  However,	   an	  alternative	   that	  we	  used	  was	  to	  extract	  the	  RNA	  and	  clear	  the	  globin	  prior	  to	  array	  hybridisation.	  
3.2.	  Results	  
3.2.1.	  Defining	  differential	  expression	  50	   patients	   with	   typical	   ACS	   symptoms	   were	   recruited	   from	   The	   Northern	  General	  Hospital	  (NGH)	  Sheffield	  from	  April	  2009.	  Blood	  samples	  were	  collected	  at	  days	  1,	  3,	   7,	   30,	  90	  and	  360	  after	   the	  acute	  event.	  Due	   to	   the	  on	  going	  and	  prospective	  nature	  of	  this	  study,	  19	  patients	  with	  data	  from	  each	  time	  point	  up	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to	   3	   months	   have	   currently	   been	   analysed.	   This	   is	   the	   cohort,	   which	   will	   be	  described	  throughout	  the	  rest	  of	  this	  thesis.	  	  We	  recruited	  five	  patients	  with	  UA,	  ten	  with	  NSTEMI	  and	  four	  with	  STEMI.	  No	  patients	  died	  during	  the	  follow-­‐up.	  	  My	   main	   time	   point	   of	   interest	   was	   1	   day	   post	   admission	   (visit	   1),	   because	  signals	  arising	  from	  plaque	  rupture	  are	  more	  likely	  to	  be	  detected	  early	  and	  the	  confounding	   effects	   of	   treatment	   and	   complications	   such	   as	   heart	   failure	   are	  less	  likely	  to	  be	  apparent	  at	  this	  early	  time	  point.	  A	  summary	  of	  the	  study	  time	  points	  is	  illustrated	  in	  figure	  3.1.	  The	  microarray	  data	  was	  normalised	  and	  statistical	  analysis	  carried	  out	  by	  Dr	  Marta	   Milo	   (CVBRU	   Bioinformatician)	   using	   published	   protocols	   of	   open	  sources	   software	   Propagating	   Uncertainty	   in	   Microarray	   Analysis	   (PUMA)	  (Pearson	  et	  al.,	  2009a).	   	  This	  approach	  to	  probe	  level	  analysis	  has	  been	  shown	  to	  improve	  the	  accuracy	  of	  differentially	  expressed	  gene	  identification	  and	  thus	  increase	  reproducibility	  of	  the	  fold	  change	  seen	  (Milo	  et	  al.,	  2003a).	  	  The	   microarray	   data	   examined	   expression	   of	   54,464	   transcripts.	   Of	   these,	  hypothetical	   genes	   as	   well	   as	   those	   that	   have	   not	   yet	   been	   annotated	   were	  removed,	   leaving	   45,490.	   To	   determine	   the	   significance	   of	   changes	   in	  expression	   the	   expression	   ratio	   was	   calculated	   as	   described	   in	   chapter	   2	  (2.5.1.2.).	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Figure	  3.1.	  Summary	  of	  sample	  collection	  	  Timeline	   demonstrates	   the	   process	   of	   patient	   recruitment	   and	   sample	  collection.	   Patients	   suffering	  with	   chest	   pains	  were	   admitted	   and	   an	   ECG	   and	  12h	   serum	  Troponin	  measurement	   performed	   to	   define	  whether	   the	   patients	  had	  suffered	  UA,	  STEMI	  or	  NSTEMI.	  Blood	  samples	  were	  taken	  at	  1,	  3,	  7,	  30	  and	  90	  days	  post	  admission,	  from	  which	  RNA	  was	  extracted	  from	  peripheral	  blood	  for	  whole	  genome	  Affymetrix	  microarray	  analysis.	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3.2.2	   Identifying	   gene	   expression	   differences	   in	   peripheral	   blood	   from	  
patients	  with	  MI	  compared	  with	  unstable	  angina	  	  Microarray	   studies	   generate	   large	   quantities	   of	   data	   that	   generally	   require	  interrogation	   in	   a	   focused	   manner.	   I	   sought	   to	   identify	   genes	   that	   are	  differentially	  expressed	  in	  peripheral	  blood	  from	  patients	  with	  both	  STEMI	  and	  NSTEMI	  compared	  with	  patients	  who	  present	   in	  a	  similar	  or	   identical	  manner	  but	   who	   have	   no	   evidence	   of	   myocardial	   necrosis	   (unstable	   angina).	   By	   this	  comparison,	   I	   sought	   to	  determine	  genes	  whose	  expression	  may	  be	  altered	  by	  the	  early	  consequences	  of	  plaque	  rupture,	  or	  even	  which	  have	  played	  a	  role	  in	  initiating	   plaque	   rupture.	   To	   identify	   such	   genes	   I	   concentrated	   on	   those	   that	  were	  differentially	  expressed	  in	  both	  the	  STEMI	  and	  NSTEMI	  groups	  compared	  to	  the	  UA	  at	  1d	  post	  admission.	  3461	   genes	   were	   differentially	   expressed	   between	   NSTEMI,	   STEMI	   and	   UA	  groups	   at	   1d	   post	   admission.	   99	   of	   these	   were	   significantly	   differentially	  expressed	  in	  both	  myocardial	  infarct	  (STEMI	  and	  NSTEMI)	  groups	  compared	  to	  the	  unstable	  angina	  group	  (table	  3.1).	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Table	   3.1.	   Showing	   genes	   significantly	   differentially	   expressed	   at	   day	   1	   in	   whole	  
blood	  in	  patients	  with	  MI	  compared	  to	  UA.	  
Gene	  Title	   Gene	  Symbol	  7-­‐dehydrocholesterol	  reductase	   DHCR7	  angiomotin	  like	  1	   AMOTL1	  ankylosis,	  progressive	  homolog	  (mouse)	   ANKH	  ankyrin	  repeat	  domain	  19	   ANKRD19	  apolipoprotein	  B	  mRNA	  editing	  enzyme,	  catalytic	  polypeptide-­‐like	  3B	   APOBEC3B	  ATP-­‐binding	  cassette,	  sub-­‐family	  D	  (ALD),	  member	  1	  	   ABCD1	  	  ATPase	  family,	  AAA	  domain	  containing	  4	   ATAD4	  beta-­‐1,3-­‐glucuronyltransferase	  3	  (glucuronosyltransferase	  I)	   B3GAT3	  BRCA1	  interacting	  protein	  C-­‐terminal	  helicase	  1	   BRIP1	  calcium	  binding	  protein	  1	   CABP1	  CD274	  molecule	   CD274	  chemokine	  (C-­‐C	  motif)	  ligand	  23	   CCL23	  Chemokine	  (C-­‐X-­‐C	  motif)	  receptor	  7	   CXCR7	  Chromosome	  1	  open	  reading	  frame	  128	   C1orf128	  chromosome	  15	  open	  reading	  frame	  43	   C15orf43	  chromosome	  16	  open	  reading	  frame	  55	   C16orf55	  chromosome	  17	  open	  reading	  frame	  47	   C17orf47	  Chromosome	  19	  open	  reading	  frame	  6	   C19orf6	  chromosome	  21	  open	  reading	  frame	  34	   C21orf34	  Coiled-­‐coil	  domain	  containing	  85B	   CCDC85B	  collagen,	  type	  VIII,	  alpha	  1	   COL8A1	  CTD	  (carboxy-­‐terminal	  domain,	  RNA	  polymerase	  II,	  polypeptide	  A)	  small	  phosphatase-­‐like	   CTDSPL	  cyclin-­‐dependent	  kinase-­‐like	  1	  (CDC2-­‐related	  kinase)	   CCNG2	  cytoskeleton	  associated	  protein	  2-­‐like	   CKAP2L	  dishevelled	  associated	  activator	  of	  morphogenesis	  2	   DAAM2	  dynein,	  cytoplasmic	  2,	  light	   DYNC2LI1	  
intermediate	  chain	  1	  E2F	  transcription	  factor	  1	   E2F1	  EP400	  N-­‐terminal	  like	   EP400NL	  EPH	  receptor	  B3	   EPHB3	  Ets	  homologous	  factor	   EHF	  family	  with	  sequence	  similarity	  125,	  member	  B	   FAM125B	  family	  with	  sequence	  similarity	  26,	  member	  F	   FAM26F	  family	  with	  sequence	  similarity	  39,	  member	  D	  pseudogene	  	   CXYorf1	  	  family	  with	  sequence	  similarity	  90,	  member	  A1	   FAM90A1	  fibroblast	  growth	  factor	  receptor	  2	  (bacteria-­‐expressed	  kinase,	  keratinocyte	  growth	  factor	  receptor,	  craniofacial	  dysostosis	  1,	  Crouzon	  syndrome,	  Pfeiffer	  syndrome,	  Jackson-­‐Weiss	  syndrome)	  
FGFR2	  
FRAS1	  related	  extracellular	  matrix	  1	   FREM1	  G	  antigen	  1	  	   CTD-­‐2248C21.2	  	  G	  protein-­‐coupled	  receptor	  56	   GPR56	  gamma-­‐aminobutyric	  acid	  (GABA)	  B	  receptor,	  2	   GABBR2	  gelsolin	  (amyloidosis,	  Finnish	  type)	   GSN	  guanine	  nucleotide	  binding	  protein,	  alpha	  transducing	  3	   GNAT3	  guanylate	  cyclase	  activator	  1C	   GUCA1C	  immunoglobulin	  heavy	  variable	  7-­‐81	   IGHV7-­‐81	  interleukin	  20	   IL20	  KIAA1109	   KIAA1109	  KIAA1632	   KIAA1632	  Leber	  congenital	  amaurosis	  5	   LCA5	  leucine	  rich	  repeat	  containing	  16	   LRRC16	  leucine-­‐rich	  repeats	  and	  transmembrane	  domains	  2	   LRTM2	  lipoma	  HMGIC	  fusion	  partner-­‐like	  4	   LHFPL4	  M-­‐phase	  phosphoprotein	  8	   MRPS18C	  Meis	  homeobox	  1	   MEIS1	  microcephalin	  1	   MCPH1	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netrin	  G1	   NTNG1	  NIMA	  (never	  in	  mitosis	  gene	  a)-­‐	  related	  kinase	  9	   NEK9	  nitric	  oxide	  synthase	  3	  (endothelial	  cell)	   NOS3	  otoancorin	   OTOA	  p21(CDKN1A)-­‐activated	  kinase	  6	   PAK6	  PDGFA	  associated	  protein	  1	   PDAP1	  phosphodiesterase	  1A,	  calmodulin-­‐dependent	   PDE1A	  potassium	  inwardly-­‐rectifying	  channel,	  subfamily	  J,	  member	  5	   KCNJ5	  POU	  class	  2	  associating	  factor	  1	   POU2AF1	  proline	  rich,	  lacrimal	  1	   PROL1	  Protein	  kinase	  C,	  zeta	   PRKCZ	  protocadherin	  21	   PCDH21	  protocadherin	  beta	  5	   PCDHB5	  pyroglutamyl-­‐peptidase	  I	   PGPEP1	  recombination	  activating	  gene	  1	   RAG1	  retinal	  G	  protein	  coupled	  receptor	   RGR	  ribonuclease	  P/MRP	  25kDa	  subunit	   RPP25	  Scavenger	  receptor	  class	  A,	  member	  5	  (putative)	   SCARA5	  selenoprotein	  P,	  plasma,	  1	   SEPP1	  SET	  binding	  factor	  2	   SBF2	  signal-­‐regulatory	  protein	  alpha	   SIRPalpha	  similar	  to	  Alu	  subfamily	  SX	  sequence	  contamination	  warning	  entry	   LOC646736	  SMAD	  family	  member	  3	   SMAD3	  SMAD	  specific	  E3	  ubiquitin	  protein	  ligase	  1	   SMURF1	  solute	  carrier	  family	  1	   SLC1A1	  
member	  1	  solute	  carrier	  family	  2	  (facilitated	  glucose	  transporter),	  member	  13	   SLC2A13	  solute	  carrier	  family	  6	  (neutral	  amino	  acid	  transporter),	  member	  19	   SLC6A19	  sperm	  flagellar	  2	   SPEF2	  spermatogenesis	  associated	  12	   SPATA12	  Src	  homology	  2	  domain	  containing	  adaptor	  protein	  B	   SHB	  suppressor	  of	  Ty	  16	  homolog	  (S.	  cerevisiae)	   SUPT16H	  synovial	  sarcoma	  translocation,	  chromosome	  18	   SS18	  tetratricopeptide	  repeat,	  ankyrin	  repeat	  and	  coiled-­‐coil	  containing	  2	   TANC2	  transcription	  factor	  Dp	  family,	  member	  3	   TFDP3	  transmembrane	  protein	  117	   TMEM117	  transmembrane	  protein	  62	   TMEM62	  tumor	  protein	  p53	  binding	  protein	  1	   TP53BP1	  unc-­‐5	  homolog	  B	  (C.	  elegans)	   UNC5B	  WD	  repeat	  domain	  42A	   WDR42A	  WD	  repeat	  domain	  60	   WDR60	  WD	  repeat	  domain	  63	   WDR63	  YY1	  transcription	  factor	   YY1	  zinc	  finger	  protein	  397	   ZNF397	  zinc	  finger	  protein	  416	   ZNF416	  zinc	  finger	  protein	  668	   ZNF668	  	   	  	   	  
	  The	  table	  above	  displays	  the	  genes	  that	  are	  differentially	  expressed	  in	  both	  STEMI	  and	  NSTEMI	  groups	  compared	  to	  the	  UA	  group.
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Since	   I	   planned	   to	   perform	   functional	   assessment	   of	   differentially	   expressed	  genes	   in	   zebrafish,	   it	   was	   necessary	   to	   identify	   which	   of	   these	   genes	   have	  zebrafish	  orthologues.	  54,464	   transcripts	  were	  analysed	  by	   the	  microarray,	  of	  which	   the	   ‘hypothetical	   genes’	   were	   removed	   from	   the	   data	   set.	   From	   the	  remaining	  genes	  those	  that	  were	  differentially	  expressed	  (a	  fold	  change	  of	  ≥2)	  were	   separated.	   From	   genes	   that	   were	   significantly	   statistically	   differentially	  expressed	  (defined	  as	  a	  PPLR	  higher	  than	  0.8	  or	  lower	  than	  0.2)	  were	  identified.	  The	  genes	  that	  were	  significantly	  differentially	  expressed	  in	  both	  MI	  groups	  vs.	  UA	   were	   selected	   and	   BLASTed	   using	   Ensembl	   for	   zebrafish	   orthologues,	   of	  which	  27	  were	   found	  to	  possess	  clear	  zebrafish	  homologues	  (table	  3.2.).	  From	  these	  27	  genes	  that	  were	  present	  in	  zebrafish	  only	  14	  had	  a	  genetic	  similarity	  of	  >50%;	  shared	  between	  zebrafish	  and	  humans.	  Of	  these	  14	  conserved	  genes,	  5	  were	  down	  regulated	  and	  9	  up	  regulated	  in	  MI	  compared	   with	   UA	   (Figure	   3.2).	   Although	   there	   are	   some	   minor	   differences	  between	  NSTEMI	  and	  STEMI	  groups,	  all	  genes	  are	  significantly	  differentially	  up-­‐	  or	  down	  regulated	  at	  1d,	  which	  resolves	  at	  later	  time	  points.	  Figure	  3.3	  shows	  a	  heat	  map	  of	  expression	  of	  these	  genes	  combining	  all	  patients	  with	  MI	  compared	  with	  UA,	  indicating	  clearly	  their	  early	  expression	  differences	  that	  return	  rapidly	  to	  similar	  levels	  as	  in	  UA.	  These	  candidates	  are	  therefore	  potentially	  implicated	  in	  the	  processes	  leading	  to,	  or	  the	  early	  response	  to,	  plaque	  rupture.	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Table	   3.2.	   Genes	   differentially	   expressed	   in	   MI	   compared	   to	   UA	   with	   zebrafish	  
homology	   	  	   	  Gene	  Symbol	   %	  Homology	  to	  zebrafish	  SMURF1	   88	  KIAA1109	   74	  C19orf6	   73	  DAAM2	   72	  UNC5B	   66	  SLC2A13	   62	  SLC1A1	   62	  WDR42A	   61	  COL8A1	   59	  CXCR7	   54	  FREM1	   50	  SBF2	   50	  SCARA5	   49	  POU2AF1	   43	  E2F1	   42	  PCDHB5	   42	  GUCA1C	   40	  AMOTL1	   38	  WDR60	   38	  MPHOSPH8	   36	  C15orf43	   35	  IL20	   35	  LRTM2	   34	  OTOA	   31	  LCA5	   31	  CKAP2L	   18	  LRRC16	   16	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Figure	  3.2:	  Heat	  maps	  of	  genes	  differentially	  expressed	  in	  MI	  compared	  to	  UA	  A)	  Genes	  that	  are	  differentially	  expressed	  in	  the	  STEMI	  group	  compared	  to	  the	  UA	  group.	  	  B)	  Genes	  that	  are	  differentially	  expressed	  in	  the	  NSTEMI	  group	  compared	  to	  the	  UA	  group.	  	  Heat	  map	  demonstrates	   the	  down	   (green	  map)	  or	  up	   (red	  map)	   regulation	  of	  differentially	  expressed	  genes,	  as	  indicated	  by	  the	  scale.	  	   	  
A	   B	  
Down	  regulated 
Up	  regulated 
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I	   next	   performed	   Gene	   Ontology	   analysis	   using	   the	   online	   database	   Protein	  
ANalysis	   THrough	   Evolutionary	   Relationships	   (PANTHER).	   This	   is	   a	  classification	   system	   that	   classifies	   genes	   by	   their	   functions,	   using	   published	  scientific	   experimental	   evidence	   and	   evolutionary	   relationships	   to	   predict	  function	  even	  in	  the	  absence	  of	  direct	  experimental	  evidence.	  	  A	  summary	  of	  the	  PANTHER	  analysis	  can	  be	  seen	  in	  table	  3.4.	  	  The	  PANTHER	  output	  table	  shows	  genes	  that	  are	  differentially	  down	  regulated	  are	  mostly	   involved	   in	   the	   cell	   communication	   biological	   processes	   as	  well	   as	  extracellular	   matrix	   structural	   molecular	   process	   and	   G	   protein	   coupled	  receptor	  and	  other	  receptor	  protein	  classes.	  Up	   regulated	   genes	   are	   involved	   in	   immune	   response,	  macrophage	   activation	  and	   response	   to	   stimulus	   biological	   processes.	   Molecular	   processes	   such	   as	  receptor	  and	  transmembrane	  activity	  are	  also	  involved	  as	  well	  as	  being	  part	  of	  transporter	   protein	   class.	   These	   findings	   link	   accordingly	   to	   known	   gene	  function	   and	   other	   processes	   that	   occur	   during	   a	   response	   to	   a	   myocardial	  infarction.	  An	  up	  regulation	  of	  macrophage	  activation	  and	  immune	  response	  is	  part	   of	   the	   coagulation	   response	   to	   a	   MI.	   As	   endothelial	   dysfunction	   plays	   a	  large	  role	  in	  precession	  to	  MI	  a	  down	  regulation	  in	  cell	  communication	  might	  be	  anticipated	  as	  well	  as	   the	  G	  protein	  coupled	  receptors.	  The	  heat	  map	   in	   figure	  3.3	   shows	   the	   significant	   differentially	   expressed	   genes	   that	   also	   have	   a	  homology	  of	  greater	  than	  50%	  with	  the	  human	  genes.	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Table	   3.3.	   PANTHER	   output	   for	   genes	   that	   are	   differentially	   expressed	   in	   MI	  
compared	  to	  UA.	  	  	  
Gene	  Symbol	   CXCR7	  
Regulation	   Up	  
Biological	  process	   Cell	  communication	  
Cellular	  process	  
Immune	  response	  
Immune	  system	  process	  
Response	  to	  stimulus	  
Signal	  transduction	  
Cell	  motion	  
Molecular	  process	   G	  protein	  coupled	  receptor	  activity	  
Receptor	  activity	  
Protein	  class	   G	  protein	  coupled	  receptor	  	  
Receptor	  
Gene	  Symbol	   C19orf6	  
Regulation	   Up	  
Molecular	  process	   Structural	  cellular	  activity	  
Gene	  Symbol	   COL8A1	  
Regulation	   Down	  




Immune	  system	  response	  
Macrophage	  activation	  
Response	  to	  stimulus	  
Signal	  transduction	  
Skeletal	  system	  development	  
Transport	  
Molecular	  process	   Receptor	  activity	  
Structural	  cellular	  activity	  
Extracellular	  matrix	  structural	  constituent	  
Cellular	  process	   Extracellular	  matrix	  
Extracellular	  region	  
Gene	  Symbol	   DAAM2	  
Regulation	   Down	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Biological	  process	   Cellular	  process	  
Cell	  motion	  
Molecular	  process	   Structural	  cellular	  activity	  
Gene	  Symbol	   FREM1	  
Regulation	   Up	  
Biological	  process	   Cell	  communication	  
Cellular	  process	  
Immune	  system	  process	  
Macrophage	  activation	  
Response	  to	  stimulus	  
Signal	  transduction	  
Transport	  
Vesicle	  mediated	  transport	  
Molecular	  process	   Receptor	  activity	  
Cellular	  process	   	  	  
Protein	  class	   Receptor	  
Gene	  Symbol	   KIAA1109	  
Regulation	   Down	  
Gene	  Symbol	   RGR	  
Regulation	   Down	  
Biological	  process	   Cell	  communication	  
Cellular	  process	  
Immune	  response	  
Immune	  system	  process	  
Response	  to	  stimulus	  
Signal	  transduction	  
Cell	  motion	  
Molecular	  process	   G	  protein	  coupled	  receptor	  activity	  
Protein	  class	   G	  protein	  coupled	  receptor	  	  
Receptor	  
Gene	  Symbol	   SCARA5	  
Regulation	   Up	  
Biological	  process	   Cell	  communication	  
Cellular	  process	  
Immune	  system	  process	  
Macrophage	  activation	  
Response	  to	  stimulus	  
Signal	  transduction	  
Transport	  
Vesicle	  mediated	  transport	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Molecular	  process	   Receptor	  activity	  
Structural	  cellular	  activity	  
Extracellular	  matrix	  structural	  constituent	  
Transporter	  activity	  
Cellular	  process	   Extracellular	  matrix	  
Extracellular	  region	  
Protein	  class	   Transporter	  
Gene	  Symbol	   SBF2	  
Regulation	   Up	  
Biological	  process	   Transport	  
Vesicle	  mediated	  transport	  
Gene	  Symbol	   SMURF1	  
Regulation	   Up	  
Biological	  process	   Skeletal	  system	  development	  
Gene	  Symbol	   SLC1A1	  
Regulation	   Up	  




Molecular	  process	   Transmembrane	  transport	  
Transmembrane	  activity	  
Protein	  class	   Transporter	  
Gene	  Symbol	   SLC2A13	  
Regulation	   Up	  
Biological	  process	   Carbohydrate	  transport	  
Transport	  
Molecular	  process	   Carbohydrate	  transmembrane	  transporter	  activity	  
Transmembrane	  transport	  
Transporter	  activity	  
Protein	  class	   Carbohydrate	  transporter	  
Transporter	  
Gene	  Symbol	   UNC5B	  
Regulation	   Down	  
Biological	  process	   Cell	  communication	  
Cellular	  process	  
Signal	  transduction	  
Molecular	  process	   Receptor	  activity	  
Protein	  class	   Receptor	  
Gene	  Symbol	   WDR42A	  
Regulation	   Up	  
Biological	  process	   Cell	  communication	  
Cellular	  process	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Figure	  3.3.	  Heat	  map	  illustrating	  expression	  patterns	  at	  different	  time	  points.	  	  Heat	  map	  demonstrates	   the	  down	   (green	  map)	  or	  up	   (red	  map)	   regulation	  of	  differentially	  expressed	  genes	  conserved	  in	  zebrafish.	  The	  gene	  names	  that	  are	  starred	  represent	  genes	  that	  have	  a	  protein	  homology>50%	  with	  zebrafish.	  	  	  	  	  
	   	  
Down	  regulated 
Up	  regulated *	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3.3.	  Discussion	  
The	  data	  presented	   in	   this	   chapter	   confirm	  my	  hypothesis	   that	   the	  peripheral	  blood	  transcriptome	  differs	   in	  patients	  with	  MI	  compared	  with	  UA.	  Due	  to	   the	  large	   amount	   of	   data	   generated	   by	   the	   time	   course	   of	   expression	   profiling,	   I	  restricted	  my	  focus	  to	  genes	  that	  were	  differentially	  expressed	  between	  groups	  at	   the	   earliest	   time	   point	   examined	   (1d	   post	   admission).	   Despite	   this	   narrow	  focus	   I	   identified	  99	  genes	   that	  were	  differentially	   expressed	  between	  MI	   and	  UA,	  even	  using	  stringent	  cut	  offs	  for	  fold	  change	  (≥2)	  and	  statistical	  significance	  (PPLR≥0.8	  or	  ≤0.2).	  Although	  these	  data	  are	  purely	  observational	  and	  do	  not	  support	  any	  causal	  link	  between	   the	   differentially	   expressed	   genes	   and	   the	   initiation	   of	   an	   ACS,	   it	   is	  interesting	  that	  the	  most	  significantly	  differentially	  expressed	  genes	  were	  those	  involved	   in	   the	   immune	   response,	   cell	   communication	   and	   macrophage	  activation,	   all	   processes	   known	   to	   be	   involved	   in	   plaque	   rupture	   and	  coagulation.	  Although	   peripheral	   whole	   blood	   has	   previously	   been	   used	   in	   cardiovascular	  research	   (Sinnaeve	   et	   al.,	   2009,	   Taurino	   et	   al.,	   2010)	   one	   of	   its	   major	  disadvantages	   is	   the	   inability	   to	   tell	   which	   cell	   type	   the	   signal	   comes	   from.	  Peripheral	   whole	   blood	   transcriptomic	   changes	   might	   include	   differential	  expression	   signatures	   from	   leukocytes,	   reticulocytes,	   platelets	   or	   even	   rare	  hematopoietic	   progenitors	   (Sinnaeve	   et	   al.,	   2009).	   My	   data	   cannot	   determine	  which	  of	  these	  cells	  are	  giving	  rise	  to	  the	  signal	  detected.	  However,	  since	  this	  is	  the	  first	  work	  attempting	  to	  identify	  a	  transcriptomic	  “signature”	  of	  MI,	  the	  use	  of	  the	  most	  comprehensive	  (and	  most	  easily	  obtained	  and	  processed)	  source	  of	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RNA	  seems	  justified	  as	  a	  first	  step.	  Further	  work	  profiling	  the	  transcriptome	  of	  isolated	  components	  of	  peripheral	  blood	   is	  necessary	   to	   identify	   the	  source	  of	  the	  differentially	  expressed	  genes.	  	  We	   used	   microarrays	   for	   this	   study	   due	   to	   their	   sensitivity	   and	   cost	  effectiveness.	  Serial	  analysis	  of	  gene	  expression	  (SAGE)	  and	  massively	  parallel	  signature	   sequencing	   (MPSS)	   are	  well-­‐established	  alternatives	   to	  microarrays.	  More	  recently,	  direct	  sequencing	  of	  transcripts	  by	  high-­‐throughput	  sequencing	  technologies	   (RNA-­‐Seq)	   has	   become	   a	   growing	   alternative	   to	  microarray	   and	  like	   SAGE	   and	  MPPS	   does	   not	   depend	   on	   genome	   annotation	   for	   prior	   probe	  selection.	   The	   main	   challenges	   of	   RNA-­‐Seq	   are	   that	   they	   present	   novel	  algorithmic	   and	   logistic	   challenges,	   and	   current	   RNA-­‐Seq	   strategies	   require	  lengthy	   and	   time-­‐consuming	   library	   preparation	   procedures.	   Microarrays	   are	  still	  widely	  used	  due	  to	  their	  robust	  sample	  processing	  and	  analysis	  pipelines,	  in	  particular	   for	   projects	   that	   involve	   large	   numbers	   of	   samples	   for	   profiling	  transcripts	   in	  model	  organisms	  with	  well-­‐annotated	  genomes	   (Baginsky	  et	   al.,	  2010).	  
The	   output	   of	   the	   microarray	   analysis	   was	   normalised	   and	   fold	   change	   (FC)	  between	   groups	   calculated.	   Filtering	   genes	   by	   FC	   has	   been	   shown	   to	   select	  genes	   that	   can	   be	   reliably	   and	   consistently	   compared	   across	   experiments	  (Mutch	   et	   al.,	   2002).	   	   Filtering	  by	  FC	   alone	  does	  not	   assure	   significance	   as	   FC	  measurements	   themselves	   do	   not	   account	   for	   measurement	   error	   or	  fluctuations	   in	   absolute	   gene	   expression	   level	   (Newton	   et	   al.,	   2001).	   These	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changes/errors	   can	   render	   results	   un-­‐reproducible	   which	   reduces	   the	  significance	   of	   findings.	   To	   improve	   the	   reproducibility	   of	   results	   expression	  results	   can	   be	   filtered	   again	   by	   P-­‐value	   (Shi	   et	   al.,	   2008).	   This	   is	   how	   the	  majority	  of	  expression	  studies	  obtain	  testable	  gene	  lists.	  Our	  analysis	  however	  has	  been	  conducted	  using	  novel	  probabilistic	  methods	  and	  requires	  filtering	  by	  different	  means.	   PUMA	  computes	  PPLR	  values	   for	   each	   gene/probe	   and	   takes	  into	  account	  probe	  level	  measurement	  error	  and	  (particularly	  important	  due	  to	  the	  small	  cohort	  being	  assessed)	  variance	  across	  replicates	  (i.e.	  between	  chips	  and	   individuals).	   This	   approach	   has	   improved	   detection	   of	   differentially	  expressed	   genes	   (Liu	   et	   al.,	   2006b)	   and	   due	   to	   the	   inclusion	   of	   sources	   of	  variation,	   can	   be	   a	   more	   accurate	   way	   of	   filtering	   than	   by	   P-­‐value.	   PPLR	  however	  can	  be	  seen	  as	  analogous	  to	  P-­‐values	  when	  considering	  the	  most	  and	  least	  significant	  genes.	  Although	  the	   insignificant	  genes	  were	  discarded	  before	  further	  analysis.	  
In-­‐silico	   methods	   were	   used	   to	   further	   analyse	   the	   list	   of	   significantly	  differentially	   expressed	   genes	   in	   order	   to	   determine	   a	   candidate	   gene.	  PANTHER	   is	   a	  widely	   used	   database	   for	   high	   throughput	   protein	   analysis.	   In-­‐
silico	   analysis	   provides	   important	   information	   on	   gene	   function	   and	   pathway	  processes	   providing	   a	   more	   in-­‐depth	   knowledge	   of	   the	   group	   as	   well	   as	  individual	  genes	   involved	   in	  myocardial	   infarctions.	   It	  can	  also	  provide	   insight	  as	   to	   the	   causative	   or	   responsive	   involvement	   of	   the	   genes	   compared	   to	  controls.	  	  From	   the	   99	   differentially	   expressed	   genes	   identified,	   only	   14	  were	   found	   to	  possess	   a	   highly	   conserved	   zebrafish	   homologue.	   Although	   reducing	   the	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stringency	   of	   the	   cut	   off	   used	   (for	   example	   accepting	   less	   protein	   homology)	  would	   increase	   the	   number	   of	   zebrafish	   orthologues,	   it	   is	   clear	   that	   unbiased	  genomic	   techniques	   in	   humans	  will	   yield	   a	   significant	   number	   of	   targets	   that	  would	  be	  difficult	  to	  functionally	  assess	  in	  zebrafish.	  However,	  it	  can	  be	  argued	  that	   the	  more	   evolutionarily	   conserved	   a	   gene	   is,	   the	  more	   fundamental	   is	   its	  likely	  role	  in	  both	  development	  and	  potentially	  in	  disease	  related	  mechanisms.	  It	  is	  noteworthy	  that	  many	  biological	  agents	  that	  therapeutically	  target	  specific	  molecules	   in	   human	   disease	   (anti-­‐TNF,	   anti-­‐IL1,	   anti-­‐VEGF)	   inhibit	   gene	  products	  that	  are	  highly	  conserved	  between	  zebrafish	  and	  humans.	  	  In	   search	   for	   a	   novel	   gene	   that	   is	   differentially	   expressed	   in	   MI	   patients	  compared	  to	  UA	  to	  further	  functionally	  assess,	  the	  most	  significant	  differentially	  expressed	  gene	  at	  1	  day	  post	  admission	  as	  well	  as	  having	  the	  highest	  sequence	  homology	  to	  zebrafish	  was	  selected.	  KIAA1109	  was	  selected	  not	  only	  due	  to	  its	  high	   homology	   to	   zebrafish,	   most	   significant	   differential	   expression	   at	   1	   day	  post	  admission	  and	  novelty	  but	  also	  due	  to	  its	  presence	  in	  endothelial	  cells	  and	  leukocytes	  as	  shown	  by	  previous	  microarrays.	  In	  this	  next	  chapter	  I	  will	  assess	  the	  functional	  role	  of	  KIAA1109	  using	  a	  zebrafish	  model.	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Chapter	  4:	  An	  examination	  of	  the	  role	  
of	  KIAA1109	  in	  vascular	  development	  
in	  zebrafish	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4.1.	  Introduction	  
4.1.1.	  Role	  of	  KIAA1109	  in	  humans	  KIAA1109,	  identified	  as	  part	  of	  the	  Kazusa	  ORFeome	  Project	  (Project)	  was	  first	  described	   as	   encoding	   a	   novel	   G8	   domain,	   related	   to	   other	   human	   disease	  related	  proteins	  (He	  et	  al.,	  2006)	  such	  as	  PKHD1	  and	  KIAA1199,	  up	  regulation	  of	  which	   is	  associated	  with	  cellular	  mortality	   (Michishita	  et	  al.,	  2006).	  KIAA1109	  was	   later	   described	   as	   part	   of	   a	   linkage	   disequilibrium	   block	  KIAA1109/TENR/IL-­‐1/IL-­‐21	   (van	  Heel	   et	   al.,	   2007).	  Van	  Heel	  et	  al	   found	   that	  the	  4q27	  celiac	  disease	  associated	   region	  which	   they	  had	   identified	   contained	  KIAA1109,	  which	  was	  widely	   expressed	   as	  multiple	   splice	   variants	   in	   various	  tissue	   types.	   They	   also	   found	   that	   although	   no	   difference	   in	   KIAA1109	  expression	   could	   be	   observed	   between	   normal	   and	   celiac	   disease	   duodenal	  tissue,	  in	  the	  presence	  of	  inflammation	  KIAA1109	  expression	  was	  reduced	  (van	  Heel	  et	  al.,	  2007).	  	  KIAA1109	   has	   further	   been	   associated	   with	   type	   1	   diabetes	   (T1D)	   and	  rheumatoid	   arthritis	   (RA)	   by	   Zhernakova	   et	   al.	   The	   authors	   carried	   out	   a	  genome	  wide	  association	  study	  and	  found	  the	  region	  to	  be	  associated	  with	  T1D	  and	  RA	  in	  Dutch	  patients	  (Zhernakova	  et	  al.,	  2007).	  In	  consideration	  of	  the	  Van	  Heel	   findings	   they	   concluded	   that	   the	   KIAA1109/TENR/IL-­‐1/IL-­‐21	   linkage	  disequilibrium	  block	  might	  be	  a	  locus	  for	  autoimmune	  disease.	  	  Tindall	  et	  al	  also	  looked	  at	  the	  4q27	  region	  in	  association	  with	  prostate	  cancer	  risk	  and	  found	  that	  genetic	  variation	  within	  the	  region	  might	  be	  associated	  with	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susceptibility	   to	   the	   disease	   in	   men	   with	   family	   history	   and	   suggested	   that	  KIAA1109	  may	  play	  a	  potential	  role	  in	  conferring	  this	  risk	  (Tindall	  et	  al.,	  2010).	  KIAA1109	  is	  also	  known	  as	  Fragile	  Site	  Associated	  (FSA)	  and	  is	  reported	  by	  Kuo	  
et	  al	   to	  play	  an	   important	  role	   in	  regulating	  mammalian	  epithelial	  growth	  and	  differentiation	  and	  tumour	  development	  (Kuo	  et	  al.,	  2006).	  These	   findings	   implicate	  KIAA1109	   in	  a	   range	  of	  human	  diseases,	  but	  without	  demonstrating	  its	  function	  either	  in	  normal	  processes	  or	  pathology.	  Since	  I	  had	  demonstrated	   KIAA1109	   is	   down	   regulated	   in	   peripheral	   blood	   following	  myocardial	  infarction	  (Chapter	  3)	  I	  sought	  to	  examine	  its	  role	  in	  cardiovascular	  development.	  The	   KIAA1109	   gene	   is	   located	   on	   chromosome	   4	   in	   humans	   and	   on	  chromosome	  13	  in	  zebrafish.	  The	  human	  gene	  has	  83	  exons	  and	  is	  15000	  base	  pairs	  long.	  It	  has	  99%	  homology	  with	  the	  murine	  gene	  and	  74%	  homology	  with	  the	  zebrafish	  gene	  and	  encodes	  a	  protein	  that	  contains	  a	  transmembrane	  helix	  domain	  and	  is	  hypothesised	  to	  be	  integral	  to	  the	  membrane	  by	  UniProtKB-­‐KW	  electronic	   annotation. The	   protein	   has	   a	   predicted	   molecular	   weight	   of	  555519.38	  daltons.	  The	  isoelectric	  point	  of	  KIAA1109	  protein	  is	  predicted	  to	  be	  6.12.	  The	   EST	   profile	   for	   KIAA1109	   as	   can	   be	   seen	   on	   the	   NCBI	   website	   (NCBI)	  KIAA1109	   is	  expressed	   in	  34	  human	   tissues	  at	  all	  developmental	   stages	  other	  than	  infancy	  (Table	  4.1	  and	  4.2.).	  	  	  Using	   Search	   Tool	   for	   the	   Retrieval	   of	   Interacting	   Genes/Proteins	   (STRING)	  known	  and	  predicted	  protein-­‐protein	  interactions	  can	  be	  observed	  (figure	  4.1).	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Table	  4.1.	  Table	  of	  KIAA1109	  in	  human	  tissue	  from	  KIAA1109	  EST	  profile.	  
Body	  sites	   transcripts	  per	  
million	  (TPM)	  
Body	  sites	   transcripts	  
per	  million	  
(TPM)	  
adipose	  tissue	   77	   mouth	   15	  
adrenal	  gland	   30	   muscle	   150	  
ascites	   0	   nerve	   64	  
bladder	   0	   ovary	   0	  
blood	   65	   pancreas	   65	  
bone	   69	   parathyroid	   242	  
bone	  marrow	   41	   pharynx	   0	  
brain	   76	   pituitary	  
gland	  
60	  
cervix	   0	   placenta	   70	  
connective	  
tissue	  
13	   prostate	   52	  
ear	   124	   salivary	  gland	   0	  
embryonic	  
tissue	  
51	   skin	   18	  
esophagus	   0	   spleen	   18	  
eye	   90	   stomach	   31	  
heart	   33	   testis	   27	  
intestine	   25	   thymus	   62	  
kidney	   14	   thyroid	   64	  
larynx	   0	   tonsil	   0	  
liver	   24	   trachea	   38	  
lung	   23	   umbilical	  
cord	  
0	  
lymph	   0	   uterus	   30	  
lymph	  node	   89	   vascular	   38	  
mammary	  gland	   99	   	   	  	  Table	   above	   demonstrates	   the	   transcripts	   per	   million	   (TPM)	   of	   KIAA1109	  expression	  in	  healthy	  tissue.	  	  	  	  	  	  
	   Sara	  Solaymani-­‐Kohal	  101	  
	  





embryoid	  body	   57	  
blastocyst	   81	  
foetus	   52	  
neonate	   64	  
infant	   0	  
juvenile	   17	  
adult	   64	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Figure	  4.1.	  	  STRING	  output	  of	  KIAA1109	  interaction	  with	  genes.	  	  Diagram	  shows	  the	  genes	  that	  strongly	  interact	  or	  are	  predicted	  to	  interact	  with	  KIAA1109.	  The	  table	  also	  contains	  a	  list	  of	  gene	  names	  included	  in	  the	  diagram.	  	  	  	   	  
Protein	   Description	  
ADAD1	   adenosine	  deaminase	  domain	  containing	  1	  (testis-­‐specific);	  Plays	  a	  role	  in	  spermatogenesis.	  	  
IL21	   interleukin	  21;	  Cytokine	  with	  immunoregulatory	  activity.	  
MEFV	   Mediterranean	   fever;	   Probably	   controls	   the	   inflammatory	  response	  in	  myelomonocytic	  cells	  at	  the	  level	  of	  the	  cytoskeleton	  organization	  
SLA	   Src-­‐like-­‐adaptor;	   Adapter	   protein,	   which	   negatively	   regulates	   T-­‐cell	   receptor	   (TCR)	   signaling.	   Inhibits	   T-­‐cell	   antigen-­‐receptor	  induced	  activation	  of	  nuclear	  factor	  of	  activated	  T-­‐cells.	  Involved	  in	   the	  negative	   regulation	  of	  positive	  selection	  and	  mitosis	  of	  T-­‐cells.	  
TNFA1P8L3	   tumour	  necrosis	  factor,	  alpha-­‐induced	  protein	  8-­‐like	  3	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There	   is	   no	   data	   on	   the	   effect	   of	   KIAA1109	   loss	   of	   function	   in	   any	   model,	   no	  KIAA1109	   knockout	  mouse	   has	   been	   generated	   and	   no	   functional	   role	   has	   ever	  been	  ascribed	  to	  this	  gene,	  aside	  from	  the	  genetic	  associations	  detailed	  above.	  Since	  KIAA1109	  was	  differentially	  expressed	   in	  peripheral	  blood	  following	  ACS.	   I	  therefore	  wished	   to	   determine	   its	   function.	   I	   chose	   to	   examine	   this	   in	   zebrafish,	  since	   this	   model	   possesses	  many	   advantages	   for	   rapid	   functional	   assessment	   of	  uncharacterized	  genes	  (see	  section	  1.3).	  
4.2.	  Results:	  
4.2.1.	  qRT-­‐PCR	  validation	  of	  KIAA1109	  down	  regulation	  In	   order	   to	   validate	   the	   differential	   expression	   of	   KIAA1109	   in	   patients	  with	  MI	  compared	  to	  UA,	  quantitative	  RT-­‐PCR	  was	  carried	  out	  alongside	  the	  housekeeping	  gene,	   DECR1	   (Stamova	   et	   al.,	   2009).	   The	   patterns	   of	   KIAA1109	   expression	   in	  STEMI,	  NSTEMI	  and	  UA	  patients	  follow	  that	  of	  the	  microarray	  as	  shown	  in	  figure	  4.2.	   There	   is	   a	   reduced	   expression	   of	   KIAA1109	   in	   the	   MI	   patients	   (STEMI	   and	  NSTEMI)	  compared	  to	  the	  UA	  group,	  however	  this	  was	  not	  statistically	  significant.	  This	  could	  be	  due	  to	  the	  quality	  of	  the	  RNA,	  which	  had	  been	  stored	  for	  a	  long	  time.	  It	  could	  also	  be	  due	  to	  the	  use	  of	  inappropriate	  housekeeping	  genes.	  	  
4.2.2.	  Expression	  of	  KIAA1109	  in	  zebrafish	  To	   determine	   the	   normal	   expression	   pattern	   of	   KIAA1109	   in	   zebrafish,	   gene	  specific	   primers	  were	   designed	   to	   produce	   an	   800bp	   product.	   Figure	   4.3	   shows	  expression	  of	  this	  partial	  KIAA1109	  transcript	  at	  1-­‐5dpf	  in	  wildtype	  nacre	  embryo	  cDNA.	  	  KIAA1109	  transcript	  could	  be	  detected	  at	  all	  time	  points,	  suggesting	  it	  is	  expressed	  throughout	  these	  stages	  of	  development.	  Although	  expression	  appears	  to	  be	  lower	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Figure	  4.2.	  qRT-­‐PCR	  validation	  of	  KIAA1109	  The	   graph	   above	   shows	   qRT-­‐PCR	   expression	   of	   KIAA1109	   in	   STEMI	   (N=4),	  NSTEMI	  (N=10)	  and	  UA	  (N=	  5)	  patient	  samples.	  Plotted	  relative	  to	  housekeeping	  gene	  DECR1.	  	  	  	  	  	  	   	  	  	  	  	  
Figure	  4.3.	  Expression	  of	  KIAA1109	  in	  1-­‐5dpf	  cDNA	  Image	  of	  gel	  electrophoresis	  demonstrates	  the	  expression	  of	  KIAA1109	  at	  1-­‐5dpf	  wildtype	  embryo	  cDNA.	  Pooled	  300	  embryos	  per	  sample.	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at	  the	  earlier	  time	  points	  with	  least	  expression	  at	  3dpf	  increasing	  to	  a	  maximum	  at	  5dpf,	  gel	  based	  PCR	  is	  semi-­‐quantitative	  at	  best.	  Bands	  were	  extracted	  and	  purified	  for	  sequencing	  which	  confirmed	  these	  bands	  do	  indeed	  represent	  amplification	  of	  KIAA1109	  at	  all	  time	  points.	  	  Using	  this	  purified	  KIAA1109	  PCR	  product	  a	  RNA	  KIAA1109	   in	  situ	  hybridisation	  probe	   was	   synthesised	   as	   described	   in	   chapter	   2	   (2.8).	   KIAA1109	   expression	  within	  whole	  embryos	  was	  observed	  at	  1-­‐3dpf	  in	  nacre	  embryos	  (figure.4.4).	  Nacre	  embryos	   are	   advantageous	   for	   whole	   mount	   in	   situ	   hybridization	   as	   they	   lack	  melanocytes	   and	  allow	   for	  better	   visualisation	  of	   the	   localisation	  of	   the	  probe.	  A	  sense	   probe	   was	   also	   synthesised	   as	   a	   control.	   At	   1dpf	   there	   was	   non-­‐specific	  expression	   in	   the	  brain	  and	   less	   in	   the	  tail.	  This	  expression	   increased	  at	  day	  2	   in	  both	  the	  head	  and	  the	  tail,	  and	  remained	  the	  same	  in	  the	  head	  at	  3dpf	  however	  it	  was	   reduced	   in	   the	   tail.	   These	   results	   have	   to	   be	   interpreted	  with	   caution,	   since	  developing	   the	   sense	   probe	   for	   the	   same	   period	   of	   time	   leads	   to	   staining	   in	   the	  head,	  but	  not	  the	  trunk	  (figure	  4.4).	  Later	  time	  points	  could	  not	  be	  performed	  due	  to	   the	   inability	   of	   the	   in	   situ	   probe	   to	   penetrate	   the	   tissue	   at	   older	   time	   points.	  From	  these	  data,	  I	  concluded	  that	  KIAA1109	  is	  ubiquitously	  expressed	  in	  zebrafish	  at	  2dpf,	   in	  particular	   in	  the	  trunk,	  and	  possibly	  also	  the	  head	  though	  the	  staining	  with	   the	   sense	   probe	   makes	   this	   uncertain.	   Ubiquitous	   or	   near	   ubiquitous	  expression	  might	  be	  expected	  given	  the	  data	  presented	  in	  table	  4.1.	  
4.2.3.	  Survival	  of	  KIAA1109	  morphant	  embryos	  In	   order	   to	   ascertain	   an	   optimum	   dosage	   of	   the	   KIAA1109	  morpholino,	   embryo	  survival	   was	   observed	   after	   injection	   of	   a	   range	   of	   concentrations.	   Initially	   the	  embryos	  were	  injected	  with	  0.05pmol	  	  morpholino	  (figure	  4.5).	  	   	  
















Figure	  4.6.	  Heart	  rate	  of	  mismatch	  control	  and	  KIAA1109	  morphant	  nacre	  embryos	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As	  shown	  in	  figure	  4.5	  there	  was	  a	  high	  death	  rate	  at	  a	  1nl	  concentration	  and	  so	  the	  dose	  was	  halved	  which	  increased	  the	  survival	  rate	  significantly	  and	  was	  therefore	  used	   for	   subsequent	   injections.	   “Optimisation”	   of	   morpholino	   dose	   according	   to	  mortality	   is	  usual,	  however,	   it	   is	  possible	   that	   the	  mortality	   seen	  was	  due	  not	   to	  toxicity	  but	  a	  specific	  and	  lethal	  effect	  of	  KIAA1109	  deficiency,	  and	  that	  the	  lower	  dose	  induced	  less	  KIAA1109	  knockdown	  to	  allow	  survival.	  As	  discussed	  in	  chapter	  1	   (1.5.2),	   use	   of	   morpholino	   antisense	   does	   suffer	   a	   number	   of	   disadvantages,	  though	  these	  are	  balanced	  by	  their	  general	  efficiency	  and	  rapidity	  of	  use.	  	  	  	  
4.2.4.	   Effect	   of	   KIAA1109	   morpholino	   knockdown	   on	   cardiovascular	  
performance	  Once	   I	   had	   determined	   a	   dose	   of	   morpholino	   that	   did	   not	   induce	   significant	  mortality,	   I	   characterised	   the	   effect	   of	   KIAA1109	   knockdown	   on	   a	   range	   of	  cardiovascular	  parameters.	  
4.2.4.1.	  Heart	  rate	  Heart	  rates	  were	  measured	  (without	  the	  administration	  of	  tricaine)	  in	  embryos	  by	  counting	  heart	  beat	  number	  for	  thirty	  seconds.	  	  Figure	  4.6	  shows	  that	  there	  was	  no	  significant	  difference	  in	  the	  heart	  rate	  of	  control	  and	  KIAA1109	  morphant	  embryos	  at	  2dpf.	  However	  the	  heart	  rate	  of	  the	  morphant	  embryos	  was	  significantly	  lower	  than	  control	   at	  3dpf	  with	  no	   significant	  difference	  again	  at	  4dpf.	   	   Schwerte	  et	  al.	  examined	  heart	  rate	  in	  zebrafish	  and	  found	  that	  average	  heartbeats	  per	  minute	  in	  zebrafish	  were	  approximately	  140bpm	  at	  2dpf,	  170bpm	  at	  3dpf	  and	  190bpm.	  My	  findings	  correspond	  to	  these	  readings	  for	  the	  control	  at	  2	  and	  3dpf	  however	  heart	  rate	   decreases	   at	   4dpf.	   In	   KIAA1109	  morphants	   heart	   rate	   is	   significantly	   lower	  than	  those	  reported	  by	  Schwerte	  at	  3	  and	  4dpf	  (Schwerte,	  2009).	  	  	  The	  reasons	  for	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Figure	  4.7.	  Example	  of	  PIV	  output.	  The	  screenshot	  above	  demonstrates	  particle	  velocimetry	  (PIV)	  output	  in	  order	  to	  measure	   erythrocyte	   velocity.	   The	   software	   assigns	   arrows	   to	   moving	   particles	  over	   the	   time	  of	   the	   video	   according	   to	   their	   direction	   and	   the	   colour	   correlates	  with	  the	  velocity	  of	  the	  moving	  particle,	  red	  being	  the	  fastest	  and	  blue	  the	  slowest.	  A	  line	  is	  drawn	  over	  the	  area	  of	  interest	  and	  the	  mean	  velocity	  is	  noted	  and	  plotted.	  	  	  	  
	  
Figure	   4.8.	   Mean	   arterial	   erythrocyte	   velocity	   in	   mismatch	   control	   and	   KIAA1109	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these	  discrepancies	  may	  lie	  in	  strain	  differences	  or	  the	  fact	  that	  I	  measured	  heart	  rate	  in	  non-­‐temperature	  controlled	  conditions	  (Denvir	  et	  al.,	  2008).	  	  
4.2.4.2.	  Arterial	  velocity	  I	   next	   measured	   aortic	   erythrocyte	   velocity	   to	   ascertain	   whether	   KIAA1109	  knockdown	  had	  any	  effect	  on	  cardiac	  output.	  Average	  arterial	  erythrocyte	  velocity	  was	  measured	   by	   using	   particle	   image	   velocimetry	   technology,	   in	  which	   arrows	  show	  direction	   of	   flow	   and	   the	   colours	   represent	   the	   erythrocyte	   velocity	   of	   the	  area	   of	   interest	   as	   shown	   in	   figure	   4.7.	   For	   arterial	   erythrocyte	   velocity,	  measurements	  along	  the	  caudal	  artery	  were	  obtained	  at	  regular	  intervals,	  of	  which	  the	  mean	  is	  shown	  in	  figure	  4.8.	  	  	  At	  2dpf	  no	  significant	  difference	  can	  be	  observed	  between	  control	  and	  morphant	  embryos.	  However	   at	   3dpf	  morphant	   embryos	  had	   a	   significantly	  higher	   arterial	  erythrocyte	  velocity	  compared	  to	  the	  control	  which	  decreased	  at	  4dpf,	  showing	  no	  significant	  difference	  between	  the	  two	  groups.	  	  
	  
4.2.4.3.	  Venous	  velocity	  I	  next	  measured	  the	  effect	  of	  KIAA1109	  knockdown	  on	  erythrocyte	  velocity	  in	  the	  caudal	   vein.	   Average	   venous	   erythrocyte	   velocity	   was	   measured	   by	   using	   PIV	  technology,	   taking	   measurements	   along	   the	   caudal	   vein	   at	   regular	   intervals,	   of	  which	  the	  mean	  is	  plotted	  as	  shown	  in	  figure	  4.9.	  	  	  No	  significant	  difference	  was	  detected	  in	  venous	  erythrocyte	  velocity	  between	  the	  groups	  over	  these	  time	  points.	  Generally,	  venous	  erythrocyte	  velocity	  is	  lower	  than	  arterial	   erythrocyte	   velocity	   at	   all	   time	   points,	   as	   expected	   given	   the	   greater	  diameter	  of	  the	  vein.	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Figure	   4.9.	   Mean	   venous	   erythrocyte	   velocity	   in	   mismatch	   control	   and	   KIAA1109	  
morphant	  nacre	  embryos	  at	  2-­‐4dpf	  Graph	  demonstrates	  average	  venous	  erythrocyte	  velocity	  in	  the	  mismatch	  control	  (white	  bars)	  and	  KIAA1109	  morphant	  (grey	  bars)	  at	  2-­‐4dpf.	  Mean	  ±	  SEM.	  One	  way	  ANOVA,	  Bonferroni	  post	  test.	  P=NS.	  N=10,	  30	  embryos	  per	  group.	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4.2.5.	   Effect	   of	   KIAA1109	   morpholino	   knockdown	   on	   embryonic	   vascular	  
development	  
4.2.5.1.	  ISV	  formation	  To	   ascertain	   the	   effect	   of	   KIAA1109	   knockdown	  on	   angiogenesis,	   the	   number	   of	  intersegmental	   vessels	   was	   counted	   within	   a	   region	   of	   interest,	   defined	   as	   the	  number	  of	   intersegment	  vessels	   from	   the	   caudal	   loop,	   as	   illustrated	   in	   chapter	  2	  (figure	  2.1).	   	  No	  significant	  difference	  in	  the	  number	  of	  ISVs	  between	  control	  and	  KIAA1109	  morphant	  groups	  were	  detected	  at	  2,	  3	  or	  4dpf	  (figure	  4.10).	  	  Although	  this	  does	  not	  exclude	  a	  minor	  effect	  on	  ISV	  angiogenesis,	  it	  excludes	  a	  major	  effect;	  for	   example	   VEGF	   knockdown	   or	   inhibition	   greatly	   impairs	   ISV	   number	   and	  formation	  (Covassin	  et	  al.,	  2006,	  Herbert	  et	  al.,	  2009).	  	  
4.2.5.2.	  Axial	  vessel	  formation	  To	   ascertain	   the	   effect	   of	   KIAA1109	   knockdown	   on	   development	   of	   the	   axial	  vessels,	  arterial	  formation	  was	  observed	  and	  arterial	  diameter	  measured	  using	  PIV	  images.	  No	  abnormality	  was	  observed	  in	  the	  KIAA1109	  morphant	  group	  compared	  to	  control	  morphants.	  There	  was	  also	  no	  significant	  difference	  in	  the	  mean	  arterial	  diameter	  between	  the	  two	  experimental	  groups	  across	  all	  time	  points.	  Similarly,	  no	  abnormal	  venous	   formation	  could	  be	  observed	   in	   the	  morphant	  group	  compared	  to	   the	   control.	   There	   was	   also	   no	   significant	   difference	   in	   the	   mean	   venous	  diameter	   between	   the	   two	   experimental	   groups	   across	   all	   time	   points	   shown	   in	  figure	  4.12.	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Figure	  4.10.	  Mean	  number	  of	  ISV	  in	  mismatch	  control	  and	  KIAA1109	  morphant	  nacre	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Figure	   4.11.	   Mean	   average	   arterial	   diameter	   in	   mismatch	   control	   and	   KIAA1109	  
morphant	  nacre	  embryos	  at	  2-­‐4dpf	  Graph	   demonstrates	   average	   arterial	   diameter	   in	   the	   mismatch	   control	   (white	  bars)	  and	  KIAA1109	  morphants	  (grey	  bars)	  at	  2-­‐4dpf.	  Mean	  ±	  SEM.	  One	  way	  ANOVA,	  Bonferroni	  post	  test.	  P=NS.	  N=10,	  30	  embryos	  per	  group.	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Figure	   4.12	   Mean	   average	   venous	   diameter	   in	   mismatch	   control	   and	   KIAA1109	  
morphant	  nacre	  embryos	  at	  2-­‐4dpf	  Graph	   demonstrates	   average	   venous	   diameter	   in	   the	   mismatch	   control	   (white	  bars)	  and	  KIAA1109	  morphants	  (grey	  bars)	  at	  2-­‐4dpf.	  Mean	  ±	  SEM.	  One	  way	  ANOVA,	  Bonferroni	  post	  test.	  P=NS.	  N=10,	  30	  embryos	  per	  group.	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4.2.5.3.	  The	  effect	  of	  KIAA1109	  morpholino	  knockdown	  on	  the	  cerebral	  vasculature	  While	   performing	   the	   phenotypic	   assessments	   detailed	   above,	   I	   observed	   a	  number	  of	  embryos	  with	  cerebral	  haemorrhage	  in	  the	  KIAA1109	  morphant	  group	  (figure	  4.13).	  To	  ensure	  that	  the	  phenotype	  was	  specific	  to	  KIAA1109	  knockdown	  	  splice	  and	  non-­‐overlapping	  morpholinos	  were	  designed	  (chapter	  2.7.1).	  	  To	  quantify	  the	  incidence	  of	  cerebral	  haemorrhage,	  several	  plates	  of	  embryos	  were	  injected	   and	   observed	   at	   2-­‐4dpf	   (figure	   4.14).	   There	   were	   significantly	   more	  embryos	  with	  cerebral	  haemorrhage	  in	  the	  KIAA1109	  morphant	  group	  compared	  to	  the	  control	  at	  all	   time	  points.	  The	  most	  significant	  difference	  was	  at	  3dpf	  with	  approximately	   50%	  of	  morphant	   embryos	   suffering	   from	   cerebral	   haemorrhage.	  Figure	   4.15	   shows	   that	   there	   is	   no	   significant	   difference	   in	   the	   percentage	   of	  embryos	   with	   cerebral	   haemorrhaging	   between	   the	   three	   different	   KIAA1109	  morpholinos.	  For	  the	  remainder	  of	  this	  thesis	  KIAA1109	  morphants	  refers	  to	  those	  injected	  with	  a	  ATG	  start	  site	  blocking	  morpholino.	  During	   these	   studies	   it	   was	   also	   observed	   that	   some	   control	   morphants	  occasionally	   had	   cerebral	   haemorrhages.	   However	   these	   appeared	   to	   be	   smaller	  compared	   to	   those	   in	   the	  morphant	   group.	   It	  was	   also	   observed	   that	   KIAA1109	  morphants	   frequently	   had	   several	   sites	   of	   haemorrhaging,	   consistently	   in	   the	  forebrain	   and	   hindbrain.	   To	   quantify	   the	   volume	   of	   haemorrhage	   in	   the	   groups	  confocal	  images	  were	  taken	  of	  morpholino	  injected	  fli1:GFP;GateDsRed	  transgenic	  embryos	   and	   using	   Volocity	   software	   z-­‐stack	   images	   were	   taken	   and	   volume	   of	  haemorrhages	  measured.	   If	   an	  embryo	  had	   several	   sites	  of	  haemorrhage,	   as	  was	  common	   in	   the	   KIAA1109	   morphant	   group,	   individual	   volumes	   would	   be	  calculated	  and	  summed	  for	  a	  total	  volume	  (figure	  4.16).	  These	  studies	  showed	  that	  KIAA1109	  morphant	  embryos	  had	  significantly	   larger	  volume	  of	  haemorrhage	  at	  all	  time	  points	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Figure	  4.13	  Bright	   field	   images	  of	  3dpf	  mismatch	   control	  and	  KIAA1109	  morphant	  
nacre	  embryos	  A)	   Illustrates	  1dpf	  mismatch	   control,	  ATG1,	  ATG2	   and	   splice	  morpholino	   injected	  embryos,	   demonstrating	   the	   lack	   of	   non-­‐specific,	   off	   target,	   effects	   in	   the	  knockdowns,	  and	  a	  control.	  B)	   Illustrates	   3dpf	   mismatch	   control	   nacre	   embryo	   with	   no	   cerebral	  haemorrhaging.	   C)	   Illustrates	   3dpf	   KIAA1109	   morphant	   nacre	   embryo	   with	  cerebral	  haemorrhaging	   in	   the	  hindbrain.	  Red	  box	   illustrates	   location	  of	  cerebral	  haemorrhaging	  in	  hindbrain.	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Figure	   4.14.	  Mean	  percentage	   of	  mismatch	   control	   and	  KIAA1109	  morphant	   nacre	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Figure	  4.15.	  Percentage	  of	  haemorrhaging	  in	  variety	  of	  morpholinos	  at	  3dpf.	  Graph	  above	  demonstrates	  the	  number	  of	  embryos	  with	  cerebral	  haemorrhages	  at	  3dpf	   using	   a	   start	   blocking	  morpholino	   (ATG	  MO),	   non-­‐overlapping	  morpholino	  (ATG-­‐2	   MO)	   and	   splice	   morpholino	   (Splice	   MO)	   compared	   to	   mismatch	   control	  injected	  embryos.	  Mean	  ±	  SEM.	  One	  way	  ANOVA,	  Bonferroni	  post	  test.	  P<0.05.	  N=3,	  100	  embryos	  per	  group.	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Figure	   4.16.	   Mean	   volume	   of	   mismatch	   control	   and	   KIAA1109	   morphant	   nacre	  
embryo	  haemorrhage	  2-­‐4dpf	  Graph	  demonstrates	  average	  volume	  of	  haemorrhage	   in	  mismatch	  control	  (white	  bars)	  and	  KIAA1109	  morphant	  (lined	  bars)	  2-­‐4dpf.	  Mean	  ±	  SEM.	  One	  way	  ANOVA,	  Bonferroni	  post	  test.	  P<0.05.	  N=10,	  30	  embryos	  per	  group.	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compared	   to	   the	  control,	  even	  at	  4dpf	  when	   there	  was	  no	  statistically	  significant	  difference	  in	  percentage	  of	  embryos	  with	  cerebral	  haemorrhage.	  
4.2.5.4.	  The	  effect	  of	  KIAA1109	  morpholino	  knockdown	  on	  endothelial	  cell	  number	  The	   haemorrhagic	   phenotype	   described	   above	   raised	   the	   possibility	   that	  KIAA1109	   knockdown	   induced	   a	   defect	   in	   vascular	   formation	   that	   was	   not	  detected	   in	   the	   previous	   assessments.	   I	   therefore	   quantified	   the	   number	   of	  endothelial	   cells	   present	   within	   the	   embryo.	   Transgenic	   embryos	   flk1:GFP-­‐NLS	  were	  used	   as	   they	   express	  GFP	   in	   the	   endothelial	   cell	   nuclei	   (Blum	  et	   al.,	   2008).	  Morphant	  and	  control	   flk1:GFP-­‐NLS	  embryos	  were	   imaged	  at	  2	  and	  3dpf	  using	  a	  spinning	   disc	   confocal	   microscope.	   The	   z-­‐stack	   images	   were	   exported	   as	   an	  extended	   focus,	   and	   particle	   image	   analysis	   was	   carried	   out	   using	   ImageJ.	  	  Endothelial	  cell	  nuclei	  were	  measured	  in	  the	  forebrain,	  eye,	  hindbrain,	  ISV,	  caudal	  artery	  and	  caudal	  vein.	  Figure	  4.17	  shows	  the	  number	  of	  endothelial	  cell	  nuclei	  in	  the	   eye	   of	   control	   and	   KIAA1109	   morphants	   at	   2	   and	   3dpf.	   There	   was	   no	  significant	  difference	   in	   the	  number	  of	  endothelial	   cell	  nuclei	   in	   the	  eye	  between	  groups.	  	  Figure	  4.18	  shows	  the	  number	  of	  endothelial	  cells	   in	  the	  forebrain	  of	  control	  and	  KIAA1109	   morphant	   embryos	   at	   2	   and	   3dpf.	   There	   were	   significantly	   fewer	  endothelial	   cell	   nuclei	   in	   the	   forebrain	   of	  KIAA1109	  morphants	  compared	   to	   the	  controls	   at	   2dpf.	   Although	   the	   same	   trend	   was	   apparent	   at	   3dpf	   it	   was	   not	  statistically	   significant.	   Very	   similar	   results	   were	   seen	   when	   I	   quantified	   the	  number	  of	  endothelial	  cells	  in	  the	  hindbrain	  (Figure	  4.19).	  Figure	   4.20	   shows	   the	   number	   of	   endothelial	   cells	   in	   the	   ISV	   of	   control	   and	  KIAA1109	  morphant	  embryos	  at	  2	  and	  3dpf.	  There	  was	  no	  significant	  difference	  in	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Figure	  4.17.	  Mean	  number	  of	  EC	  nuclei	   in	   eyes	   of	  mismatch	   control	   and	  KIAA1109	  
morphant	  nacre	  embryos	  2-­‐3dpf	  Graph	   demonstrates	   average	   number	   of	   EC	   nuclei	   in	   eyes	   of	   mismatch	   control	  (white	  bars)	  and	  KIAA1109	  morphant	  (lined	  bars)	  at	  	  2-­‐3dpf.	  Mean	  ±	  SEM.	  One	  way	  ANOVA,	  Bonferroni	  post	  test.	  P=NS.	  N=10,	  10	  embryos	  per	  group.	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Figure.	   4.18.	   Mean	   number	   of	   EC	   nuclei	   in	   forebrain	   of	   mismatch	   control	   and	  
KIAA1109	  morphant	  nacre	  embryos	  2-­‐3dpf	  .	  Image	  above	  graph	  demonstrates	  area	  of	  interest,	  circled	  in	  orange.	  Graph	  demonstrates	  average	  number	  of	  EC	  nuclei	  in	  forebrain	  of	  mismatch	  control	  (white	  bars)	  and	  KIAA1109	  morphant	  (lined	  bars)	  at	  2-­‐3dpf.	  Mean	  ±	  SEM.	  One	  way	  ANOVA,	  Bonferroni	  post	   test.	  P=<0.05.	  N=10,	  10	  embryos	  per	  group.	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Figure	   4.19.	   Mean	   number	   of	   EC	   nuclei	   in	   hindbrain	   of	   mismatch	   control	   and	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the	  number	  of	  endothelial	  cell	  nuclei	  in	  the	  ISV	  of	  KIAA1109	  morphants	  compared	  to	  the	  control	  embryos	  at	  either	  time	  point.	  	  Figure	  4.21	  shows	  the	  number	  of	  endothelial	  cells	   in	   the	  caudal	  artery	  of	  control	  and	   KIAA1109	   morphant	   embryos	   at	   2	   and	   3dpf.	   There	   was	   no	   significant	  difference	   in	   the	   number	   of	   endothelial	   cells	   in	   the	   caudal	   artery	   of	   KIAA1109	  morphants	  compared	  to	  the	  control	  embryos	  at	  either	  time	  point.	  Figure	  4.22	  shows	  the	  number	  of	  endothelial	  cells	  in	  the	  caudal	  vein	  of	  control	  and	  KIAA1109	   morphant	   embryos	   at	   2	   and	   3dpf.	   There	   were	   significantly	   fewer	  endothelial	  cell	  nuclei	  in	  the	  caudal	  vein	  of	  KIAA1109	  morphants	  compared	  to	  the	  control	  embryos	  at	  2dpf.	  Although	  the	  same	  trend	  was	  apparent	  at	  3dpf	  it	  was	  not	  statistically	   significant.	   Thus,	   KIAA1109	   knockdown	   induces	   a	   reduction	   of	  endothelial	   cell	   number	   selectively	   in	   hindbrain,	   forebrain	   and	   vein	   but	   not	   eye,	  artery	  or	  intersegmental	  vessels	  at	  2dpf.	  
4.2.5.5.	  Vascular	  integrity	  In	   order	   to	   better	   visualise	   vascular	   patterning	   as	   well	   as	   the	   site	   of	  haemorrhaging,	   morphant	   fli1:GFP;GataDsRed	   embryos	   were	   imaged	   using	  spinning	   disc	   confocal	   microscopy	   (figure	   4.23).	   As	   early	   as	   2dpf	   a	   pooling	   of	  erythrocytes	  can	  be	  visualised	  in	  the	  KIAA1109	  embryos	  compared	  to	  the	  control	  embryos	   of	   the	   same	   age.	   At	   3dpf	   there	   is	   a	   substantial	   accumulation	   of	  erythrocytes	   in	   the	   forebrain	  and	  hindbrain.	  However	  vascular	  patterning	   seems	  to	   occur	   normally.	   At	   4dpf	   there	   are	   residual	   erythrocytes	   remaining	   in	   the	  hindbrain	  of	  the	  KIAA1109	  morphant	  with	  normal	  circulation	  observed	  compared	  to	   the	   control.	   To	   better	   visualise	   the	   site	   of	   haemorrhage,	   high	   magnification	  images	  were	  taken	  using	  transgenic	  fli1:GFP;GataDsRed	  at	  3dpf	  ,	  as	  this	  is	  the	  time	  point	  at	  which	  there	  is	  the	  greatest	  proportion	  of	  embryos	  with	  haemorrhage	  and	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Figure	   4.20.	  Mean	   number	   of	   EC	   nuclei	   in	   ISV	   of	  mismatch	   control	   and	   KIAA1109	  
morphant	  nacre	  embryos	  2-­‐3dpf	  Image	  above	  graph	  demonstrates	  intersegmental	  vessels	  in	  black	  dots.	  Graph	   demonstrates	   average	   number	   of	   EC	   nuclei	   in	   ISV	   of	   mismatch	   control	  (white	  bars)	  and	  KIAA1109	  morphant	  (lined	  bars)	  at	  	  2-­‐3dpf.	  Mean	  ±	  SEM.	  One	  way	  ANOVA,	  Bonferroni	  post	  test.	  P=NS.	  N=10,	  10	  embryos	  per	  group.	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Figure	  4.21.	  Mean	  number	  of	  EC	  nuclei	  in	  artery	  of	  mismatch	  control	  and	  KIAA1109	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Figure	  4.22.	  Mean	  number	   of	  EC	  nuclei	   in	   vein	   of	  mismatch	   control	   and	  KIAA1109	  

















	   Sara	  Solaymani-­‐Kohal	  129	  
with	  the	  largest	  volume.	  Figure	  4.23	  shows	  a	  magnified	  region	  of	  the	  hindbrain	  of	  a	  control	   embryo.	   The	   subsequent	   panels	   show	   that	   the	   red	   erythrocytes	   are	  contained	  within	  the	  green	  vessel.	  However	  as	  can	  be	  seen	  in	  figure	  4.23	  the	  same	  region	  in	  the	  KIAA1109	  morphant	  embryo	  shows	  a	  pooling	  of	  erythrocytes	  around	  the	  vessel	  but	  also	  a	  gap	  within	  the	  vasculature	  from	  which	  an	  erythrocyte	  can	  be	  seen	  leaving	  the	  inside	  of	  the	  vessel	  towards	  the	  outside.	  	  This	   suggests	   that	   there	   is	   an	   increase	   in	   vascular	   permeability,	   in	   order	   for	   the	  erythrocytes	  to	  be	  able	  to	  move	  to	  the	  outside	  of	  the	  vessel.	  A	  red	  hydrophilic	  polysaccharide	  dye,	  Dextran,	  was	  injected	  into	  the	  bloodstream	  of	   embryos	   at	   3dpf	   via	   the	   vena	   cava.	   After	   10	   minutes	   post	   injection	   the	  localization	   of	   the	   dextran	   can	   be	   visualized	   using	   a	   fluorescent	  microscope.	   	   Z-­‐stack	  time-­‐lapse	  videos	  were	  carried	  out	  every	  3	  minutes	  for	  one	  hour.	  	  A	  snapshot	  of	  the	  extended	  focus	  was	  exported	  and	  displayed	  as	  figure	  4.25.	  The	  dextran	   injections	   further	  demonstrate	   the	   increased	  permeability	  of	  vessels	  within	  the	  hindbrain	  of	  KIAA1109	  morphant	  embryos,	  by	  leaking	  out	  of	  the	  vessel,	  an	  effect	  that	  was	  not	  seen	  in	  control	  embryos.	  
4.2.6.	  VEGF	  rescue	  of	  cerebral	  haemorrhaging	  My	  finding	  that	  the	  cerebral	  vessels	   in	  KIAA1109	  morphants	  had	  less	  endothelial	  nuclei	   and	   appeared	   more	   permeable	   raised	   the	   possibility	   of	   defective	   VEGF	  function	   to	  account	   for	   these	  phenotypes.	  As	  detailed	   in	  section	  1.4.2	  VEGF	   is	  an	  essential	   angiogenic	   growth	   factor	   that	   also	   induces	   vascular	   permeability.	   I	  therefore	  examined	  what	  affect	   the	  small	  molecule	  VEGF	   inducer	  GS4012	  had	  on	  the	   phenotype	   in	   KIAA1109	   morphants.	   Control	   and	   morphant	   embryos	   were	  treated	   with	   GS4012	   at	   24hpf	   and	   observed	   at	   2	   and	   3dpf.	   I	   used	   a	   5μg/ml	  concentration,	  at	  which	  there	  was	  minimal	  embryo	  lethality.	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Figure	  4.23.	  Confocal	  images	  of	  3dpf	  mismatch	  control	  transgenic	  embryos	  All	   images	   using	   Fli1:GFP;	   Gata:dsRed.	   A)	   3dpf	   control	   dorsal	   view	   of	   the	   head	  demonstrating	   normal	   vasculature	   and	   flow.	   Yellow	   box	   demonstrates	   site	   of	  lower	   panel.	   B)	   3dpf	   control	   magnification	   of	   the	   hindbrain	   demonstrating	  erythrocyte	  movement	  confined	  within	  the	  vessel.	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Figure	   4.25.	   Confocal	   images	   of	   Dextran	   injected	   3dpf	   mismatch	   control	   and	  
KIAA1109	  morphant	  nacre	  embryos	  A)	   Illustrates	   3dpf	   mismatch	   control	   nacre	   embryo	   injected	   with	   Dextran.	   B)	  Illustrates	   3dpf	   KIAA1109	   morphant	   nacre	   embryo	   injected	   with	   Dextran	  displaying	   vascular	   leakage.	   Yellow	   box	   illustrates	   location	   of	   cerebral	  haemorrhaging	  in	  hindbrain.	  C)	  Magnification	  of	  the	  leakage	  area	  in	  the	  KIAA1109	  morphant	  embryos,	  as	  indicated	  by	  the	  yellow	  box	  on	  panel	  B.	  	  	  
A	   B 	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KIAA1109	   morphant	   embryos	   treated	   with	   GS4012	   displayed	   a	   statistically	  significant	   reduction	   in	   cerebral	   haemorrhage	   in	   comparison	   to	   untreated	  KIAA1109	  morphants	   (figure	  4.26	  and	  4.27).	  There	  are	  also	  a	  significantly	   lower	  number	  of	  morphant	  embryos	  with	  cerebral	  haemorrhaging	  in	  the	  GS4012	  group	  compared	  to	  the	  control	  in	  the	  same	  treatment	  group.	  Treatment	  with	  GS4012	  also	  rescued	   the	   reduction	  of	   endothelial	   cells	   in	   the	   forebrain	  and	  hindbrain	  at	  2dpf	  (figure	  4.28)	  seen	  in	  KIAA1109	  morphants	  (figure	  4.19,	  4.20).	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Figure	   4.26.	   Brightfield	   images	   of	   3dpf	  mismatch	   control	   and	  KIAA1109	  morphant	  
nacre	  embryo	  	  Image	  illustrates	  3dpf	  mismatch	  control	  and	  KIAA1109	  morphant	  nacre	  embryos	  treated	  with	  GS4012	  and	  DMSO.	  	  	  	  	  	  	  	  	   	  
KIAA1109	  Morphant	   Mismatch	  control	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  Figure	   4.27.	   Percentage	   of	   mismatch	   control	   and	   KIAA1109	   morphant	   nacre	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Figure	   4.28.	  Mean	  number	   of	   EC	  nuclei	   in	   forebrain	   and	  hindbrain	   of	  mismatch	  









































	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Sara	  Solaymani-­‐Kohal	  137	  
4.3.	  Thrombocyte	  adhesion	  and	  thrombosis	  Since	   haemorrhage	   may	   be	   a	   consequence	   of	   impaired	   thrombostasis,	   I	  examined	   whether	   KIAA1109	   knockdown	   impairs	   thrombocyte	   adhesion	   and	  thrombosis	  at	  a	  site	  of	  endothelial	  injury.	  An	  established	  laser	  injury	  technique	  in	  our	   lab	  was	  used	  to	  cause	  a	  small	   injury	  at	   the	  arterial	  wall	  above	  the	  anus	  using	  a	   laser	   and	   the	   time	   to	  adhesion	  was	  measured	   for	   two	  minutes	   (figure	  4.29).	  	  	  The	   results	   show	   that	   thrombocytes	   (the	   zebrafish	   equivalent	   of	   platelets)	   of	  KIAA1109	  morphants	   take	   significantly	   longer	   to	   adhere	   to	   the	   site	   of	   injury	  compared	  to	  controls.	  Although	  there	  is	  no	  statistically	  significant	  difference	  in	  the	   size	   of	   the	   thrombus,	   KIAA1109	  morphants	   showed	   a	   trend	   towards	   less	  thrombus	  formation.	  The	  lack	  of	  significance	  could	  be	  due	  to	  a	  too	  small	  group	  size,	  as	  this	  method	  of	  measurement	  of	  thrombus	  formation	  can	  be	  technically	  challenging.	   It	   is	   noteworthy	  however;	   that	   in	   our	   group	  we	  have	   shown	   that	  knockdown	   of	   the	   P2Y12	   receptor	   induces	   highly	   significant	   inhibition	   of	  thrombus	   formation,	   without	   inducing	   cerebral	   haemorrhage.	   It	   is	   unlikely	  therefore	   that	   impaired	   haemostasis	   is	   the	   sole	   cause	   for	   the	   haemorrhagic	  phenotype	  observed	  in	  KIAA1109	  morphants.	  
	   	  








Figure	  4.29.	  Time	  taken	  to	  adhesion	  in	  mismatch	  control	  and	  KIAA1109	  morphant	  

























Figure	  4.30.	  Size	  of	  thrombus	  in	  mismatch	  control	  and	  KIAA1109	  morphant	  nacre	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4.4.	  Discussion	  
Since	   KIAA1109	   is	   significantly	   down	   regulated	   in	   human	   peripheral	   blood	  following	   MI	   (Chapter	   3)	   and	   no	   direct	   evidence	   exists	   for	   the	   function	   of	  KIAA1109	   in	   any	   system,	   I	   sought	   to	   characterize	   its	   role	   in	   cardiovascular	  development	   in	   zebrafish.	   Although	   bioinformatics	   based	   on	   genome	  sequencing	  provided	  us	  with	  a	  zebrafish	  homolog	  of	  KIAA1109,	  this	  was	  yet	  to	  be	  proven	  to	  be	  expressed	   in	  vivo.	  Sequence	  specific	  primers	  were	  designed	  in	  order	  to	  amplify	  the	  gene	  using	  PCR,	  but	  due	  to	  the	  large	  size	  of	  the	  gene	  only	  exons	   6-­‐13	  were	   amplified	   and	   confirmed	   to	   be	   KIAA1109	   by	   sequencing.	   rt-­‐PCR	  showed	  that	  KIAA1109	  was	  detectable	  in	  zebrafish	  cDNA	  1-­‐5dpf.	  However	  KIAA1109	  could	  not	  be	  detected	  in	  maternal	  cDNA.	  Once	  I	  had	  established	  that	  KIAA1109	  was	  expressed	  at	  these	  early	  stages	  of	  zebrafish	  development,	  I	  used	  whole	   mount	   in-­‐situ	   hybridization	   to	   characterize	   the	   spatial	   expression	   of	  KIAA1109.	  Within	   the	   limitations	  of	   the	   technique,	   it	  appeared	  that	  KIAA1109	  was	   ubiquitously	   expressed	   in	   the	   trunk	   at	   2dpf.	   Such	   expression	   might	   be	  expected	  from	  the	  available	  data	  in	  other	  systems,	  but	  since	  optimization	  of	   in	  
situ	   hybridization	   is	   biased	   (overdeveloping	   will	   always	   suggest	   ubiquitous	  expression,	   whereas	   under	   developing	   leads	   to	   an	   impression	   of	   limited	  expression)	  I	  consider	  these	  data	  preliminary.	  	  To	  establish	  the	  function	  of	  KIAA1109,	  I	  attempted	  to	  induce	  KIAA1109	  loss-­‐of-­‐function.	  Within	   the	   zebrafish	   community	  morpholino	   antisense	   is	   by	   far	   the	  most	   commonly	   used	   technique	   for	   this	   purpose,	   despite	   the	   disadvantages	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listed	   in	  Chapter	  1	   (1.5.2).	  Morpholinos	  generally	  do	  not	  cause	  degradation	  of	  their	  RNA	  targets;	  instead,	  they	  block	  translation	  of	  the	  target	  mRNA	  until	  that	  RNA	  is	  degraded	  naturally.	  This	  means	  that	  RT-­‐PCR	  is	  not	  suitable	  for	  assaying	  translation	  blocking	  by	  morpholinos.	  By	  blocking	  sites	  involved	  in	  splicing	  pre-­‐mRNA,	  morpholinos	  can	  be	  used	  to	  modify	  and	  control	  normal	  splicing	  events.	  This	   activity	   can	   be	   assayed	   by	   RT-­‐PCR,	   with	   successful	   splice-­‐modification	  appearing	  as	  changes	  in	  the	  RT-­‐PCR	  product	  band	  on	  an	  electrophoretic	  gel.	  The	  band	   might	   shift	   to	   a	   new	   mass	   or,	   if	   splice-­‐modification	   triggers	   nonsense-­‐mediated	   decay	   of	   the	   transcript,	   the	   band	   will	   lose	   intensity	   or	   disappear.	  Nevertheless,	  confirming	  aberrant	  splicing	  does	  not	  confirm	  that	  the	  phenotype	  is	   due	   to	   specific	   gene	   knockdown.	   Although	   western	   blotting	   to	   confirm	  KIAA1109	  protein	  knockdown	  is	  the	  best	  way	  to	  confirm	  the	  morpholino	  effect,	  there	   are	   no	   antibodies	   available	   to	   zebrafish	   KIAA1109,	   and	   cross-­‐reactivity	  with	  other	   species	   is	  unlikely.	  There	   is	  however	   a	  human	  KIAA1109	  antibody	  available.	   It	   would	   be	   possible	   to	   use	   the	   human	   antibody	   on	   zebrafish	  morphants,	  as	  well	  as	  using	  monoclonal	  antibodies	  to	  fragments	  of	  the	  protein,	  or	   using	   a	   combination	   of	   monoclonal	   antibodies	   instead	   of	   a	   polyclonal.	  Although	  this	  work	  was	  not	  carried	  out,	  it	  would	  be	  worth	  trying	  in	  the	  future.	  	  Even	   if	   morpholino	   induced	   protein	   knockdown	   is	   confirmed,	   this	   does	   not	  confirm	  that	  the	  phenotype	  observed	  is	  specific	  to	  this	  effect,	  and	  it	  can	  still	  be	  due	   to	   off	   target	   effects.	   Ideally,	   this	   should	   be	   confirmed	   by	   rescuing	   the	  phenotype	   by	   injection	   of	   the	  mRNA.	  However,	   this	   is	   technically	   challenging,	  and	  I	  was	  unable	  to	  clone	  the	  entire	  KIAA1109	  transcript,	  due	  to	  its	  large	  size.	  In	  addition,	   unrestricted	   overexpression	   from	   the	   earliest	   time	   points	   is	   not	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necessarily	   the	   reverse	   of	   inducing	   knockdown	   specifically	   in	   KIAA1109	  expressing	   cells	   (the	   morpholino	   effect)	   and	   mRNA	   overexpression	   and	   the	  morpholino	   antisense	   effect	   have	   different	   kinetics.	   Therefore,	   a	   failure	   to	  rescue	  the	  morpholino	  effect	  is	  not	  clear	  evidence	  that	  the	  phenotype	  is	  due	  to	  off-­‐target	   effects.	   Some	   groups	   have	   used	   co-­‐injection	  with	   a	   p53	  morpholino	  (since	  many	  off-­‐target	  effects	  are	  deemed	  to	  be	  due	  to	  p53	  activation)	  and	   if	   I	  had	  had	  sufficient	  time	  I	  would	  have	  performed	  these	  studies,	  or	  examined	  the	  effect	  of	  the	  KIAA1109	  morpholinos	  in	  p53	  stable	  mutants.	  Withstanding	   these	   reservations,	   it	   seems	   most	   likely	   that	   the	   cerebral	  haemorrhage	   induced	   by	   KIAA1109	   knockdown	   was	   a	   specific	   effect.	   This	   is	  supported	   by	   the	   fact	   that	   three	   separate	   morpholinos	   induced	   the	   same	  phenotype,	   that	   our	   group	  has	  used	  dozens	   of	  morpholinos	   and	  not	   observed	  similar	  phenotypes,	  and	  that	  the	  effect	  can	  be	  rescued	  by	  small	  molecule	  VEGF	  induction,	  which	  seems	  less	  likely	  in	  the	  case	  of	  off-­‐target	  or	  non-­‐specific	  effects.	  The	   initial	   observation	   of	   gene	   knockdown	   experiments	   is	   the	   general	  development	   and	   survival	   of	   the	   embryos.	   Upon	   finding	   a	   morpholino	  concentration	   in	   which	   embryos	   exhibited	   healthy	   behaviour	   and	   motility,	  KIAA1109	  gene	  function	  was	  knocked	  down	  using	  a	  ATG	  morpholino.	  However	  what	  was	  very	  noticeable	  in	  the	  KIAA1109	  morphant	  group	  was	  the	  presence	  of	  haemorrhages	   in	   consistent	   locations	  within	   the	   head	   of	   the	   embryos.	   Before	  the	  development	  of	  haemorrhage,	  morphants	  are	  indistinguishable	  from	  control	  embryos	   and	   establish	   a	   robust	   circulation	   and	   the	  window	   of	   time	   in	  which	  haemorrhages	  appear	  corresponds	  to	  a	  period	  of	  active	  angiogenesis.	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Cerebral	   haemorrhage	   is	   a	   phenotype	   observed	   in	   several	   mutant	   lines	  generated	  in	  forward	  genetic	  studies	  such	  as	  a	  redhead,	  which	  has	  a	  mutation	  in	  the	  pak2a	  gene	  (Buchner	  et	  al.,	  2007),	  mindbomb	  which	  carry	  mutations	  on	  the	  
mib	  gene,	  which	  encodes	  a	  RING	  E3	  ligase	  required	  for	  Notch	  activation	  (Itoh	  et	  al.,	   2003)	   and	  bubblehead	  which	   carry	   a	  mutation	   in	   the	  βpix	   gene	  (Liu	   et	   al.,	  2006a).	   	  These	   mutants,	   even	   where	   the	   causative	   mutation	   has	   not	   been	  isolated,	  show	  that	   this	  phenotype	  can	  be	  associated	  with	   loss-­‐of-­‐function	  of	  a	  single	   gene.	   Buchner	   et	  al	   found	   cerebral	   haemorrhaging	   in	   redhead	   at	   2	   and	  3dpf,	  which	   is	   consistent	  with	   our	   findings	   however	   in	   redhead	   haemorrhage	  resolved	   in	   some	   embryos	   as	   they	   got	   older,	   which	   was	   not	   the	   case	   for	  KIAA1109	   morphant	   embryos.	   The	   mindbomb	   mutant	   also	   exhibits	   cerebral	  haemorrhaging	  caused	  by	  a	  loss	  of	  Notch	  signalling.	  Upon	  further	  investigation	  Lawson	   et	   al	   found	   that	   the	   embryos	   exhibit	   normal	   vascular	   patterning	  however	  the	  vessel	   itself	   lacked	  any	  structure	  (Lawson	  et	  al.,	  2001).	  To	  better	  understand	  the	  cause	  of	  leakage	  of	  the	  erythrocyte	  from	  the	  cerebral	  vessels,	  I	  used	   the	   transgenic	   embryo,	   fli1:EGFP;GataDsRed,	   in	   which	   endothelial	   cells	  express	  GFP	  and	   the	  erythrocytes	  express	  GataRed.	  The	  expression	  of	  EGFP	   is	  detectable	  as	  early	  as	  the	  three-­‐somite	  stage	  (Lawson	  and	  Weinstein,	  2002)	  and	  therefore	  the	  transgenic	  lines	  are	  very	  useful	  for	  the	  study	  of	  vascular	  formation	  from	   an	   early	   to	   late	   time	   point.	   I	   used	   spinning	   disc	   confocal	  microscopy	   to	  obtain	   time-­‐lapse	   images;	   microangiography	   has	   traditionally	   been	   used	   to	  observe	   vascularization	   however	   it	   only	   allows	   for	   visualization	   of	   patent	  vessels	  limiting	  the	  scope	  of	  investigation	  into	  defective	  vessels	  or	  vessels	  that	  have	   yet	   to	   be	   lumenised.	   Confocal	   imaging	   of	   the	   dorsal	   brain	   of	   embryos	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revealed	  normal	  vascular	  patterning	  within	  the	  brain,	  as	  reported	  for	  mindbomb	  mutants.	   Upon	   higher	   magnification	   imaging	   it	   was	   obvious	   that	   KIAA1109	  morphant	   embryos	   had	   increased	   permeability	   compared	   to	   the	   controls	   as	  displayed	   by	   escaping	   erythrocytes	   seen	   in	   figure	   4.24.	   To	   further	   investigate	  the	   vascular	  permeability	  of	   the	  morphant	  embryos	  Dextran	  was	   injected	   into	  live	   embryos	   at	   3dpf	   and	   embryos	   imaged	   on	   a	   spinning	   disc	   confocal	  microscope	   after	   5	   minutes,	   after	   which	   the	   dye	   was	   taken	   up	   into	   the	  circulation	  and	  could	  be	  visualized	   for	   time-­‐lapse	  videos.	  The	  videos	  show	  the	  leakage	  of	  erythrocytes	   in	   the	  morphant	  embryos	  at	   the	   sites	  of	  haemorrhage,	  compared	   to	   the	   control	   embryos,	   which	   display	   the	   dye	   only	   within	   the	  vasculature.	  This	   is	   in	  comparison	  to	   the	  work	  carried	  out	  by	  Buchner	  et	  al	   in	  which	   they	   injected	   fluorescent	   quantum	   dots	   into	   the	   circulation	   of	   pak2a	  deficient	  embryos	  and	  found	  that	  the	  blood	  vessels	  were	  more	  prone	  to	  rupture	  rather	   than	   general	   leakiness,	   which	   suggests	   a	   loss	   of	   junctional	   integrity	  rather	  than	  an	  increase	  in	  permeability	  (Buchner	  et	  al.,	  2007).	  	  As	   the	   confocal	   imaging	   and	  dextran	   injections	   suggested	   the	  haemorrhage	   in	  KIAA1109	  morphants	  might	  be	  caused	  by	  decreased	  vascular	  integrity	  I	  treated	  the	  morphants	  with	  the	  VEGF	  inducer	  GS4012.	  VEGF	  is	  traditionally	  associated	  with	  angiogenesis	  and	  VEGF	   increases	  vascular	  permeability	   in	  order	   to	  guide	  tip	  cells	  (Olsson	  et	  al.,	  2006).	  VEGF	  is	  also	  involved	  in	  vascular	  maintenance	  and	  endothelial	  cell	  survival	  (Murakami	  et	  al.,	  2011).	  In	  order	  to	  not	  interfere	  with	  early	   vascular	   development	   and	   angiogenesis,	   GS4012	   was	   added	   to	   the	  morphant	  embryos	  and	  control	  embryos	  at	  24hpf,	  in	  which	  they	  were	  incubated	  until	   observations	   at	   2	   and	   3dpf.	   The	   up	   regulation	   of	   VEGF	   in	   the	  morphant	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embryos	  prevented	  the	  haemorrhage	  in	  the	  drug	  treated	  group	  compared	  to	  the	  DMSO	  and	  E3	  group,	  implying	  that	  either	  the	  KIAA1109	  phenotype	  was	  due	  to	  reduction	  of	  VEGF	  signalling,	  or	  that	  it	  can	  be	  overcome	  by	  up	  regulating	  VEGF	  signalling.	  To	   attempt	   to	   better	   understand	   the	  mechanism	   for	   the	   KIAA1109	  morphant	  phenotype,	   I	   next	   attempted	   to	   define	   the	   transcriptional	   effect	   of	   KIAA1109	  loss-­‐of-­‐function.	  These	  studies	  are	  described	  in	  the	  following	  chapter.	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Chapter	  5:	  Transcriptional	  profiling	  of	  
KIAA1109	  morphants	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5.1.	  Introduction	  
Having	  characterised	  differentially	  expressed	  genes	  in	  whole	  blood	  following	  an	  ACS	  and	  identifying	  and	  functionally	  assessing	  KIAA1109	  function	  in	  zebrafish,	  I	  next	  examined	  the	  transcriptional	  effects	  of	  KIAA1109	  knockdown	  in	  zebrafish.	  Although	  not	  all	  phenotypes	  are	  determined	  at	  a	   transcriptional	   level,	   such	  as	  an	  effect	  on	  adhesion	  molecule	  expression	  it	  is	  of	  interest	  to	  gain	  insight	  into	  the	  transcriptional	   changes	   that	   occur	   upon	   knockdown	   of	   the	   gene,	  which	   could	  lead	  to	  the	  induction	  of	  decreased	  vascular	  integrity.	  	  
5.1.1.	  Bioinformatic	  analysis	  of	  microarray	  datasets	  Microarray	   studies	   generate	   a	   large	   amount	   of	   data,	   which	   often	   presents	  challenges	   in	   analysis	   and	   interpretation.	  Many	  bioinformatic	   tools	   have	  been	  developed	  to	  assist	  researchers	  in	  interpreting	  microarray	  datasets,	  and	  below	  I	  briefly	  describe	  those	  used	  in	  this	  chapter.	  
5.1.1.1.	  PANTHER	  
Protein	   ANalysis	   THrough	   Evolutionary	   Relationships	   (PANTHER)	   is	   an	  ontological	   system	   that	   classifies	   genes	   by	   their	   functions,	   using	   published	  scientific	   experimental	   evidence	   and	   evolutionary	   relationships	   to	   predict	  function	  even	  in	  the	  absence	  of	  direct	  experimental	  evidence.	  The	  database	  was	  designed	  for	  the	  high-­‐throughput	  analysis	  of	  protein	  sequences	  (Huang	  da	  et	  al.,	  2009).	  (PANTHER)	  
5.1.1.2.	  STRING	  Search	   Tool	   for	   the	   Retrieval	   of	   Interacting	   Genes/Proteins	   (STRING)	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is	  a	  database	  of	  known	  and	  predicted	  protein	  interactions.	   The	   interactions	  include	  direct	  (physical)	  and	  indirect	  (functional)	  associations;	  they	  are	  derived	  from	   four	   sources:	   genomic	   context,	   high	   throughput	   experiments,	   conserved	  co-­‐expression	  and	  published	  data.	  STRING	  quantitatively	  integrates	  interaction	  data	   from	   these	   sources	   for	   a	   large	   number	   of	   organisms,	   and	   transfers	  information	  between	  these	  organisms	  where	  applicable.	  The	  database	  currently	  covers	  5,214,234	  proteins	  from	  1133	  organisms.	  (STRING)	  
5.2.	  Results	  
5.2.1.	  RNA	  extraction	  RNA	  was	  extracted	  from	  ~300	  whole	  embryos	  at	  36hpf	  which	  were	  injected	  at	  1-­‐2	   cell	   stage	   with	   either	   the	   ATG	   blocking	   KIAA1109	   or	   mismatch	   control	  morpholino.	  	  4	   injections	   and	   extractions	   were	   carried	   out	   on	   separate	   days,	   providing	   4	  replicates	   per	   group.	   The	   RNA	   was	   dispatched	   to	   the	   Singapore	   Institute	   of	  Genomics,	  and	  was	  kindly	  carried	  out	  by	  Serene	  Lee	  Gek	  Ping,	  using	  a	  custom	  microarray	  developed	  by	  the	  group	  of	  our	  collaborator	  Sinnakarupan	  Mathavan.	  These	   studies	   performed	   one	  microarray	   per	   group	   (i.e.	   eight	   arrays	   total)	   to	  provide	   estimates	   of	   variability	   between	   replicates.	  We	   then	   used	  Genespring	  software	   to	   analyse	   the	   data	   and	   identify	   genes	   that	   were	   differentially	  expressed	  with	  statistical	  significance	  (p>0.05).	  From	   this	   list	   of	   differentially	   expressed	   transcripts,	   I	   removed	   unannotated,	  hypothetical	  proteins,	  as	  although	  these	  may	  be	  mechanistically	  important	  they	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are	   unable	   to	   provide	   insight	   into	   the	   effect	   of	   KIAA1109	   as	   they	   have	   no	  identified	   function	   or	   participation	   in	   biological	   pathways.	   The	   remaining	  differentially	  expressed	  genes	  are	  shown	  in	  table	  5.1	  (up	  regulated	  in	  KIAA1109	  morphants)	  and	  table	  5.2	  (down	  regulated	  in	  KIAA1109	  morphants).	  	  Compared	   with	   other	   microarray	   studies	   we	   have	   performed,	   the	   number	   of	  differentially	   expressed	   genes	   induced	   by	   KIAA1109	   knockdown	   is	   relatively	  small.	  For	  example,	  previous	  studies	  in	  our	  group	  examining	  the	  effect	  of	  blood	  flow	   on	   transcription,	   or	   the	   transcriptional	   effect	   of	   specific	   mutations	   have	  yielded	   hundreds	   of	   differentially	   expressed	   genes.	   It	   appears	   therefore	   that	  KIAA1109	  is	  unlikely	  to	  play	  a	  major	  role	  in	  transcriptional	  regulation.	  Each	  differentially	  expressed	  gene	  was	  put	  through	  a	  literature	  search,	  looking	  for	  expression	  patterns	  in	  the	  zebrafish	  model	  organism	  database	  (Zfin)	  which	  showed	  mainly	  expression	  in	  the	  head	  of	  embryos	  or	  ubiquitous	  expression,	  as	  well	  as	  using	  PANTHER	  to	  determine	   if	   the	  genes	  are	   involved	   in	  any	   	  specific	  pathways.	  	  
5.2.2.	  PANTHER	  analysis	  of	  differentially	  expressed	  genes	  A	  list	  of	  the	  PANTHER	  outputs	  can	  be	  seen	  for	  differentially	  expressed	  genes	  in	  table	  5.3.	  The	   first	  numerical	   column	  contains	   the	  number	  of	   genes	   in	   the	  uploaded	   list	  that	  map	  to	  the	  PANTHER	  classification	  category.	  The	  second	  numerical	  column	  contains	  the	  expected	  value,	  which	  is	  the	  number	  of	  genes	  you	  would	  expect	  in	  the	  reference	  list	  for	  the	  PANTHER	  category,	  based	  on	  the	  reference	  list.	  The	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Table	   5.1.	   Differentially	   expressed	   genes	   that	   are	   up	   regulated	   by	   KIAA1109	  
knockdown.	  
Gene	  name	   Gene	  Symbol	   p-­‐value	   Fold	  change	  
Cell	  adhesion	  molecule	  1b	   cadm1b	   0.03	   3.02	  
Glutamate	  receptor,	  ionotropic,	  AMPA	  2a	   gria2a	   0.04	   2.13	  
Leucine-­‐rich	  repeat	  LGI	  family,	  member	  2b	   lgi2b	   0.01	   2.23	  
Ligand	  of	  numbe	  protein	  X1	   lnx1	   0.02	   2.40	  
Neuropeptides	  B/W	  receptor	   npbwr2	   0.03	   2.32	  
Solute	  carrier	  family	  17	  (sodium-­‐
dependent	  inorganic	  phosphate	  
cotransporter),	  member	  6a	  
slc17a6a	   0.02	   2.51	  
Renin	   ren	   0.01	   2.17	  
synaptotagmin	  XIb	   syt11b	   0.01	   2.04	  
HtrA	  serine	  peptidase	  3a	   htra3a-­‐001	   0.01	   2.78	  
kelch	  repeat	  and	  BTB	  (POZ)	  domain	  
containing	  12	   kbtbd12	   0.01	   2.53	  
proline	  rich	  15-­‐like	  b	   prr15lb	   0.01	   2.03	  
zgc:136908	   zgc:136908	   0.03	   2.19	  
glycine	  N-­‐methyltransferase	   gnmt	   0.00	   2.07	  
im:7147183	   im:7147183	   0.04	   3.06	  
glutamate	  receptor,	  ionotropic,	  N-­‐methyl	  
D-­‐aspartate	  1a	   grin1a	   0.00	   2.08	  
crystallin,	  gamma	  N1	   crygn1	   0.00	   3.33	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Table	   5.2.Differentially	   expressed	   genes	   that	   are	   down	   regulated	   by	   KIAA1109	  
knockdown.	  
Gene	  name	   Gene	  Symbol	   p-­‐value	  
Fold	  
change	  
Otoferlin	   otof	   0.02	   3.47	  
MACRO	  domain	  containing	  2	   macrod2	   0.01	   2.09	  
protocadherin	  1	  gamma	  2	   pcdh1g2	   0.01	   2.02	  
growth	  regulation	  by	  estrogen	  in	  breast	  
cancer	  1	   greb1	   0.02	   2.03	  
coiled-­‐coil	  domain	  containing	  120	   ccdc120	   0.02	   2.59	  
zinc	  finger	  protein	  729	   ZNF729	   0.00	   2.05	  
late	  endosomal/lysosomal	  adaptor,	  MAPK	  
and	  MTOR	  activator	  2	   lamtor2-­‐001	   0.01	   2.14	  
ankyrin	  repeat	  and	  death	  domain	  containing	  
1B	   ankdd1b	   0.04	   2.07	  
RNA	  binding	  motif	  protein	  41	   rbm41	   0.00	   2.05	  
ribosomal	  protein	  L21	   rpl21	   0.03	   2.20	  
nodal-­‐related	  2	   ndr2	   0.00	   2.35	  
ribosomal	  protein	  S23	   rps23	   0.03	   2.44	  
apolipoprotein	  A-­‐1	   apoa1	   0.02	   2.51	  
regulator	  of	  G-­‐protein	  signalling	  12	   rgs12	   0.01	   2.49	  
carboxyl	  ester	  lipase	  (bile	  salt-­‐stimulated	  
lipase)	   cel.1	   0.02	   2.74	  
cerebellin	  1	  precursor	   cbln1	   0.04	   2.12	  
si:dkeyp-­‐59a8.1	   si:dkeyp-­‐59a8.1	   0.05	   2.28	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third	  numerical	  column	  is	  a	  fold	  change	  representation	  of	  the	  number	  of	  genes	  in	   the	   reference	   list	   compared	   to	   the	   expected	   value.	   Of	   the	   34	   differentially	  expressed	   genes	   all	   were	  mapped	   by	   PANTHER	   however	  most	   of	   these	  were	  ‘unclassified’	  and	  therefore	  removed	  from	  the	  table	  (table	  5.3).	  	  The	  findings	  are	  also	  not	  statistically	  significant	  as	  there	  is	  a	  small	  list	  of	  differentially	  expressed	  genes	  and	  so	  there	  may	  be	  only	  one	  gene	  involved	  in	  a	  pathway.	  The	  Notch	  signalling	  pathway	  has	  the	  highest	   fold	  representation,	  which	   is	   for	  the	   gene	   LNX1.	   This	   is	   of	   particular	   interest	   as	   the	   role	   of	   Notch	   in	   vascular	  remodelling	   and	   integrity	   is	   well	   established.	   Gria2a	   also	   has	   a	   high	   fold	  representation	   in	   both	   metabotropic	   and	   ionotropic	   glutamate	   receptor	  pathways.	   The	   metabotropic	   glutamate	   receptor	   group	   III	   pathway	   is	   a	   G-­‐protein	   coupled	   receptor	   that	   is	   activated	   by	   L-­‐AP-­‐4	   and	   inhibits	   adenylate	  cyclase	   activity.	   The	   ionotropic	   glutamate	   receptor	   pathway	   is	   a	   series	   of	  molecular	  signals	  initiated	  by	  glutamate	  binding	  to	  a	  glutamate	  receptor	  on	  the	  surface	  of	  the	  target	  cell,	  followed	  by	  the	  movement	  of	  ions	  through	  a	  channel	  in	  the	  receptor	  complex.	  	  The	  highest	  fold	  representation	  for	  biological	  processes	  are	  asymmetric	  protein	  localization,	   protein	   localization	   and	   dorsal/ventral	   axis	   specification,	   which	  also	   involve	   LNX1.	   The	   highest	   fold	   represented	   molecular	   function	   was	  glutamate	  receptor	  activity	  for	  gria2a	  and	  aspartic	  type	  endopeptidase	  activity.	  	  Interestingly	   the	   highest	   fold	   represented	   in	   the	   cellular	   component	   is	   cell	  junction	   for	   the	   LNX1	   gene.	   There	   is	   an	   equally	   high	   fold	   representation	   of	  plasma	  membrane	  for	  the	  same	  gene.	  The	  fold	  representation	  for	  protein	  class	  includes	   over	   representation	   in	   cadherin	   protein	   class	   for	   Pcdh1γ2	   and	   cell	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junction	  for	  the	  LNX1	  gene.	  Although	  not	  greatly	  over	  represented	  there	  are	  also	  many	   relevant	   processes	   such	   as	   cell	   adhesion	   molecule	   and	   cell	   junction	  protein.	  	  As	   the	   phenotype	   was	   rescued	   using	   a	   VEGF	   inducer	   it	   would	   have	   been	  expected	   that	   there	  may	   have	   been	   some	   down	   regulation	   in	   VEGF,	   however	  VEGFaa,	   VEGFab	   and	   VEGFc	   showed	   no	   statistically	   significant	   differential	  expression.	  As	  the	  mechanism	  by	  which	  GS4012	  up	  regulates	  VEGF	  is	  currently	  unknown	   and	   since	   the	   microarray	   was	   custom	   made,	   it	   could	   be	   that	   the	  relevant	   VEGF	   component	   was	   not	   included	   on	   the	   chip	   or	   not	   differentially	  expressed	  at	  36hpf.	  Although	  there	  is	  not	  a	  large	  list	  of	  genes	  that	  are	  differentially	  expressed	  genes	  and	   the	   fold	   representation	   of	   some	   processes	   are	   not	   significant,	   it	   does	  however	   provide	   us	   with	   a	   greater	   knowledge	   of	   the	   kinds	   of	   pathways	   and	  processes	  that	  may	  be	  affected	  by	  the	  knockdown	  of	  KIAA1109.	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Table	  5.3.	  PANTHER	  output	  of	  differentially	  expressed	  genes	  of	  KIAA1109	  morphants	  










Notch	  signalling	  pathway	   1	   0.04	   25	  
Ionotropic	  glutamate	  receptor	  
pathway	  
1	   0.06	   16.67	  
Metabotropic	  glutamate	  receptor	  
group	  III	  pathway	  
1	   0.07	   14.29	  
Cadherin	  signalling	  pathway	   1	   0.11	   9.09	  
Heterotrimeric	  G-­‐protein	  
signalling	  pathway-­‐Gq	  alpha	  and	  
Go	  alpha	  mediated	  pathway	  
1	   0.13	   7.69	  
Heterotrimeric	  G-­‐protein	  
signalling	  pathway-­‐Gi	  alpha	  and	  
Gs	  alpha	  mediated	  pathway	  
1	   0.17	   5.88	  
Wnt	  signalling	  pathway	   1	   0.27	   3.70	  
	  









1	   0.03	   33.33	  
protein	  localization	   1	   0.03	   33.33	  
dorsal/ventral	  axis	  
specification	  
1	   0.03	   33.33	  
localization	   1	   0.06	   16.67	  
nerve-­‐nerve	  synaptic	  
transmission	  
1	   0.09	   11.11	  
lipid	  transport	   1	   0.12	   8.33	  
pattern	  specification	  
process	  
1	   0.21	   4.76	  
neurotransmitter	  
secretion	  
1	   0.21	   4.76	  
synaptic	  
transmission	  
2	   0.45	   4.44	  
exocytosis	   1	   0.23	   4.35	  
translation	   1	   0.28	   3.57	  
neurological	  system	  
process	  
4	   1.23	   3.25	  
	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Sara	  Solaymani-­‐Kohal	  155	  
endocytosis	   1	   0.33	   3.03	  
vesicle-­‐mediated	  
transport	  
2	   0.7	   2.86	  
visual	  perception	   1	   0.36	   2.78	  
system	  process	   4	   1.49	   2.68	  
cell-­‐cell	  signalling	   2	   0.76	   2.63	  
cell-­‐cell	  adhesion	   1	   0.38	   2.63	  
sensory	  perception	   1	   0.46	   2.17	  
cation	  transport	   1	   0.47	   2.13	  	  













1	   0.02	   50.00	  
neuropeptide	  
hormone	  activity	  
1	   0.03	   33.33	  
lipid	  transporter	  
activity	  
1	   0.05	   20.00	  
hormone	  activity	   1	   0.08	   12.50	  
ligand-­‐gated	  ion	  
channel	  activity	  




1	   0.14	   7.14	  
small	  GTPase	  
regulator	  activity	  
2	   0.3	   6.67	  
calcium	  ion	  binding	   2	   0.34	   5.88	  
nuclease	  activity	   1	   0.21	   4.76	  
structural	  molecule	  
activity	  
3	   0.96	   3.13	  
enzyme	  regulator	  
activity	  
2	   0.68	   2.94	  
ion	  channel	  activity	   1	   0.36	   2.78	  
peptidase	  activity	   1	   0.49	   2.04	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Cellular	  
Component	  







cell	  junction	   1	   0.12	   8.33	  
plasma	  
membrane	  
1	   0.12	   8.33	  
extracellular	  
matrix	  
1	   0.39	   2.56	  
extracellular	  
region	  
1	   0.39	   2.56	  	  









1	   0.02	   50.00	  
aspartic	  protease	   1	   0.02	   50.00	  
neuropeptide	   1	   0.03	   33.33	  
apolipoprotein	   1	   0.05	   20.00	  
cadherin	   1	   0.08	   12.50	  
peptide	  hormone	   1	   0.08	   12.50	  
basic	  helix-­‐loop-­‐helix	  
transcription	  factor	  
1	   0.09	   11.11	  
ligand-­‐gated	  ion	  
channel	  
1	   0.11	   9.09	  
cell	  junction	  protein	   1	   0.12	   8.33	  
structural	  protein	   1	   0.14	   7.14	  
ribosomal	  protein	   1	   0.14	   7.14	  
membrane	  traffic	  
protein	  
2	   0.3	   6.67	  
G-­‐protein	  modulator	   2	   0.3	   6.67	  
nuclease	   1	   0.21	   4.76	  
calcium-­‐binding	  
protein	  
1	   0.26	   3.85	  
transfer/carrier	  
protein	  
1	   0.3	   3.33	  
ion	  channel	   1	   0.33	   3.03	  
extracellular	  matrix	  
protein	  
1	   0.39	   2.56	  
transporter	   2	   0.92	   2.17	  
cell	  adhesion	  molecule	   1	   0.49	   2.04	  
protease	   1	   0.49	   2.04	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5.3.	  Differentially	  expressed	  genes	  
Upon	   PANTHER	   analysis	   it	   became	   obvious	   that	   some	   genes	   had	   high	   fold	  representations	   in	  many	  different	  pathways	  and	  processes,	   in	  particular	   those	  that	  were	  related	  to	  angiogenic	  processes.	  	  
5.3.1.	  Ligand	  of	  numb	  protein	  X-­‐1	  (LNX1)	  
LNX1	   is	   significantly	   up	   regulated	   in	   KIAA1109	   morphants	   compared	   to	  controls.	   	   	   This	   was	   validated	   using	   quantitative	   RT-­‐PCR	   (figure	   5.1)	   using	   a	  commercially	  ready	  Taqman	  probe	  as	  described	  in	  chapter	  2.4.	  	  	  
LNX1	  has	  65%	  homology	  to	  human	  LNX1.	  LNX1	  was	  identified	  as	  a	  protein	  that	  interacts	  with	  Numb	  and	  named	  Ligand	  of	  Numb	  protein	  X	  (Nie	  et	  al.,	  2002)	  zfin	  showed	  that	  LNX1	  has	  been	  shown	  to	  be	  expressed	  maternally	  and	  ubiquitously	  (Ro	  and	  Dawid,	  2009).	  
PANTHER	  analysis	  output	  showed	  that	  LNX1	  is	  involved	  in	  the	  Notch	  signalling	  pathway	   and	   can	   be	   visualized	   using	   STRING	   database	   (figure	   5.1).	   The	   role	  played	  by	  LNX1	   is	   in	   targeting	  Numb,	  a	  component	  of	   the	  Notch	  pathway	   that	  functions	  in	  the	  specification	  of	  cell	   fates	  during	  development	  and	  is	  known	  to	  control	  cell	  numbers	  during	  neurogenesis	  in	  vertebrates	  (Johnson,	  2003).	  LNX1	  ubiquitinates	  Numb,	  leading	  to	  proteasomal	  degradation	  and	  has	  been	  shown	  to	  modulate	  Notch	  signalling	   in	  cultured	  cells	  (Nie	  et	  al.,	  2002).	  Ubiquitination	  of	  
Numb	  by	  LNX1	  is	  also	  thought	  to	  have	  an	  effect	  on	  the	  formation	  or	  remodelling	  of	   cell-­‐cell	   junctions,	   as	   ectopic	   expression	  of	  LNX1	   can	   remove	   claudins	   from	  cell	  junction	  and	  enhance	  TGFβ-­‐induced	  epithelial	  to	  mesenchymal	  transition	  in	  epithelial	   cells	   (Takahashi	   et	   al.,	   2009).	   STRING	   analysis	   also	   shows	   that	   it	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interacts	   with	   CXADR,	   which	   is	   a	   component	   of	   the	   epithelial	   apical	   junction	  complex	  that	  is	  essential	  for	  the	  tight	  junction	  integrity,	  proposed	  to	  function	  as	  a	   homophilic	   cell	   adhesion	   molecule.	   In	   zebrafish	   depletion	   of	   Lnx-­‐l	   using	  specific	  antisense	  morpholinos	  caused	  strong	  embryonic	  dorsalization	  (Ro	  and	  Dawid,	  2009).	   	  
















Figure	   5.1.	   qRT-­‐PCR	   validation	   and	   STRING	   output	   of	   LNX1	   interaction	   with	  
genes.	  	  Diagram	  shows	  the	  genes	  that	  strongly	  interact	  with	  LNX1	  and	  the	  colour	  of	  the	  lines	   represents	   the	   type	   of	   interaction	   shown	   in	   the	   table.	   	   The	   table	   also	  contains	  a	  list	  of	  gene	  names	  included	  in	  the	  diagram.	  Mean	  ±	  SEM.	  T-­‐test.	  p=NS.	  N=3,	  100	  embryos	  per	  group.	  
Gene	   Gene	  name	  
LNX2	   ligand	  of	  numb-­‐protein	  X	  2	  
RASL11B	   RAS-­‐like,	  family	  11,	  member	  B	  
NOTCH1	   Notch	  homolog	  1	  
SNW1	   SNW	  domain	  containing	  1	  
NUMB	   numb	  homolog	  
PARK2	   Parkinson	  disease	   (autosomal	   recessive,	  
juvenile)	  2	  
NUMBL	   numb	  homolog	  -­‐like	  
RHOC	   ras	  homolog	  gene	  family	  
IGSF5	   immunoglobulin	  superfamily,	  member	  5	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5.3.2	  Renin	  (ren)	  	  
Renin	   is	   significantly	   up	   regulated	   in	   the	   KIAA1109	   morphants	   compared	   to	  controls.	  	  	  This	  was	  validated	  using	  quantitative	  RT-­‐PCR	  (figure	  5.2).	  	  	  
Renin	   maintains	   blood	   pressure	   through	   vasoconstriction	   by	   generating	  angiotensin	   I	   from	   angiotensinogen	   in	   the	   plasma,	   initiating	   a	   cascade	   of	  reactions	   that	   produce	   an	   elevation	   of	   blood	   pressure	   and	   increased	   sodium	  retention	  by	  the	  kidney	  as	  part	  of	  the	  renin-­‐angiotensin	  system	  (RAS)	  (Brown,	  2007).	  Pathological	  activation	  of	   the	  RAS	  results	   in	  excessive	  vasoconstriction,	  sodium	   retention,	   abnormal	   vascular	   smooth	  muscle	   and	   cardiac	  hypertrophy	  and	  fibrosis	  (Ma	  et	  al.,	  2010).	  Elevated	  plasma	  renin	  activity	  is	  associated	  with	  increased	   morbidity	   and	   mortality	   in	   patients	   with	   cardiovascular	   disease	  (Volpe	  et	  al.,	  2012)	  and	  pharmacological	  inhibition	  of	  RAS	  has	  led	  to	  reductions	  on	  cardiovascular	  morbidity	  and	  mortality.	  
It	  might	   be	   expected	   that	   renin	   is	   significantly	   up	   regulated	   in	   the	   KIAA1109	  morphants,	   as	   due	   to	   cerebral	   haemorrhaging	   the	   blood	   pressure	   would	   be	  predicted	   to	   be	   reduced	   in	   the	   KIAA1109	   morphants.	   	   Liang	   et	   al	   found	  expression	   of	   renin	   in	   the	   kidney	   of	   zebrafish	   (Liang	   et	   al.,	   2004),	   in	   keeping	  with	  its	  expression	  pattern	  in	  humans	  and	  its	  role	  in	  activation	  of	  RAS.	  	  
	   	  















Figure	   5.2.	   qRT-­‐PCR	   validation	   and	   STRING	   output	   of	   Renin	   interaction	   with	  
genes.	  	  Diagram	  shows	  the	  genes	  that	  strongly	  interact	  with	  Renin	  and	  the	  colour	  of	  the	  lines	   represents	   the	   type	   of	   interaction	   shown	   in	   the	   table.	   	   The	   table	   also	  contains	  a	  list	  of	  gene	  names	  included	  in	  the	  diagram.	  Mean	  ±	  SEM.	  T-­‐test.	  p=NS.	  N=3,	  100	  embryos	  per	  group.	  
Gene	   Gene	  name	  
SCNN1B	   sodium	   channel,	   nonvoltage-­‐gated	   1,	  
beta	  
POMC	   proopiomelanocortin	  
KNG1	   kininogen	  1	  
AGTR2	   angiotensin	  II	  receptor,	  type	  2	  
ACE	   	  angiotensin	  I	  converting	  enzyme	  1	  
CYP11B2	   cytochrome	  P450,	  family	  11,	  subfamily	  B,	  
polypeptide	  2	  
AGTR1	   angiotensin	  II	  receptor,	  type	  1	  
AGT	   angiotensinogen	  
ATP6AP2	   	  ATPase,	   H+	   transporting,	   lysosomal	  
accessory	  protein	  2	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5.3.3.	  Calcium/calmodulin-­‐dependent	  protein	  kinase	  (camk2g2)	  
Camk2g2	  is	  significantly	  up	  regulated	  in	  the	  KIAA1109	  morphants	  compared	  to	  controls.	  	  	  This	  was	  validated	  using	  quantitative	  RT-­‐PCR	  (figure	  5.3).	  	  CaMK-­‐II	  is	  highly	   conserved	   Ca2+	   _	   /calmodulin-­‐dependent	   protein	   kinase	   expressed	  throughout	  the	  lifespan	  of	  all	  vertebrates.	  Zfin	  shows	  that	  Camk2g2	  is	  expressed	  in	   the	   forebrain,	   hindbrain	   and	   liver.	   	   During	   early	   development,	   CaMK-­‐II	  regulates	  cell	  cycle	  progression	  and	  non-­‐	  canonical	  Wnt-­‐dependent	  convergent	  extension	   (Rothschild	   et	   al.,	   2007).	   They	   found	   that	   there	   were	   significant	  expression	  levels	  of	  camk2g2	  transcripts	  from	  the	  8-­‐cell	  through	  to	  72hpf	  in	  the	  forebrain,	  midbrain	  and	  hindbrain	  and	  claim	  that	  this	  CaMK-­‐II	  localization	  in	  the	  zebrafish	   is	   consistent	   with	   its	   involvement	   in	   non-­‐canonical	   Wnt	   pathways	  (Rothschild	  et	  al.,	  2007)	  
5.3.4	  Glutamate	  receptor,	  ionotropic,	  N-­‐methyl	  D-­‐aspartate	  1a	  (grin1a)	  
Grin1a	   is	   significantly	   up	   regulated	   in	   the	   KIAA1109	  morphants	   compared	   to	  controls.	   	   	   This	   was	   validated	   using	   quantitative	   RT-­‐PCR	   (figure	   5.4)	   using	   a	  commercially	  ready	  Taqman	  probe	  as	  described	  in	  chapter	  2.5.4.	  	  Glutamate	  is	  the	  main	  excitatory	  neurotransmitter	  in	  vertebrates,	  and	  its	  effects	  are	  mediated	  by	  means	  of	  two	  classes	  of	  receptors:	  G	  protein-­‐coupled	  receptors	  (metabotropic	  glutamate	   receptors)	  and	   ligand-­‐gated	   ion	  channels	   (ionotropic	  receptors)	   (Cox	   et	   al.,	   2005).	   PANTHER	   analysis	   had	   shown	   that	   the	  differentially	  expressed	  genes	  had	  a	  significantly	  larger	  representation	  of	  genes	  in	  both	  of	  these	  pathways.	  	   	  













Figure	  5.3.	   qRT-­‐PCR	  validation	  and	   	   STRING	  output	   of	   Camkg2	   interaction	  with	  
genes.	  	  Diagram	  shows	  the	  genes	  that	  strongly	  interact	  with	  Camk2g	  and	  the	  colour	  of	  the	   lines	  represents	   the	   type	  of	   interaction	  shown	   in	   the	   table.	   	  The	  table	  also	  contains	  a	  list	  of	  gene	  names	  included	  in	  the	  diagram.	  Mean	  ±	  SEM.	  T-­‐test.	  p=NS.	  N=3,	  100	  embryos	  per	  group.	   	  
Gene	   Gene	  name	  
CALM1	   calmodulin	  1	  (phosphorylase	  kinase,	  delta)	  
GRIA1	   glutamate	  receptor,	  ionotropic	  
ADCY3	   adenylate	  cyclase	  3	  
SYN1	   synapsin	  I	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Figure	   5.4.	   qRT-­‐PCR	   validation	   and	   	   STRING	   output	   of	   Grin1a	   interaction	   with	  
genes.	  	  Diagram	  shows	   the	  genes	   that	   strongly	   interact	  with	  Grin1a	   and	   the	   colour	  of	  the	   lines	  represents	   the	   type	  of	   interaction	  shown	   in	   the	   table.	   	  The	  table	  also	  contains	  a	  list	  of	  gene	  names	  included	  in	  the	  diagram.	  Mean	  ±	  SEM.	  T-­‐test.	  p=NS.	  N=3,	  100	  embryos	  per	  group.	  
Gene	   Gene	  Name	  
DLG4	   discs,	  large	  homolog	  4	  
GRIN3B	   glutamate	   receptor,	   ionotropic,	   N-­‐methyl-­‐
D-­‐aspartate	  3B	  
GRIN3A	   glutamate	   receptor,	   ionotropic,	   N-­‐methyl-­‐
D-­‐aspartate	  3A	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Expression	  analysis	  via	  in	  situ	  hybridization	  shows	  that	  Grin1a	   is	  expressed	  in	  the	  brain,	  diencephalon,	  hindbrain	  (Tzeng	  et	  al.,	  2007)	  as	  well	  as	  the	  midbrain	  and	  forebrain	  (Cox	  et	  al.,	  2005).	  	  
5.3.5.	  Protocadherin	  1	  gamma	  2	  (PCDH1γ2)	  
Pcdh1γ2	  is	  significantly	  down	  regulated	  in	  the	  KIAA1109	  morphants	  compared	  to	   controls.	   The	   clustered	   protocadherins	   are	   a	   subfamily	   of	   neuronal	   cell	  adhesion	  molecules	  that	  play	  an	  important	  role	  in	  development	  of	  the	  nervous	  systems	   in	   vertebrates	   (Tan	  et	   al.,	   2010).	   Zebrafish	   contains	   two	   independent	  protocadherin	  clusters,	  Pcdh1	   and	  Pcdh2,	   that	   collectively	  contain	  at	   least	  107	  genes	  (Noonan	  et	  al.,	  2003).	  	  Wu	  et	  al	  found	  that	  similar	  to	  the	  mammalian	  Pcdh	  genes,	   the	   zebrafish	   Pcdh	   genes	   are	   also	   expressed	   in	   the	   CNS	   and	   that	  expression	  of	  the	  Pcdh1γ	  from	  zebrafish	  brain	  total	  RNA	  preparations	  by	  using	  RT-­‐PCR	  (Wu,	  2005).	  PANTHER	  analysis	  showed	  that	  pcdh1γ2	  is	  involved	  in	  the	  cadherin	  signalling	  pathway	  as	  well	  as	  the	  wnt	  pathway.	  STRING	  analysis	  shows	  that	  pcdh1γ2	   interacts	  with	  many	   genes	   that	   interact	  with	   these	   pathways	   as	  well	  as	  being	  involved	  in	  other	  relevant	  mechanisms.	  	  
5.3.6.	  Nodal	  related	  2	  (ndr2)	  
Ndr2	   is	  significantly	  down	  regulated	   in	  the	  KIAA1109	  morphants	  compared	  to	  controls.	  
Nodal-­‐related	   factors	   have	   been	   implicated	   in	   mesodermal	   and	   neural	  patterning,	   and	   left-­‐right	  asymmetry,	   in	   several	   animal	  models	  and	  Erter	  et	  al	  were	  able	  to	  isolate	  and	  characterize	  the	  zebrafish	  ndr2	  and	  found	  that	  it	  	   	  













Figure	  5.5.	  STRING	  output	  of	  pcdh1γ2	  interaction	  with	  genes.	  	  Diagram	  shows	  the	  genes	  that	  strongly	  interact	  with	  pcdh1γ2	  and	  the	  colour	  of	  the	   lines	  represents	   the	   type	  of	   interaction	  shown	   in	   the	   table.	   	  The	  table	  also	  contains	  a	  list	  of	  gene	  names	  included	  in	  the	  diagram.	  	  	  
	  
	  
Gene	   Gene	  Name	  
AHNAK	   AHNAK	  nucleoprotein	  
RYK	   RYK	  receptor-­‐like	  tyrosine	  kinase	  
TLE1	   transducin-­‐like	  enhancer	  of	  split	  1	  
FZD4	   frizzled	  homolog	  4	  
PLEK2	   pleckstrin	  2	  
ME1	   malic	  enzyme	  1	  
EFNA1	   ephrin-­‐A1	  
TINAGL1	   tubulointerstitial	  nephritis	  antigen-­‐like	  1	  
PLSCR2	   phospholipid	  scramblase	  2	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encodes	   a	   robust	   mesendodermal	   inducer	   that	   signals	   non	   autonomously	  during	  the	  earliest	  stages	  of	  embryonic	  patterning,	  and	  that	  part	  of	  this	  activity	  arises	  from	  within	  the	  YSL	  (Erter	  et	  al.,	  1998).	  PANTHER	  analysis	  showed	  that	  
ndr2	  is	  involved	  in	  the	  TGFβ	  pathway,	  as	  the	  nodal	  family	  of	  proteins	  is	  a	  subset	  of	   the	   TGFβ	   superfamily	   and	   work	   as	   part	   of	   a	   positive	   feedback	   loop	   by	  interacting	   with	   other	   proteins	   to	   induce	   gene	   transcription.	   In	   zebrafish	   the	  
Cyclops	   locus	   encodes	   ndr2	   and	   Rebagliati	   et	   al	   showed	   that	   in	   the	   Cyclops	  mutant,	   a	   loss	   of	   Ndr2	   signalling	   causes	   abnormal	   patterning	   and	  morphogenesis	  of	  mesoderm	  and	  forebrain	  (Rebagliati	  et	  al.,	  1998).	  	  
The	   role	   of	  ndr2	   played	   in	   patterning	   can	   also	   be	   confirmed	  by	   STRING	   in	   its	  interaction	  with	  genes	  such	  as	  shha	  which	  is	  a	  signal	  produced	  by	  the	  notochord	  that	  induces	  somite	  patterning,	  dorso-­‐ventral	  patterning	  of	  the	  brain	  and	  early	  patterning	  of	  the	  developing	  eyes.	   	  









Figure	  5.6.	  STRING	  output	  of	  ndr2	  interaction	  with	  genes.	  	  Diagram	  shows	  the	  genes	  that	  strongly	  interact	  with	  ndr2	  and	  the	  colour	  of	  the	  lines	   represents	   the	   type	   of	   interaction	   shown	   in	   the	   table.	   	   The	   table	   also	  contains	  a	  list	  of	  gene	  names	  included	  in	  the	  diagram.	  	  	   	  
Gene	   Gene	  Name	  
shha	   Sonic	  hedgehog	  protein	  A	  
oep	   one-­‐eyed	  pinhead	  
flh	   floating	  head	  
pitx2	   Pituitary	  homeobox	  2	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5.4.	  Discussion	  	  
In	  this	  chapter	  I	  performed	  a	  microarray	  on	  KIAA1109	  morphants	  and	  used	  in-­‐
silico	  methods	  to	  analyse	  the	  transcriptional	  effect	  of	  KIAA1109	  knockdown,	  in	  an	  attempt	  to	  gain	  insight	  into	  the	  mechanisms	  by	  which	  KIAA1109	  is	  involved	  in	  vascular	  integrity.	  
In-­‐silico	  methods	  of	  research	  have	  been	  widely	  used	  by	  biologists	  to	  further	  gain	  information	   on	   their	   area	   of	   interest.	   The	   majority	   of	   bioinformatics	   tools	  available	   are	   not	   user	   friendly	   without	   a	   computing	   background	   and	   often	  require	  substantial	  time	  to	  familiarize	  oneself	  with	  the	  output	  format	  as	  well	  as	  personalizing	   the	   uploaded	   list	   to	   the	   specifications	   of	   that	   particular	   system.	  The	  output	  lists	  can	  also	  require	  the	  specialist	  knowledge	  of	  a	  bioinformatician	  and	   can	   be	   hard	   for	   biologists	   to	   analyse	   efficiently.	   Most	   annotational	  databases	  use	  numerous	  public	  sources	  of	  protein	  and	  gene	  annotation	  and	  are	  therefore	  dependent	  on	  vigilant	  and	  regular	  updates.	  As	  this	   is	  not	   the	  case	   in	  some	   public	   source	   databases,	   many	   genes	   remain	   unannotated	   and	   the	  uploaded	   list	   may	   need	   to	   be	   reanalysed	   at	   regular	   intervals	   or	   by	   several	  databases	  in	  order	  to	  gain	  a	  complete	  list	  of	  annotations,	  which	  can	  be	  very	  time	  consuming.	  	  	  However	   there	   are	   user	   friendly	   and	   reliable	   databases	   used	   regularly	   for	  annotation,	  which	  can	  provide	  informative	  insight	  into	  pathways	  and	  functions	  of	  genes	  of	  interest.	  Using	  a	  combination	  of	  PANTHER	  for	  pathway	  inclusion	  and	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STRING	  for	  protein	  interaction,	  I	  was	  able	  to	  visualize	  biological	  interactions	  for	  genes	  that	  I	  identified	  as	  differentially	  expressed	  by	  KIAA1109	  knockdown.	  	  Genes	   were	   validated	   using	   qRT-­‐PCR	   and	   Taqman	   probes	   which	   were	  commercially	   available.	   Only	   two	   genes	   did	   not	   have	   commercially	   available	  probes	  which	  were	  designed	  using	  the	  inbuilt	  probe	  design	  software	  within	  the	  Applied	   Biosystems	   website.	   Of	   the	   six	   genes	   only	   four	   showed	   the	   same	  differential	  expression	  using	  qRT-­‐PCR.	  The	  genes	  that	  were	  significantly	  down	  regulated,	  pcdh1γ2	  and	  ndr2	  did	  not	  show	  significant	  reduction	  compared	  to	  the	  control.	  This	  could	  be	  due	  to	  the	  sensitivity	  of	  the	  assay	  being	  less	  than	  that	  of	  a	  microarray	   and	   therefore	   not	   showing	   a	   significant	   difference.	   Although	   not	  validated	  by	  qPCR,	   in-­‐silico	  analysis	  showed	  that	  suppression	  of	  some	  of	   these	  genes	   might	   plausibly	   account	   for	   the	   KIAA1109	   knockdown	   phenotype.	  
Pcdh1γ2	   is	   part	   of	   the	   cadherin	   family,	   which	   plays	   a	   large	   role	   in	   vascular	  integrity,	  which	  is	  down	  regulated	  in	  KIAA1109	  morphants.	  In	  humans	  renin	  is	  released	  upon	  a	  fall	  in	  blood	  pressure,	  in	  particular	  due	  to	  haemorrhaging.	  This	  was	   also	   reflected	   in	   the	   KIAA1109	   morphant	   group,	   with	   a	   significant	   up	  regulation	   of	   renin	   in	   the	   morphants	   where	   the	   main	   phenotype	   is	   cerebral	  haemorrhaging.	   It	   is	   also	   of	   interest	   that	   LNX1	   which	   is	   part	   of	   the	   Notch	  pathway	  is	  up	  regulated	  in	  KIAA1109	  morphants	  in	  which	  the	  phenotype	  can	  be	  rescued	  by	  VEGF	  induction.	  An	  induction	  of	  Notch	  ligand	  dll4	  has	  been	  shown	  to	  reduce	   VEGF,	   likely	   via	   down	   regulation	   of	   VEGFR-­‐2	   expression,	   in	   cultured	  endothelial	   cells	   (Williams	   et	   al.,	   2006).	   As	   previously	   shown	   KIAA1109	   is	  expressed	   in	   endothelial	   cells,	   and	   can	   be	   rescued	   with	   VEGF	   induction,	  however	   the	   mechanism	   by	   which	   GS4012	   induces	   VEGF	   is	   unknown.	   The	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findings	  using	  pathway	  analysis	  as	  well	  as	  protein	  interaction	  could	  shine	  a	  light	  on	  the	  induction	  pathway	  of	  VEGF	  in	  order	  to	  rescue	  the	  morphant	  phenotype.	  
The	   in-­‐silico	   findings	   of	   this	   chapter	   lead	   to	   many	   speculations	   as	   to	   the	  mechanism	  by	  which	  the	  knockdown	  of	  KIAA1109	  causes	  a	  decrease	  in	  vascular	  integrity	  as	  well	  as	  which	  pathway	  this	  gene	  could	  be	  involved	  in	  and	  proteins	  that	   it	   is	   interacting	   with.	   	   As	   mentioned	   these	   are	   in-­‐silico	   findings	   and	  speculations	   of	   the	   function	   of	   KIAA1109	   can	   only	   be	   fully	   understood	   by	  further	  experiments.	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Chapter	  6:	  General	  discussion	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6.1.	  General	  discussion	  
Cardiovascular	  disease	  is	  the	  largest	  cause	  of	  death	  worldwide.	  Although	  useful	  biomarkers	   for	  diagnosis	  of	  acute	  coronary	  syndromes	  are	  well	  established	   in	  order	   to	   obtain	   more	   information	   about	   the	   pathogenesis	   of	   myocardial	  infarctions	  we	  investigated	  gene	  expression	  patterns	  in	  peripheral	  blood	  of	  UA	  patients	  compared	  to	  those	  having	  suffered	  MI.	  A	   limitation	   of	   the	   study	   was	   the	   patient	   demographics.	   	   As	   a	   result	   of	   all	  recruited	   patients	   living	   within	   the	   South	   Yorkshire	   area	   with	   100%	   of	  participants	   are	   White	   British;	   the	   results	   will	   be	   highly	   specific	   to	   this	  population	  and	  less	  transferable	  to	  others.	  	  In	  order	   to	   investigate	  gene	  expression	  patterns	   in	  peripheral	  blood	  RNA	  was	  extracted	  from	  peripheral	  blood	  of	  UA	  and	  MI	  patients	  at	  serial	  time	  points,	  of	  which	  my	  results	  have	  concentrated	  on	  1	  day	  post	  admission	  as	  this	  is	  the	  time	  point	  at	  which	  most	  deaths	  post	  MI	  occur.	  	  Gene	   expression	   profiling	   of	   RNA	   extracted	   from	   peripheral	   blood	   is	   a	  potentially	   informative	  method	   for	   identifying	   biomarkers,	   examining	   disease	  states,	  and	  investigating	  immune	  responses.	  In	  cardiovascular	  disease	  there	  are	  many	   advantages	   to	   studying	   gene	   expression	   from	  whole	   blood	   rather	   than	  from	   fractionated	   subpopulations	   such	   as	   neutrophils.	   Firstly,	   when	  fractionation	   steps	   are	  performed,	  α	   and	  β	   globin	  mRNA	   transcripts	   are	  often	  still	  rich	  in	  total	  RNA	  extracted	  from	  leukocyte-­‐enriched	  populations	  (Feezor	  et	  al.,	  2004)	  while	  the	  fractionation	  itself	  can	  contribute	  to	  an	  increase	  in	  sample-­‐to-­‐sample	  variability	  in	  the	  microarray	  assay	  (Fan	  et	  al.,	  2007).	  	  Secondly,	  there	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are	   a	   multitude	   of	   populations	   within	   whole	   blood	   including	   neutrophils,	  monocytes,	   and	   dendritic	   cells.	   While	   some	   studies	   may	   require	   analysis	   of	  individual	  cell	  types	  it	  may	  be	  advantageous	  in	  this	  study	  to	  investigate	  them	  as	  a	  whole	   so	   as	   not	   to	   exclude	   any	   potential	  markers,	   additionally	   it	  was	  more	  cost	   and	   time	   efficient	   to	   study	   these	   together.	   Finally,	   working	   with	   whole	  blood	  across	  multiple	  sites	  instead	  of	  fractionation	  facilitates	  a	  uniformity	  that	  is	   diminished	   with	   each	   additional	   step	   in	   the	   processing	   of	   the	   blood	  (Vartanian	   et	   al.,	   2009).	   However,	   the	   relatively	   high	   proportion	   of	   globin	  messenger	  RNA	  present	  in	  total	  RNA	  extracted	  from	  whole	  blood	  can	  reduce	  the	  efficacy	  of	  the	  microarray	  assay	  by	  interfering	  with	  the	  hybridization	  step	  of	  the	  microarray	   and	   therefore	   the	   detection	   of	   less	   abundant	   gene	   transcripts	  (Feezor	   et	   al.,	   2004).	   Fractionation	   of	   whole	   blood	   components	   prior	   to	   RNA	  extraction	  is	  a	  common	  occurrence	  and	  depending	  on	  the	  fractionation	  method	  selected,	   partial	   or	   complete	   removal	   of	   reticulocytes,	   the	   primary	   source	   of	  globin	  RNA,	  may	  be	  achieved.	  In	  preparing	  the	  RNA	  the	  Ambion	  GLOBINclear™	  kit	  was	  used	  to	  remove	  globin	  from	  the	  RNA	  to	  ensure	  efficient	  hybridization.	  	  	  	  The	  use	   of	  microarrays	  has	   expanded	   rapidly	   as	   an	  unbiased	   approach	   to	   the	  identification	  of	  novel	  genes	  for	  research.	  Its	  flexibility,	  reducing	  cost	  and	  high-­‐throughput	  has	  allowed	  its	  use	  in	  studying	  a	  variety	  of	  human	  diseases.	  The	  use	  of	  Affymetrix	  GeneChip	  allows	  us	  to	  gain	  large	  numbers	  of	  gene	  expression	  data	  from	  large	  cohorts	  of	  patients	   for	  comparison.	  The	  output	  of	  a	  microarray	  can	  range	   from	   4,000–50,000	   measurements	   of	   gene	   expression	   per	   biological	  sample	  making	  correctly	  analysing	  the	  data	  one	  of	  the	  biggest	  challenges.	  This	  is	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dependent	  on	  many	  different	  databases	   for	  annotation	  of	  probe	  sets	  and	  gene	  names,	  which	  are	  not	  always	  up	  to	  date	  and	  are	  ever	  changing.	  It	  can	  also	  be	  an	  overwhelming	  process	  to	  identify	  the	  most	  significant	  list	  of	  genes,	  which	  puts	  an	  emphasis	  on	  the	  parameters	  set,	  such	  as	  p	  values	  and	  fold	  change,	  to	  ensure	  an	   unbiased	   end-­‐list	   of	   genes.	   However	   analysis	   software	   such	   as	   PUMA	   and	  several	  annotation	  databases	  have	  been	  designed	  to	  help	  researchers	  efficiently	  deal	   with	   large	   data	   sets.	   Using	   such	   software	   and	   databases	   I	   was	   able	   to	  identify	  a	  novel	  candidate	  gene,	  KIAA1109.	  	  It	   is	   important	   to	   confirm	   differential	   expression	   of	   candidate	   genes	   using	  quantitative	  RT-­‐PCR.	  qRT-­‐PCR	  is	  a	  technically	  challenging	  technique,	  that	  can	  be	  time	  consuming	  and	  expensive.	  There	  is	  also	  no	  general	  consensus	  in	  the	  use	  of	  appropriate	   control	   genes	   as	  well	   as	   the	   accurate	   analysis	   of	   data,	  with	   some	  using	   the	   delta	   ct	   method	   and	   others	   the	   pfaffl	   method	   as	   well	   as	   relative	  quantification	  making	  validation	  subjective	   to	   the	  operator.	  The	  housekeeping	  genes	  I	  used	  were	  DECR1	  and	  TRAP1	  which	  have	  been	  published	  as	  being	  the	  most	   stably	   expressed	   genes	   needed	   for	   accurate	   normalization	   in	   RNA	  expression	  studies	  of	  human	  whole	  blood	  (Stamova	  et	  al.,	  2009).	  Although	  the	  qRT-­‐PCR	  data	  acquired	  is	  not	  statistically	  significant,	  the	  trend	  does	  follow	  that	  seen	  in	  the	  microarray	  data.	  	  Although	  RNA	  based	  biomarkers	  are	  unlikely	   to	  be	  amenable	   to	  direct	  clinical	  introduction	  given	  their	  technical	  difficulty	  and	  susceptibility	  to	  variability,	  the	  ability	   of	   arrays	   to	   provide	   whole	   genome	   level	   assessments	   (at	   the	   mRNA	  level)	   is	   extremely	   powerful.	   It	   is	   possible	   that	   differentially	   expressed	  transcripts	  (such	  as	  KIAA1109)	  are	  differentially	  expressed	  at	  the	  protein	  level.	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I	  did	  not	  examine	  this,	  but	  such	  changes	  in	  protein	  transcription	  are	  much	  more	  practically	  suitable	  for	  use	  as	  biomarkers	  and	  diagnostics.	  	  Upon	   selecting	   a	   candidate	   gene	   it	   is	   important	   to	   assess	   the	   function	   of	   the	  gene	  in	  an	  appropriate	  animal	  model.	  Zebrafish	  have	  many	  advantages	  for	  such	  a	  purpose	  due	  to	  their	  small	  size,	  high	   fecundity,	  genetic	  homology	  to	  humans	  and	  the	  established	  use	  of	  genetic	  manipulation	  for	  gene	  knockdown	  and	  over	  expression	   studies.	  Morpholino	   technology	  has	   long	  been	  used	   in	   zebrafish	   to	  temporarily	   knockdown	   target	   gene	   expression.	   This	   can	   provide	   important	  information	  as	  to	  the	  effect	  of	  KIAA1109	  knockdown	  in	  the	  development	  of	  the	  embryo.	  Morpholino	  antisense	  does	  have	  its	  pitfalls	  as	  it	  is	  only	  active	  up	  to	  3-­‐4dpf	   and	   so	   cannot	   be	   used	   for	   long-­‐term	   investigation	   as	   well	   as	   some	   off	  target	  effects	  that	  can	  be	  misinterpreted	  as	  a	  phenotype.	  However,	  it	  is	  difficult	  to	  carry	  out	  western	  blotting	  in	  zebrafish	  as	  there	  are	  very	  few	  antibodies	  that	  are	   effective	   and	   available.	   The	   creation	   of	   a	   stable	   mutant	   to	   confirm	  morpholino	  data	  is	  now	  possible	  (Buchner	  et	  al.,	  2007,	  Itoh	  et	  al.,	  2003,	  Jiang	  et	  al.,	  1996),	  however	  is	  time	  consuming	  (see	  future	  work).	  	  Upon	   knocking	   down	   KIAA1109	   I	   observed	   severe	   cerebral	   haemorrhaging,	  which	  was	  not	  present	  in	  control	  morphants.	  To	  increase	  my	  confidence	  in	  the	  specificity	   of	   the	   phenotype	   to	   KIAA1109	   knockdown	   two	   other	  morpholinos	  were	   designed,	   a	   splice	   site	   and	   non-­‐overlapping	   morpholino,	   both	   of	   which	  induced	   a	   similar	   percentage	   of	   cerebral	   haemorrhaging.	   I	   was	   unable	   to	  perform	   mRNA	   rescue	   as	   I	   was	   unable	   to	   clone	   the	   entire	   KIAA1109	   gene.	  However,	   the	  ability	  of	   the	  VEGF	  inducer,	  GS4012,	  to	  rescue	  the	  haemorrhagic	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phenotype	  is	  compelling,	  suggesting	  that	  the	  phenotype	  is	  specific	  to	  the	  actions	  of	   the	   KIAA1109	   morpholino,	   and	   that	   haemorrhaging	   may	   be	   caused	   by	   a	  disruption	  in	  the	  VEGF	  pathway.	  	  I	  speculate	  that	  although	  the	  down	  regulation	  of	  KIAA1109	  after	  MI	  could	  have	  multiple	  explanations,	  my	  findings	  could	  indicate	  a	  potential	  causative	  role	  for	  KIAA1109	   in	   initiation	  of	  myocardial	   infarction.	  The	  presence	  of	  neovessels	   in	  an	   atherosclerotic	   plaque	   makes	   it	   prone	   to	   rupture	   due	   to	   their	   fragile	  structure,	  making	  them	  susceptible	  to	  interplaque	  haemorrhage.	  This	  neovessel	  haemorrhaging	   releases	   red	   blood	   cells	   into	   the	   plaque,	   increasing	   lipid	  peroxidation	  and	  macrophage	  activation	  and	  eventually	  leading	  to	  a	  myocardial	  infarction.	  Reduced	  expression	  of	  KIAA1109	  disrupts	  vascular	  integrity	  of	  these	  neovessels,	   increasing	   leakage	   into	   the	   plaque	   and	   promoting	   interplaque	  haemorrhaging.	  However,	  since	  we	  cannot	   identify	  patients	  who	  will	  suffer	  an	  ACS	   prior	   to	   presentation,	   it	   would	   be	   difficult	   to	   examine	   whether	   reduced	  KIAA1109	   indicates	   higher	   risk	   for	   plaque	   rupture	   at	   the	   present	   time.	   If	  advances	  in	  imaging	  allow	  identification	  of	  vulnerable	  plaques	  prior	  to	  rupture,	  it	   would	   be	   interesting	   to	   examine	   KIAA1109	   expression	   in	   these	   patients’	  blood.	  	  To	  better	  understand	  the	  mechanism	  by	  which	  KIAA1109	  is	  disrupting	  vascular	  integrity,	   a	   custom	  made	   microarray	   was	   carried	   out	   using	   RNA	   from	   whole	  embryos	  36hpf.	  After	  analysis	  of	   the	  data,	  six	  differentially	  expressed	  genes	  of	  interest	  were	  selected.	  Of	  those	  LNX1	  was	  up	  regulated	  and	  is	  known	  to	  be	  part	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of	   the	   Notch	   pathway,	   Protocadherin	   is	   down	   regulated	   and	   is	   part	   of	   the	  cadherin	   family,	  which	   play	   an	   important	   role	   in	   vascular	   integrity	   as	  well	   as	  being	  part	  of	   the	  Wnt	  pathway.	  LNX1	  has	  been	   involved	   in	  many	  pathways	  as	  well	  as	  biological,	   cellular	  and	  molecular	   functions,	  as	   identified	  by	  PANTHER,	  which	  are	  essential	  for	  vascular	  integrity.	  It	  has	  also	  been	  previously	  indicated	  in	  a	  study	  by	  Kansaku	  et	  al	  implicating	  its	  involvement	  in	  reorganization	  of	  cell	  junctions	  (Kansaku	  et	  al.,	  2006).	  The	  mutant,	   Cyclops,	   is	   caused	   by	   a	   loss	   of	  Ndr2	   signalling	   causing	   abnormal	  patterning	   and	   morphogenesis	   of	   mesoderm	   and	   forebrain	   (Rebagliati	   et	   al.,	  1998).	  These	   findings	   can	   allow	   speculation	   of	   the	   potential	   interaction	   between	  KIAA1109,	   VEGF	   and	   Notch.	   The	   KIAA1109	   morphant	   microarray	   findings	  showed	   no	   significant	   difference	   in	   the	   expression	   of	   VEGF	   ligands	   VEGFaa,	  VEGFab	  and	  VEGFc.	  However	  the	  microarray	  did	  not	   look	  at	   the	  expression	  of	  VEGF	   receptors.	   Ruch	   et	   al	   showed	   that	   if	   VEGF	   ligands	   are	   stabilised	   VEGF	  receptor	  differential	  regulation	  can	  still	  have	  an	  independent	  effect	  (Ruch	  et	  al.,	  2007).	  An	  induction	  of	  Notch	  ligand	  dll4	  has	  also	  shown	  to	  reduce	  VEGF,	  likely	  via	   down	   regulation	   of	   VEGFR-­‐2	   expression,	   in	   cultured	   endothelial	   cells	  (Williams	  et	  al.,	  2006).	  The	  morphant	  microarray	  results	  also	  show	  that	  there	  is	  an	  induction	  of	  Notch	  via	  LNX1.	  As	  VEGFR2	  is	  associated	  with	  vascular	  integrity	  and	   the	   process	   by	   which	   GS4012	   induces	   VEGF,	   in	   order	   to	   rescue	  haemorrhaging	  in	  the	  KIAA1109	  morphants	  is	  unknown,	  it	  could	  be	  speculated	  that	   it	   rescues	   the	   phenotype	   via	   an	   interaction	   of	   VEGFR2	   and	   Notch.	   As	  previously	   suggested	   if	   KIAA1109	   down	   regulation	   in	   neovessels	   within	   the	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plaque	  can	   lead	   to	  an	   increase	   in	  neovessel	   rupture	  and	   therefore	   interplaque	  haemorrhage	   inducing	   an	   MI,	   it	   could	   potentially	   introduce	   VEGF	   therapy	   to	  reduce	  the	  occurrence	  of	  plaque	  rupture.	  	  	  The	   identification	   of	   these	   genes	   and	   subsequent	   investigation	   into	   their	  interaction	   with	   KIAA1109	   will	   provide	   a	   more	   thorough	   insight	   into	   the	  mechanism	  by	  which	  KIAA1109	  knockdown	  disrupts	  vascular	  integrity.	  	  
6.2.	  Future	  work	  
Due	  to	  time	  constraints	  I	  was	  unable	  to	  pursue	  many	  aspects	  that	  would	  benefit	  from	  further	  investigation.	  
• During	   this	   work,	   I	   requested	   generation	   of	   a	   KIAA1109	   mutant	  zebrafish	  by	  the	  Wellcome	  Trust	  Sanger	  institute,	  which	  provides	  such	  a	  service	  as	  part	  of	  the	  on	  going	  effort	  to	  generate	  mutant	  zebrafish	  lines	  in	  all	  protein	  coding	  genes	  (Sanger).	  Although	  these	  were	  not	  available	  for	  examination	   during	   my	   PhD,	   four	   mutant	   alleles	   have	   since	   been	  generated	   three	  of	  which,	   sa3868,	   sa2675	  and	  sa2712	  bear	  a	  nonsense	  mutations	  and	  another,	  sa4495	  contains	  a	  mutation	  in	  an	  essential	  splice	  site.	  	  
• These	  mutants	  will	  side	  step	  the	  limitations	  of	  morpholino	  experiments	  and	  allow	  investigation	  of	  the	  effect	  of	  KIAA1109	  loss	  of	  function	  in	  adult	  fish	  as	  well.	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• Mutant	   embryos	   could	   be	   used	   for	   high	   throughput	   drug	   screens	   for	  potential	   new	   treatments	   for	   vascular	   stability	   (seeking	   to	   rescue	   the	  haemorrhagic	  phenotype).	  
• Another	  microarray	   could	  be	   carried	  out	  using	   a	   stable	   line	   to	   confirm	  my	  data	  from	  morphants.	  	  
• The	  natural	  progression	  from	  a	  zebrafish	  model	  is	  to	  a	  higher	  model	  such	  as	  mice,	   which	   are	  more	   genetically	   similar	   to	   humans	   and	   have	   been	  used	  widely	  to	  study	  cardiovascular	  disease.	  Currently	  a	  mouse	  line	  with	  a	   mutation	   in	   the	   KIAA1109	   gene	   is	   being	   generated	   as	   part	   of	   the	  international	  knockout	  mouse	  consortium.	  They	  have	  generated	  ES	  cells	  for	  10	  gene	  trap	  and	  1	  targeted	  mutation	  knockout	  mouse	  models,	  which	  have	  also	  not	  yet	  been	  phenotyped.	  	  
• Myocardial	   infarction	   could	   be	   induced	   in	   KIAA1109	   knockdown	  mice	  crossed	  with	   apoE/LDLR	   -­‐/-­‐ knock	   out	  models	   and	   the	   effect	   on	   infarct	  size	  and	  survival	  assessed.	  
• It	  would	  be	  important	  to	  attempt	  to	  reproduce	  our	  findings	   in	  different	  patient	   cohorts,	   using	   more	   time	   points,	   as	   well	   as	   recruiting	   healthy	  patients	  as	  controls.	  
• A	   microarray	   could	   be	   carried	   out	   on	   isolated	   cell	   types	   such	   as	  leukocytes	   of	   ACS	   patients,	   to	   determine	   the	   origin	   of	   KIAA1109	  expression.	  	  
• A	  microarray	  could	  be	  carried	  out	  on	  samples	  taken	  from	  patients	  before	  and	   after	   an	   angioplasty.	   Since	   this	   frequently	   induces	   small	   MI,	   this	  might	  inform	  whether	  KIAA1109	  is	  down	  regulated	  in	  response	  to	  MI.	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